Agilent (A) 10-K19 Dec 192019 FY Annual reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - USD ($) $ in Billions	12 Months Ended
Document And Entity Information - USD ($) $ in Billions	Oct. 31, 2019	Dec. 10, 2019	Apr. 30, 2019
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Oct. 31, 2019
Document Transition Report	false
Entity File Number	001-15405
Entity Registrant Name	Agilent Technologies, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0518772
Entity Address, Address Line One	5301 Stevens Creek Blvd.
Entity Address, City or Town	Santa Clara,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95051
City Area Code	(800)
Local Phone Number	227-9770
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	A
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 18.9
Entity Common Stock, Shares Outstanding		310,183,415
Documents Incorporated by Reference [Text Block]	Portions of the Proxy Statement for the Annual Meeting of Stockholders (the "Proxy Statement") to be held on March 18, 2020, and to be filed pursuant to Regulation 14A within 120 days after registrant's fiscal year ended October 31, 2019 are incorporated by reference into Part III of this Report
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--10-31
Entity Central Index Key	0001090872

CONSOLIDATED STATEMENT OF OPERA

CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Net revenue:
Net revenue	$ 5,163	$ 4,914	$ 4,472
Costs and expenses:
Cost of revenue	2,358	2,234	2,073
Research and development	404	387	341
Selling, general and administrative	1,460	1,389	1,251
Total costs and expenses	4,222	4,010	3,665
Income from operations	941	904	807
Interest income	36	38	22
Interest expense	(74)	(75)	(79)
Other income (expense), net	16	79	53
Income before taxes	919	946	803
Provision (benefit) for income taxes	(152)	630	119
Net income	$ 1,071	$ 316	$ 684
Net income per share:
Net income per share - basic	$ 3.41	$ 0.98	$ 2.12
Net income per share - diluted	$ 3.37	$ 0.97	$ 2.10
Weighted Averge Shares Used In Computing Net Income Per Share
Basic (in shares)	314	321	322
Diluted (in shares)	318	325	326
Products
Net revenue:
Net revenue	$ 3,877	$ 3,746	$ 3,397
Costs and expenses:
Cost of revenue	1,680	1,595	1,473
Services and Other
Net revenue:
Net revenue	1,286	1,168	1,075
Costs and expenses:
Cost of revenue	$ 678	$ 639	$ 600

CONSOLIDATED STATEMENT OF COMPR

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Statement of Comprehensive Income [Abstract]
Net income	$ 1,071	$ 316	$ 684
Other comprehensive income (loss):
Gain (loss) on derivative instruments, net of tax expense (benefit) of $(2), $1 and $0	(4)	6	0
Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $(2), $1 and $0	(6)	3	(1)
Foreign currency translation, net of tax expense (benefit) of $(10), $7 and $3	10	(58)	41
Net defined benefit pension cost and post retirement plan costs:
Change in actuarial net loss, net of tax expense (benefit) of $(25), $(3) and $52	(93)	(7)	123
Change in net prior service benefit, net of tax benefit of $(2), $(2) and $(3)	(6)	(6)	(6)
Other comprehensive income (loss)	(99)	(62)	157
Total comprehensive income	$ 972	$ 254	$ 841

CONSOLIDATED STATEMENT OF COM_2

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Gain (loss) on derivative instruments, tax expense (benefit)	$ (2)	$ 1	$ 0
Amounts reclassified into earnings related to derivative instruments, tax expense (benefit)	(2)	1	0
Foreign currency translation, tax expense (benefit)	(10)	7	3
Change in actuarial net loss, tax expense (benefit)	(25)	(3)	52
Change in net prior service benefit, tax (benefit)	$ (2)	$ (2)	$ (3)

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($) $ in Millions	Oct. 31, 2019	Oct. 31, 2018
Current assets:
Cash and cash equivalents	$ 1,382	$ 2,247
Accounts receivable, net	930	776
Inventory	679	638
Other current assets	198	187
Total current assets	3,189	3,848
Property, plant and equipment, net	850	822
Goodwill	3,593	2,973
Other intangible assets, net	1,107	491
Long-term investments	102	68
Other assets	611	339
Total assets	9,452	8,541
Current liabilities:
Accounts payable	354	340
Employee compensation and benefits	334	304
Deferred revenue	336	324
Short-term debt	616	0
Other accrued liabilities	440	203
Total current liabilities	2,080	1,171
Long-term debt	1,791	1,799
Retirement and post-retirement benefits	360	239
Other long-term liabilities	473	761
Total liabilities	4,704	3,970
Commitments and contingencies (Note 16)
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding	0	0
Common stock; $0.01 par value; 2 billion shares authorized; 309 million shares at October 31, 2019 and 318 million shares at October 31, 2018 issued	3	3
Additional paid-in-capital	5,277	5,308
Accumulated deficit	(18)	(336)
Accumulated other comprehensive loss	(514)	(408)
Total stockholders' equity	4,748	4,567
Non-controlling interest	0	4
Total equity	4,748	4,571
Total liabilities and equity	$ 9,452	$ 8,541

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares shares in Millions	Oct. 31, 2019	Oct. 31, 2018
Stockholders' equity:
Preferred stock par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock shares authorized (in shares)	125	125
Preferred Stock, Shares Issued (in shares)	0	0
Preferred Stock, Shares Outstanding (in shares)	0	0
Common stock par value (in dollars per share)	$ 0.01	$ 0.01
Common stock shares authorized (in shares)	2,000	2,000
Common stock issued (in shares)	309	318

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Cash flows from operating activities:
Net income	$ 1,071	$ 316	$ 684
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	238	210	212
Share-based compensation	72	70	60
Deferred taxes	(255)	(16)	102
Excess and obsolete inventory related charges	19	26	24
Gain on step acquisition	0	(20)	0
Asset impairment charges	0	21	0
Loss on extinguishment of debt	9	0	0
Other	6	9	7
Changes in assets and liabilities:
Accounts receivable, net	(106)	(65)	(81)
Inventory	(36)	(83)	(61)
Accounts payable	29	40	2
Employee compensation and benefits	23	31	38
Change in assets and liabilities due to Tax Act	0	552	0
Treasury lock agreement payment	(6)	0	0
Other assets and liabilities	(43)	(4)	(98)
Net cash provided by operating activities	1,021	1,087	889
Cash flows from investing activities:
Investments in property, plant and equipment	(155)	(177)	(176)
Proceeds from the sale of property, plant and equipment	0	1	0
Proceeds from divestitures	0	0	2
Payment to acquire fair value investment	23	11	1
Payment in exchange for convertible note	(3)	(2)	(1)
Payment to acquire intangible assets	(1)	0	0
Acquisitions of businesses and intangible assets, net of cash acquired	(1,408)	(516)	(128)
Net cash used in investing activities	(1,590)	(705)	(304)
Cash flows from financing activities:
Issuance of common stock under employee stock plans	54	56	66
Payment of taxes related to net share settlement of equity awards	(16)	(30)	(14)
Treasury stock repurchases	(723)	(422)	(194)
Payment of dividends	(206)	(191)	(170)
Issuance of senior notes	497	0	0
Debt issuance costs	(4)	0	0
Purchase of non-controlling interest	4	0	0
Proceeds from credit facility and short-term loan	805	483	400
Repayments of debt and credit facility	702	693	290
Net cash used in financing activities	(299)	(797)	(202)
Effect of exchange rate movements	2	(17)	8
Net increase (decrease) in cash, cash equivalents and restricted cash	(866)	(432)	391
Cash, cash equivalents and restricted cash at beginning of year	2,254	2,686	2,295
Cash, cash equivalents and restricted cash at end of year	1,388	2,254	2,686
Supplemental Cash Flow Information [Abstract]
Income tax payments, net	159	102	63
Interest payments	80	80	82
Non-cash changes in investments in property, plant and equipment increase (decrease)	$ (21)	$ (5)	$ 29

CONSOLIDATED STATEMENT OF EQUIT

CONSOLIDATED STATEMENT OF EQUITY - USD ($) shares in Thousands, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Income (Loss)	Total Stockholders Equity	Non-controlling Interest
Treasury Stock, Number of shares				(290,075)
Treasury Stock, Value				$ (10,508)
Balance (in shares) at Oct. 31, 2016		613,536
Balance at Oct. 31, 2016	$ 4,246	$ 6	$ 9,159		$ 6,089	$ (503)	$ 4,243	$ 3
Components of comprehensive income, net of tax:
Net income	684				684		684
Other comprehensive income (loss)	157					157	157
Total comprehensive income	841						841
Non-controlling interest	1							1
Cash dividends declared	(170)				(170)		(170)
Share-based awards issued (in shares)		2,621
Share-based awards issued	51		51				51
Repurchase of common stock (in shares)				(4,107)
Repurchase of common stock	(194)			$ (194)			(194)
Retirement of treasury stock (shares)		(294,182)		(294,182)
Retirement of treasury stock, cost method		$ (3)	(3,970)	$ (10,702)	(6,729)
Share-based compensation	60		60				60
Balance at Oct. 31, 2017	4,835	$ 3	5,300		(126)	(346)	4,831	4
Balance (in shares) at Oct. 31, 2017		321,975
Treasury Stock, Number of shares				0
Treasury Stock, Value				$ 0
Components of comprehensive income, net of tax:
Net income	316				316		316
Other comprehensive income (loss)	(62)					(62)	(62)
Total comprehensive income	254						254
Cash dividends declared	(191)				(191)		(191)
Share-based awards issued (in shares)		2,176
Share-based awards issued	25		25				25
Repurchase of common stock (in shares)				(6,436)
Repurchase of common stock	(422)			$ (422)			(422)
Retirement of treasury stock (shares)		(6,436)		(6,436)
Retirement of treasury stock, cost method		$ 0	(87)	$ (422)	(335)
Share-based compensation	70		70				70
Balance at Oct. 31, 2018	4,571	$ 3	5,308		(336)	(408)	4,567	4
Balance (in shares) at Oct. 31, 2018		317,715
Treasury Stock, Number of shares				0
Treasury Stock, Value				$ 0
Components of comprehensive income, net of tax:
Adjustment due to adoption of ASU 2019-09	26				33	(7)	26
Net income	1,071				1,071		1,071
Other comprehensive income (loss)	(99)					(99)	(99)
Total comprehensive income	972						972
Non-controlling interest	(4)							(4)
Cash dividends declared	(206)				(206)		(206)
Share-based awards issued (in shares)		1,792
Share-based awards issued	40		40				40
Repurchase of common stock (in shares)				(10,436)
Repurchase of common stock	(723)			$ (723)			(723)
Retirement of treasury stock (shares)		(10,436)		(10,436)
Retirement of treasury stock, cost method		$ 0	(143)	$ (723)	(580)
Share-based compensation	72		72				72
Balance at Oct. 31, 2019	$ 4,748	$ 3	$ 5,277		$ (18)	$ (514)	$ 4,748	$ 0
Balance (in shares) at Oct. 31, 2019		309,071
Treasury Stock, Number of shares				0
Treasury Stock, Value				$ 0

CONSOLIDATED STATEMENT OF EQU_2

CONSOLIDATED STATEMENT OF EQUITY (Parenthetical) - $ / shares	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Statement of Stockholders' Equity [Abstract]
Cash Dividends Declared (per common share)	$ 0.656	$ 0.596	$ 0.528

OVERVIEW AND SUMMARY OF SIGNIFI

OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Oct. 31, 2019
Accounting Policies [Abstract]
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Basis of Presentation. The accompanying consolidated financial statements have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and is in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years and dates refer to our fiscal year. Principles of Consolidation. The consolidated financial statements include the accounts of the company and our wholly- and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Use of Estimates. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement plan assumptions and accounting for income taxes. Retirement of Treasury Shares. Upon the formal retirement of treasury shares, we deduct the par value of the retired treasury shares from common stock and allocate the excess of cost over par as a deduction to additional paid-in capital, based on the pro-rata portion of additional paid-in-capital, and the remaining excess as a deduction to retained earnings. All retired treasury shares revert to the status of authorized but unissued shares. Revenue Recognition. We enter into contracts to sell products, services or combinations of products and services. Products may include hardware or software and services may include one-time service events or services performed over time. We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers (“ASC 606’’). See also Note 2, "New Accounting Pronouncements" and Note 4, "Revenue" for additional information on revenue recognition. Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled in exchange for those products or services, the transaction price. For equipment, consumables, and most software licenses, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded. Service revenue includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. Revenue for these contracts is recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls not included in a support contract are recognized to revenue at the time a service is performed. We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis. Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue. For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per country for each performance obligation. Standalone selling prices are determined for each distinct good or service in the contract and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations. A portion of our revenue relates to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 840, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance. Deferred Revenue. Contract liabilities (deferred revenue) primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements (performance obligations) to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either in current liabilities in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation. Accounts Receivable, net. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Such accounts receivable have been reduced by an allowance for doubtful accounts, which is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on customer specific experience and the aging of such receivables, among other factors. The allowance for doubtful accounts as of October 31, 2019 and 2018 was not material. We do not have any off-balance-sheet credit exposure related to our customers. Accounts receivable are also recorded net of estimated product returns which are not material. Shipping and Handling Costs. Our shipping and handling costs charged to customers are included in net revenue, and the associated expense is recorded in cost of products for all periods presented. Inventory. Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory. Acquisitions. Agilent accounts for the acquisition of a business using the acquisition method of accounting and we allocate the fair value of the purchase price to the tangible assets acquired, liabilities assumed, and intangible assets acquired, including in-process research and development (“IPR&D”), based on their estimated fair values. The excess value of the cost of an acquired business over the fair value of the assets acquired and liabilities assumed is recognized as goodwill. The fair value of IPR&D is initially capitalized as an intangible asset with an indefinite life. When an IPR&D project is completed, the IPR&D is reclassified as an amortizable purchased intangible asset and amortized to costs of revenues over the asset’s estimated useful life. Our determination of the fair value of the intangible assets acquired involves the use of significant estimates and assumptions. Specifically, our determination of the fair value of the developed product technology and IPR&D acquired involve significant estimates and assumptions related to revenue growth rates and discount rates. Our determination of the fair value of customer relationships acquired involved significant estimates and assumptions related to revenue growth rates, discount rates, and customer attrition rates. Our determination of the fair value of the tradename acquired involved the use of significant estimates and assumptions related to revenue growth rates, royalty rates and discount rates. The company believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use. Actual results could differ materially from these estimates. Goodwill and Purchased Intangible Assets. Under the authoritative guidance we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e. greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required. The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers. If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units. In fiscal year 2019 , we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a qualitative test for goodwill impairment of the three reporting units, as of September 30, 2019 , our annual impairment test date. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of each reporting unit is greater than its respective carrying value. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2019 , 2018 and 2017 . Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years . IPR&D is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's consolidated statement of operations in the period it is abandoned. Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e. greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2019 . Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of these indefinite-lived intangible assets is greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible asset is indicated. During the year ended October 31, 2019 , 2018 and 2017 there were no impairments of indefinite-lived intangible assets. Share-Based Compensation. For the years ended 2019 , 2018 and 2017 , we accounted for share-based awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our Employee Stock Purchase Plan ("ESPP") and performance share awards under Agilent Technologies, Inc. Long-Term Performance Program ("LTPP") using the estimated grant date fair value method of accounting. Under the fair value method, we recorded compensation expense for all share-based awards of $72 million in 2019 , $71 million in 2018 and $61 million in 2017 . See Note 5, "Share-based Compensation" for additional information. Retirement and Post-Retirement Plans. Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Assumptions used to determine the benefit obligations and the expense for these plans are derived annually. See Note 14, “Retirement plans and post-retirement pension plans” for additional information. Taxes on Income. Income tax expense or benefit is based on income or loss before taxes. Deferred tax assets and liabilities are recognized principally for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. See Note 6, "Income Taxes" for more information. Warranty. Our standard warranty terms typically extend for one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net product revenue. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. See Note 15, "Guarantees". Advertising. Advertising costs are generally expensed as incurred and amounted to $36 million in 2019 , $41 million in 2018 and $38 million in 2017 . Research and Development. Costs related to research, design and development of our products are charged to research and development expense as they are incurred. Sales Taxes. Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue. Net Income Per Share. Basic net income per share is computed by dividing net income - the numerator - by the weighted average number of common shares outstanding - the denominator - during the period excluding the dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense are assumed proceeds to be used to repurchase hypothetical shares. See Note 7, "Net Income Per Share". Cash, Cash Equivalents and Short-Term Investments. We classify investments as cash equivalents if their original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value. As of October 31, 2019 , approximately $1,310 million of our cash and cash equivalents is held outside of the U.S. by our foreign subsidiaries. Our cash and cash equivalents mainly consist of short-term deposits held at major global financial institutions, institutional money market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our funds. We classify investments as short-term investments if their original maturities are greater than three months and their remaining maturities are one year or less. Currently, we have no short-term investments. Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). The company evaluates its investments in privately held companies on an ongoing basis. We account for these investments under either the equity method or as equity investments without determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. During the year ended October 31, 2016, Agilent made a preferred stock investment in Lasergen, Inc. ("Lasergen") for $80 million . This investment in Lasergen was accounted for under the cost method. Agilent’s initial ownership stake was 48 percent and included an option to acquire the remaining shares until March 2018. During the year ended October 31, 2018, we exercised our option and acquired all of the remaining shares of Lasergen that we did not already own for an additional cash consideration of approximately $107 million . The fair value remeasurement of our previous investment immediately before the acquisition resulted in a net gain of $20 million and was recorded in other income. Lasergen was previously considered a VIE. As of October 31, 2019 and 2018 , we have no material VIE's. Investments. Equity investments without readily determinable fair value consist of non-marketable equity securities (typically investments in privately-held companies). These investments are accounted for using the measurement alternative at cost and we adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) included in net income as and when it occurs. Equity investments with readily determinable fair value consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Prior to fiscal year 2019, both equity investments without determinable fair value and with determinable fair value were accounted for using cost method of accounting, measured at historical cost less other-than-temporary investment. Trading securities, which is comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. There are no equity method investments as of October 31, 2019 and 2018 . The company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy exceeds the carrying value by approximately $62 million as of October 31, 2019 and is lower than the carrying value by approximately $15 million as of October 31, 2018 . The change in the fair value over carrying value in the year ended October 31, 2019 is primarily due to fluctuations in market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 12, "Fair Value Measurements" for additional information on the fair value of financial instruments. Concentration of Credit Risk. Financial instruments that potentially subject Agilent to significant concentration of credit risk include money market fund investments, time deposits and demand deposit balances. These investments are categorized as cash and cash equivalents. In addition, Agilent has credit risk from derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of financial instruments and limit the amount of credit exposure with any one financial institution. We have a comprehensive credit policy in place and credit exposure is monitored on an ongoing basis. Credit risk with respect to our accounts receivable is diversified due to the large number of entities comprising our customer base and their dispersion across many different industries and geographies. Credit evaluations are performed on customers requiring credit over a certain amount and we sell the majority of our products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of accounts receivable as of October 31, 2019 , or 2018 . Derivative Instruments. Agilent is exposed to global foreign currency exchange rate and interest rate risks in the normal course of business. We enter into foreign exchange hedging contracts, primarily forward contracts and purchased options, interest rate swaps and interest rate locks to manage financial exposures resulting from changes in foreign currency exchange rates and interest rates. In the vast majority of cases, these contracts are designated at inception as hedges of the related foreign currency or interest exposures. Foreign currency exposures include committed and anticipated revenue and expense transactions and assets and liabilities that are denominated in currencies other than the functional currency of the subsidiary. Interest rate exposures are associated with the company's fixed-rate debt. For option contracts, we exclude time value from the measurement of effectiveness. To qualify for hedge accounting, contracts must reduce the foreign currency exchange rate and interest rate risk otherwise inherent in the amount and duration of the hedged exposures and comply with established risk management policies. Foreign exchange hedging contracts generally mature within twelve months , interest rate swaps mature at the same time as the maturity of the debt and interest rate locks mature at the same time as the issuance of debt. In order to manage foreign currency exposures in a few limited jurisdictions we may enter into foreign exchange contracts that do not qualify for hedge accounting. In such circumstances, the local foreign currency exposure is offset by contracts owned by the parent company. We do not use derivative financial instruments for trading or speculative purposes. All derivatives are recognized on the balance sheet at their fair values. For derivative instruments that are designated and qualify as a fair value hedge, changes in value of the derivative are recognized in the consolidated statement of operations in the current period, along with the offsetting gain or loss on the hedged item attributable to the hedged risk. For derivative instruments that are designated and qualify as a cash flow hedges, changes in the value of the effective portion of the derivative instrument is recognized in comprehensive income (loss), a component of stockholders' equity. Amounts associated with cash flow hedges are reclassified and recognized in income when either the forecasted transaction occurs or it becomes probable the forecasted transaction will not occur. Derivatives not designated as hedging instruments are recorded on the balance sheet at their fair value and changes in the fair values are recorded in the income statement in the current period. Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet. Changes in the fair value of the ineffective portion of derivative instruments are recognized in earnings in the current period. Ineffectiveness in 2019 , 2018 and 2017 was not material. Cash flows from derivative instruments are classified in the statement of cash flows in the same category as the cash flows from the hedged or economically hedged item, primarily in operating activities. Property, Plant and Equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their useful lives or the remaining term of the lease and machinery and equipment over 3 years to 10 years . We use the straight-line method to depreciate assets. Leases. We lease buildings, machinery and equipment under operating and capital leases for original terms ranging generally from less than 1 year to 30 years . Certain leases contain renewal options for periods up to 6 years . In addition, we lease equipment to customers in connection with our diagnostics business using both capital and operating leases. As of October 31, 2019 and 2018 our diagnostics and genomics segment has approximately $37 million and $32 million , respectively, of lease receivables related to capital leases and approximately $17 million and $20 million , respectively, of net assets for operating leases. We depreciate the assets related to the operating leases over their estimated useful lives, typically five years. Capitalized Software. We capitalize certain internal and external costs incurred to acquire or create internal use software. Capitalized software is included in property, plant and equipment and is depreciated over 3 years to 5 years once development is complete. Impairment of Long-Lived Assets. We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets. During 2019, there were no impairments of other assets or intangible assets. During 2018, we recorded an impairment charge of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable. During 2017, there were no impairments of other assets or intangible assets. Employee Compensation and Benefits. Amounts

NEW ACCOUNTING PRONOUNCEMENTS

NEW ACCOUNTING PRONOUNCEMENTS	12 Months Ended
NEW ACCOUNTING PRONOUNCEMENTS	Oct. 31, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
NEW ACCOUNTING PRONOUNCEMENTS	NEW ACCOUNTING PRONOUNCEMENTS Recently Adopted Accounting Pronouncements In May 2014, the FASB issued new revenue recognition guidance, ASC Topic 606, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. The objective of the new revenue standard is to significantly enhance comparability and clarify principles of revenue recognition practices across entities, industries, jurisdictions and capital markets. Under the new guidance, there are specific criteria to determine if a performance obligation should be recognized over time or at a point in time. On November 1, 2018, we adopted ASC 606 using the modified retrospective approach only to contracts not completed as of this date. Results for reporting periods after November 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and continue to be reported in accordance with ASC Topic 605, Revenue Recognition . We recorded a net increase to beginning retained earnings of $23 million as of November 1, 2018 due to the cumulative impact of adopting ASC 606. The impact to beginning retained earnings is primarily due to an increase in contract assets (unbilled accounts receivable), a reduction in inventory and a reduction in contract liabilities (deferred revenue). The net increase in retained earnings and resulting changes in assets and liabilities was mainly driven by the change in timing of the recognition of revenue from the fulfillment of separate performance obligations as control transfers to the customer. Had we continued to use the revenue recognition guidance in effect prior to fiscal year 2019, no material changes would have resulted to the consolidated statements of income, comprehensive income, or cash flows for the year ended October 31, 2019 . As a result, comparisons of revenue and operating profit performance between periods are not materially affected by the adoption of this standard. Refer to Note 1, "Overview and Summary of Significant Accounting Policies"for a description of the company’s revenue recognition policies and Note 4, "Revenue" for the disclosures required by the standard. As of November 1, 2018, we elected to early adopt new accounting guidance which amends reporting comprehensive income to allow a reclassification from accumulated other comprehensive income ("AOCI") to retained earnings for the deferred taxes previously recorded in AOCI that exceed the current federal tax rate of 21 percent resulting from the enacted corporate tax rate in the U.S. Tax Cuts and Jobs Act ("the Tax Act"). The adoption of this guidance resulted in a reclassification of $7 million from AOCI to beginning retained earnings on our consolidated balance sheet. As of November 1, 2018, we adopted new accounting guidance which eliminates the exception in ASC 740, Income Taxes against immediate recognition of income tax consequences of intra-entity transfers of assets other than inventory. The amendment in this update should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of period of adoption. We recorded a net decrease in beginning retained earnings of $2 million as of November 1, 2018 due to removing unamortized tax expense previously deferred. As of November 1, 2018, we adopted new accounting guidance which addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments and also the related guidance which addresses technical corrections and improvements to this guidance. The guidance requires entities to measure equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize any changes in fair value in net income. The total impact of adoption to our consolidated balance sheet was an increase of $7 million to long-term investments and a net increase of $5 million to beginning retained earnings. The following table summarizes the impacts of recently adopted accounting pronouncements on our consolidated balance sheet as of November 1, 2018: October 31, Impact of Adopting New November 1, As Reported Revenue Recognition Guidance Tax Effects on Items in AOCI Guidance Intra-Entity Tax Guidance Investments Valuation Guidance As Adopted (in millions) ASSETS Current assets: Cash and cash equivalents $ 2,247 $ — $ — $ — $ — $ 2,247 Accounts receivable, net 776 24 — — — 800 Inventory 638 (10 ) — — — 628 Other current assets 187 3 — — — 190 Total current assets 3,848 17 — — — 3,865 Property, plant and equipment, net 822 — — — — 822 Goodwill 2,973 — — — — 2,973 Other intangible assets, net 491 — — — — 491 Long-term investments 68 — — — 7 75 Other assets 339 (3 ) — (2 ) (2 ) 332 Total assets $ 8,541 $ 14 $ — $ (2 ) $ 5 $ 8,558 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 340 $ — $ — $ — $ — $ 340 Employee compensation and benefits 304 — — — — 304 Deferred revenue 324 (11 ) — — — 313 Other accrued liabilities 203 — — — — 203 Total current liabilities 1,171 (11 ) — — — 1,160 Long-term debt 1,799 — — — — 1,799 Retirement and post-retirement benefits 239 — — — — 239 Other long-term liabilities 761 2 — — — 763 Total liabilities 3,970 (9 ) — — — 3,961 Total equity: Stockholders’ equity: Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding — — — — — — Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018 issued 3 — — — — 3 Additional paid-in-capital 5,308 — — — — 5,308 Accumulated deficit (336 ) 23 7 (2 ) 5 (303 ) Accumulated other comprehensive loss (408 ) — (7 ) — — (415 ) Total stockholders' equity 4,567 23 — (2 ) 5 4,593 Non-controlling interest 4 — — — — 4 Total equity 4,571 23 — (2 ) 5 4,597 Total liabilities and equity $ 8,541 $ 14 $ — $ (2 ) $ 5 $ 8,558 As of November 1, 2018, we adopted new accounting guidance which requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows: October 31 2019 2018 2017 (in millions) Cash and cash equivalents $ 1,382 $ 2,247 $ 2,678 Restricted cash included in other assets 6 7 8 Total cash, cash equivalents and restricted cash $ 1,388 $ 2,254 $ 2,686 As of November 1, 2018, we adopted new accounting guidance which requires employers that present a measure of operating income in their statements of operations to include only the service cost component of net periodic postretirement benefit cost in operating expenses. The service cost component of net periodic pension and postretirement benefit cost should be presented in the same operating expense line items as other employee compensation costs arising from services rendered during the period. The other components of net periodic pension and postretirement benefit costs, including interest costs, expected return on assets, amortization of prior service cost/credit and actuarial gains/losses, and settlement and curtailment effects, are to be included separately and outside of any subtotal of operating income. The adoption of this guidance resulted in a reclassification of income from our income from operations to other income (expense), net on our consolidated statement of operations of approximately $10 million , $24 million and $34 million in the year ended October 31, 2019, 2018 and 2017, respectively. As adoption is required to be on a retrospective basis, we have recast our historical consolidated statements of operations and segment information to conform to current year presentation. New Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued guidance which amends the existing accounting standards for leases. Consistent with existing guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification. Under the new guidance, a lessee will be required to recognize right-of-use assets ("ROU") and lease liabilities on the balance sheet. On November 1, 2019, we adopted the lease accounting guidance using the modified retrospective method for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning November 1, 2019 will be presented under the new accounting guidance, while prior period amounts will not be adjusted. As of November 1, 2019, the new accounting guidance had a material impact on our consolidated balance sheet but is expected to have an insignificant impact on the consolidated net income and cash flows. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases, while the accounting for capital leases remained substantially unchanged. For leases that commenced before the effective date of adoption of the new accounting guidance, we elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) capitalization of initial direct costs for any existing leases. As a result of the cumulative impact of adopting the new accounting guidance we will record operating lease ROU assets around $195 million and operating lease liabilities of the same amounts, primarily related to real estate and automobile leases. The accounting applied to lease arrangements in which we are the lessor is largely unchanged from that applied under the prior standard and will not have a significant impact to our consolidated balance sheet, net income or cash flows In January 2017, the FASB issued an amendment to modify the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. The amendment also simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. The amendments are effective for us beginning November 1, 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not expect to early adopt nor do we expect this guidance to have a material impact on our consolidated financial statements and disclosures. In August 2018, the FASB issued updates to improve the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement which eliminates certain disclosure requirements and modifies others. These amendments are effective for us beginning November 1, 2020, and for interim periods within that year with early adoption permitted. We currently do not expect this guidance to have a material impact on our consolidated financial statements and disclosures. In August 2018, the FASB issued updates to improve the effectiveness of disclosures for defined benefit plans under Accounting Standard Codification Topic 715-20. The amendments in this guidance remove disclosures that no longer are considered cost beneficial, clarify the specific requirements of disclosures, and add disclosure requirements identified as relevant. These amendments are effective for us beginning November 1, 2021, with early adoption permitted. We currently do not expect this guidance to have a material impact on our consolidated financial statements and disclosures. Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

ACQUISITIONS (Notes)

ACQUISITIONS (Notes)	12 Months Ended
ACQUISITIONS (Notes)	Oct. 31, 2019
Business Combinations [Abstract]
Acquisitions Disclosure	ACQUISITIONS Acquisition of BioTek and ACEA On August 23, 2019 we completed the acquisition of privately-owned Lionheart Technologies LLC ("BioTek"), a leader in the design, manufacture and distribution of innovative life science instrumentation for $1.17 billion , under the merger agreement. As a result of the acquisition, BioTek has become a wholly-owned subsidiary of Agilent. Accordingly, the results of BioTek are included in Agilent's consolidated financial statements from the acquisition date. For the period from August 24, 2019 to October 31, 2019 , BioTek’s net revenue was $35 million and net loss was $12 million . The acquisition of BioTek and its portfolio is another step to expand our position in the cell analysis market. The consideration paid was $1.17 billion . Agilent funded the acquisition using existing cash of $470 million and debt of $700 million . The BioTek acquisition was accounted for in accordance with the authoritative accounting guidance. The acquired assets and assumed liabilities were recorded by Agilent at their estimated fair values. Agilent determined the estimated fair values with the assistance of appraisals or valuations performed by third party specialists, discounted cash flow analyses, and estimates made by management. We expect to realize revenue synergies, leverage and expand the existing sales channels and product development resources, and utilize the assembled workforce. These factors, among others, contributed to a purchase price in excess of the estimated fair value of BioTek’s net identifiable assets acquired (see summary of net assets below), and, as a result, we have recorded goodwill in connection with this transaction. Goodwill acquired was allocated to our operating segments and reporting units as a part of the purchase price allocation. All goodwill was allocated to the life sciences and applied markets reporting unit. Agilent’s acquisition of BioTek is treated as an asset purchase for tax purposes. The tax basis of the acquired assets equals the fair market value on acquisition date. The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions): Cash and cash equivalents $ 10 Accounts receivable 28 Inventories 21 Other current assets 2 Property, plant and equipment 8 Intangible assets 641 Goodwill 483 Total assets acquired 1,193 Accounts payable (4 ) Deferred revenue (5 ) Employee compensation and benefits (7 ) Other accrued liabilities (2 ) Long-term debt (4 ) Net assets acquired $ 1,171 The fair value of cash and cash equivalents, accounts receivable, other current assets, accounts payable and other accrued liabilities were generally determined using historical carrying values given the short-term nature of these assets and liabilities. The fair values for acquired intangible assets and deferred revenue were determined with the input from third party valuation specialists. The fair values of certain other assets, inventory, property, plant and equipment, investments, long-term debt, and certain other long-term liabilities were determined internally using historical carrying values and estimates made by management. Valuations of intangible assets acquired The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions): Fair Value Estimated Useful Life Developed product technology $ 387 5-13 years Customer relationships 202 3-8 years Backlog 5 2 months Tradenames and trademarks 43 10 years Total intangible assets subject to amortization 637 In-process research and development 4 Total intangible assets $ 641 As noted above, the intangible assets, including in-process research and development, were valued with input from valuation specialists. Agilent used variations of the income approach in determining the fair value of intangible assets acquired in the BioTek acquisition. Specifically, the developed product technology and in-process research and development were valued using the multi-period excess earnings method under the income approach by discounting forecasted cash flows directly related to the products expecting to result from the projects, net of returns on contributory assets. The Company utilized the incremental cash flow method for determining the fair value of the customer relationships acquired, and the relief from royalty method to determine the fair value of the tradename. Order backlog was valued on a direct cash flow basis. The primary in-process research and development project acquired relates to a next version of a product which will be released in 2020. Total costs to complete for all BioTek in-process research and development were estimated at approximately $2 million as of the close date. Acquisition and integration costs directly related to the BioTek acquisition totaled $4 million for the year ended October 31, 2019 and were recorded in selling, general and administrative expenses. Such costs are expensed in accordance with the authoritative accounting guidance. On November 14, 2018, we acquired 100 percent of the stock of ACEA Biosciences (“ACEA”), a developer of cell analysis tools, for $250 million . The financial results of ACEA have been included in our financial results from the acquisition date. The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's consolidated statements of operations as of the beginning of fiscal 2018 (in millions, except per share amounts): 2019 2018 Net revenue $ 5,308 $ 5,112 Net income $ 1,012 $ 210 Net income per share — basic $ 3.22 $ 0.65 Net income per share — diluted $ 3.18 $ 0.65 The unaudited proforma financial information assumes that the companies were combined as of November 1, 2017 and include business combination accounting effects from the acquisition including amortization charges from acquired intangible assets, the impact on cost of sales due to the respective estimated fair value adjustments to inventory, changes to interest income for cash used in the acquisition, interest expense and currency losses associated with debt paid in connection with the acquisition and acquisition related transaction costs and tax related effects. The proforma information as presented above is for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal 2018 . The unaudited proforma financial information for the year ended October 31, 2019 combines the historical results of Agilent for the year ended October 31, 2019 (which includes BioTek and ACEA after the acquisition date) and for BioTek for the ten months ended August 23, 2019. The unaudited proforma financial information for the year ended October 31, 2018 combines the historical results of Agilent and ACEA for the year ended October 31, 2018 and BioTek for the year ended December 31, 2018 (due to differences in reporting periods).

REVENUE REVENUE (Notes)

REVENUE REVENUE (Notes)	12 Months Ended
REVENUE REVENUE (Notes)	Oct. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer	REVENUE The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: Year Ended October 31, 2019 Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Revenue by Region Americas $ 692 $ 505 $ 664 $ 1,861 Europe 551 368 522 1,441 Asia Pacific 1,059 148 654 1,861 Total $ 2,302 $ 1,021 $ 1,840 $ 5,163 The following table presents the company’s total revenue disaggregated by end markets and by revenue type: Year Ended October 31, 2019 (in millions) Revenue by End Markets Pharmaceutical and Biopharmaceutical $ 1,604 Chemical and Energy 1,199 Diagnostics and Clinical 785 Food 486 Academia and Government 474 Environmental and Forensics 615 Total $ 5,163 Revenue by Type Instrumentation $ 2,150 Non-instrumentation and other 3,013 Total $ 5,163 Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue includes sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services. Contract Balances Contract Assets Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheet. The balance of contract assets as of October 31, 2019 and as of November 1, 2018, the date of adoption of ASC 606, were $110 million and $57 million , respectively. The increase in unbilled receivables during the year ended October 31, 2019 is a result of recognition of revenue upon the transfer of the control to the customer. In some instances, transfer of control is prior to invoicing the customers and excluding amounts transferred to trade receivables during the period amounted to $53 million . Contract Liabilities The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the year ended October 31, 2019 : Contract (in millions) Ending balance as of October 31, 2018 $ 367 Impact of adoption of new revenue recognition guidance (11 ) Net revenue deferred in the period 303 Revenue recognized that was included in the contract liability balance at the beginning of the period (287 ) Change in deferrals from customer cash advances, net of revenue recognized 5 Contract liabilities acquired in business combinations 9 Currency translation and other adjustments — Ending balance as of October 31, 2019 $ 386 Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation. Contract Costs Incremental costs of obtaining a contract with a customer are recognized as an asset if it expects the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The change in total capitalized costs to obtain a contract was immaterial during the year ended October 31, 2019 and are included in other current and long-term assets on the consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities. Transaction Price Allocated to the Remaining Performance Obligations We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized for remaining performance obligations that have an original term of more than one year, as of October 31, 2019 , was $207 million

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
SHARE-BASED COMPENSATION	Oct. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION Agilent accounts for share-based awards in accordance with the provisions of the accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our ESPP and performance share awards granted to selected members of our senior management under the LTPP based on estimated fair values. Description of Share-Based Plans Employee Stock Purchase Plan. Effective November 1, 2000, we adopted the ESPP. The ESPP allows eligible employees to contribute up to ten percent of their base compensation to purchase shares of our common stock at 85 percent of the closing market price at purchase date. Currently, there are 75 million shares authorized for issuance in connection with the ESPP. Under our ESPP, employees purchased 603,488 shares for $37 million in 2019 , 558,116 shares for $32 million in 2018 and 618,270 shares for $26 million in 2017 . As of October 31, 2019 , the number of shares of common stock authorized and available for issuance under our ESPP was 26,055,571 . This excludes the number of shares of common stock to be issued to participants in consideration of the aggregate participant contributions totaling $20 million as of October 31, 2019 . Incentive Compensation Plans. On November 15, 2017 and March 21, 2018, the Board of Directors and the stockholders, respectively, approved the Agilent Technologies, Inc. 2018 Stock Plan (the "2018 Plan") which amends, including renaming and extending the term of, the Agilent Technologies, Inc. 2009 Stock Plan (the "2009 Plan"). The 2009 plan replaced the Agilent Technologies, Inc. Amended and Restated 1999 Stock Plan and 1999 Non-Employee Director Stock Plan. The 2018 Plan provides for the grant of awards in the form of stock options, stock appreciation rights ("SARs"), restricted stock, restricted stock units ("RSUs"), performance shares and performance units with performance-based conditions on vesting or exercisability, and cash awards. The 2018 Plan has a term of ten years . As of October 31, 2019 , 28,676,526 shares were available for future awards under the 2018 Stock Plan. Stock options under the 2018 Stock Plan may be either "incentive stock options", as defined in Section 422 of the Internal Revenue Code, or non-statutory. Options were granted prior to November 1, 2015 and generally vest at a rate of 25 percent per year over a period of four years from the date of grant with a maximum contractual term of ten years . The exercise price for stock options is generally not less than 100 percent of the fair market value of our common stock on the date the stock award is granted. Agilent issues new shares of common stock when employee stock options are exercised. Effective November 1, 2003, the Compensation Committee of the Board of Directors approved the LTPP, which is a performance stock award program administered under the 2018 Stock Plan, for the company's executive officers and other key employees. Participants in this program are entitled to receive unrestricted shares of the company's stock after the end of a three-year period, if specified performance targets are met. Certain LTPP awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the Total Stockholders’ Return (“TSR”) set at the beginning of the performance period. Effective November 1, 2015, the Compensation Committee of the Board of Directors approved another type of performance stock award, for the company's executive officers and other key employees. Participants in this program are also entitled to receive unrestricted shares of the company's stock after the end of a three-year period, if specified performance targets over the three-year period are met. The performance target for grants made in 2016 were based on Operating Margin (“OM”) and the performance grants made in 2017, 2018 and 2019 were based on Earnings Per Share ("EPS"). In the case of LTPP-OM, the performance targets for all the three years of performance period were set at the time of grant. The performance targets for LTPP-EPS grants for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. All LTPP awards granted after November 1, 2015, are subject to a one-year post-vest holding period. Based on the performance metrics the final LTPP award may vary from zero to 200 percent of the target award. The maximum contractual term for awards under the LTPP program is three years and the maximum award value for awards granted in 2017 and 2016 cannot exceed 300 percent of the grant date target value. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met. We also issue restricted stock units under our share-based plans. The estimated fair value of the restricted stock unit awards granted under the Stock Plans is determined based on the market price of Agilent's common stock on the date of grant adjusted for expected dividend yield. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant. All restricted stock units granted to our executives after November 1, 2015, are subject to a one-year post-vest holding period. Impact of Share-based Compensation Awards We have recognized compensation expense based on the estimated grant date fair value method under the authoritative guidance. For all share-based awards we have recognized compensation expense using a straight-line amortization method. As the guidance requires that share-based compensation expense be based on awards that are ultimately expected to vest, estimated share-based compensation has been reduced for estimated forfeitures. The impact on our results for share-based compensation was as follows: Years Ended October 31, 2019 2018 2017 (in millions) Cost of products and services $ 18 $ 16 $ 15 Research and development 7 7 6 Selling, general and administrative 47 48 40 Total share-based compensation expense $ 72 $ 71 $ 61 At October 31, 2019 and 2018 there was no share-based compensation capitalized within inventory. Valuation Assumptions For all periods presented, shares granted under the LTPP (TSR) were valued using a Monte Carlo simulation. The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the fair market value at the purchase date. The estimated fair value of restricted stock unit awards, LTPP (OM) and LTPP (EPS) was determined based on the market price of Agilent's common stock on the date of grant adjusted for expected dividend yield and as appropriate, a discount related to the one-year post vesting. The compensation cost for LTPP (OM) and LTPP (EPS) awards reflect the cost of awards that are probable to vest at the end of the performance period. The following assumptions were used to estimate the fair value of awards granted. Years Ended October 31, 2019 2018 2017 LTPP: Volatility of Agilent shares 22% 21% 23% Volatility of selected peer-company shares 15%-66% 14%-66% 15%-63% Pair-wise correlation with selected peers 30% 32% 36% Post-vest restriction discount for all executive awards 5.0% 4.8% 5.3% Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulation model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock. For LTPP (TSR) grants in 2017 and thereafter, we used our own historical stock price volatility. All LTPP awards granted to our executives have a one-year post-vest holding restriction. The estimated discount associated with post-vest holding restrictions is calculated using the Finnerty model. The model calculates the potential lost value if the employee were able to sell the shares during the lack of marketability period, instead of being required to hold the shares. Share-Based Payment Award Activity Employee Stock Options The following table summarizes employee stock option award activity of our employees and directors for 2019 . Options Outstanding Weighted Average Exercise Price (in thousands) Outstanding at October 31, 2018 1,997 $ 35 Exercised (552 ) $ 33 Forfeited — $ — Outstanding at October 31, 2019 1,445 $ 36 The options outstanding and exercisable for equity share-based payment awards at October 31, 2019 were as follows: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate Intrinsic Value Number Exercisable Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate Intrinsic Value (in thousands) (in years) (in thousands) (in thousands) (in years) (in thousands) $25.01 - 30 483 2.5 $ 26 23,769 483 2.5 $ 26 23,769 $30.01 - 40 296 4.1 $ 39 10,845 296 4.1 $ 39 10,845 $40.01 - over 666 5.0 $ 41 23,211 666 5.0 $ 41 23,211 1,445 4.0 $ 36 $ 57,825 1,445 4.0 $ 36 $ 57,825 The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value, based on the company's closing stock price of $75.75 at October 31, 2019 , which would have been received by award holders had all award holders exercised their awards that were in-the-money as of that date. The total number of in-the-money awards exercisable at October 31, 2019 was approximately 1.4 million . The following table summarizes the aggregate intrinsic value of options exercised in 2019 , 2018 and 2017 : Aggregate Intrinsic Value Weighted Average Exercise Price (in thousands) Options exercised in fiscal 2017 $ 36,175 $ 30 Options exercised in fiscal 2018 $ 28,417 $ 32 Options exercised in fiscal 2019 $ 24,409 $ 33 As of October 31, 2019 , the unrecognized share-based compensation costs for outstanding stock option awards, net of expected forfeitures, was zero . The amount of cash received from the exercise of share-based awards granted was $54 million in 2019 , $56 million in 2018 and $66 million in 2017 . Non-Vested Awards The following table summarizes non-vested award activity in 2019 primarily for our LTPP and restricted stock unit awards. Shares Weighted Average Grant Price (in thousands) Non-vested at October 31, 2018 3,181 $ 57 Granted 1,309 $ 68 Vested (1,530 ) $ 45 Forfeited (78 ) $ 60 Change in LTPP shares in the year due to exceeding performance targets 291 $ — Non-vested at October 31, 2019 3,173 $ 60 As of October 31, 2019 , the unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures, was approximately $94 million which is expected to be amortized over a weighted average period of 2.2 years. The total fair value of restricted stock awards vested was $69 million for 2019 , $58 million for 2018 and $42 million for 2017 .

INCOME TAXES

INCOME TAXES	12 Months Ended
INCOME TAXES	Oct. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The domestic and foreign components of income before taxes are: Years Ended October 31, 2019 2018 2017 (in millions) U.S. operations $ 189 $ 169 $ 116 Non-U.S. operations 730 777 687 Total income before taxes $ 919 $ 946 $ 803 The provision for income taxes is comprised of: Years Ended October 31, 2019 2018 2017 (in millions) U.S. federal taxes: Current $ (191 ) $ 520 $ 15 Deferred — 51 110 Non-U.S. taxes: Current 290 95 1 Deferred (267 ) (22 ) (7 ) State taxes, net of federal benefit: Current 4 1 1 Deferred 12 (15 ) (1 ) Total provision (benefit) $ (152 ) $ 630 $ 119 The differences between the U.S. federal statutory income tax rate and our effective tax rate are: Years Ended October 31, 2019 2018 2017 (in millions) Profit before tax times statutory rate $ 193 $ 221 $ 281 Non-U.S. income taxed at different rates (8 ) (93 ) (43 ) Change in unrecognized tax benefits (13 ) (17 ) (110 ) Impact of the Tax Act — 552 — Extension of the tax incentive in Singapore (299 ) — — Other, net (25 ) (33 ) (9 ) Provision (benefit) for income taxes $ (152 ) $ 630 $ 119 Effective tax rate (16.5 )% 66.6 % 14.8 % For 2019, the company's income tax benefit was $152 million with an effective tax rate of (16.5) percent . For the year ended October 31, 2019, our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete benefit of $299 million related to the extension of the company’s tax incentive in Singapore. As part of the business integration of some of our prior acquisitions, we undertook corporate restructurings in the fourth quarter of fiscal year 2019 that involved on-shoring certain intangible properties held by our foreign subsidiaries to the United States. These restructurings resulted in a cash tax liability of $231 million . These taxes generate tax attributes that will offset our transition tax liability which is included in other long-term liabilities in our consolidated balance sheet. For 2018, the company's income tax expense was $630 million with an effective tax rate of 66.6 percent . For the year ended October 31, 2018, our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete charge of $552 million related to the enactment of the U.S. Tax Cuts and Jobs Act (the “Tax Act”) as discussed below. For 2017, the company’s income tax expense was $119 million with an effective tax rate of 14.8 percent . Our effective tax rate is impacted by earnings realized in foreign jurisdictions with statutory tax rates lower than the federal statutory tax rate. During the year, the company determined a portion of current year foreign earnings from its low tax jurisdictions would not be considered as indefinitely reinvested. As such, a deferred tax liability for that portion of unremitted foreign earnings was accrued causing an increase in the annual tax expense. Our annual effective tax rate also included tax benefits due to the settlement of an audit in Germany for the years 2005 through 2008 and the lapse of U.S. statute of limitation for the fiscal years 2012 and 2013. This benefit was offset by a deferred tax liability required for the tax expected upon repatriation of related unremitted foreign earnings that were not asserted as indefinitely invested outside the U.S. The company has negotiated tax holidays in several different jurisdictions, most significantly in Singapore. The tax holidays provide lower rates of taxation on certain classes of income and require various thresholds of investments and employment or specific types of income in those jurisdictions. In December 2018, the tax holiday in Singapore was renegotiated and extended through 2027. Other tax holidays are due for renewal in 2020. As a result of the incentives, the impact of the tax holidays decreased income taxes by $368 million , $87 million , and $93 million in 2019 , 2018 , and 2017 , respectively. The benefit of the tax holidays on net income per share (diluted) was approximately $1.16 , $0.27 , and $0.29 in 2019 , 2018 and 2017 , respectively. The increase in the benefit from 2018 to 2019 is primarily due to the Singapore restructuring and tax incentive modifications completed in 2019 in response to Singapore tax law changes. Of the $1.16 benefit of the tax incentives on net income per share (diluted) in 2019, $0.94 of the benefit relates to one-time items from the Singapore restructuring. 2017 U.S. Tax Reform - Tax Cuts and Jobs Act On December 22, 2017, the Tax Act was enacted into law. The Tax Act enacted significant changes affecting our fiscal year 2018, including, but not limited to, (1) reducing the U.S. federal corporate tax rate and (2) imposing a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries that had not been previously taxed in the U.S. The Tax Act also established new tax provisions affecting our fiscal year 2019, including, but not limited to, (1) creating a new provision designed to tax global intangible low-tax income (“GILTI”); (2) generally eliminating U.S. federal taxes on dividends from foreign subsidiaries; (3) eliminating the corporate alternative minimum tax (“AMT”); (4) creating the base erosion anti-abuse tax (“BEAT”); (5) establishing a deduction for foreign derived intangible income ("FDII"); (6) repealing domestic production activity deduction; and (7) establishing new limitations on deductible interest expense and certain executive compensation. ASC 740, Income Taxes, requires companies to recognize the effect of the tax law changes in the period of enactment. However, the SEC staff issued Staff Accounting Bulletin 118 ("SAB 118") which allowed companies to record provisional amounts during a measurement period not extending beyond one year from the Tax Act enactment date. For the year ended October 31, 2018, the company recognized income tax expense related to the Tax Act of $552 million which includes (1) an expense of $499 million of U.S. transition tax and correlative items on deemed repatriated earnings of non-U.S. subsidiaries and (2) an expense of $53 million associated with the impact on deferred taxes resulting from the decreased U.S. corporate tax rate as described below. Deemed Repatriation Transition Tax ("Transition Tax") : The Transition Tax is based on the company’s total unrepatriated post-1986 earnings and profits ("E&P") of its foreign subsidiaries and the amount of non-U.S. taxes paid (Tax Pools) on such earnings. Historically, the company permanently reinvested a significant portion of these post-1986 E&P outside the U.S. For the remaining portion, the company previously accrued deferred taxes. Since the Tax Act required all foreign earnings to be taxed currently, the company recorded an income tax expense of $651 million for its one-time transition U.S. federal tax and a benefit of $152 million for the reversal of related deferred tax liabilities. The resulting $499 million net transition tax, reduced by existing tax credits, will be paid over 8 years in accordance with the election available under the Tax Act. We have completed our accounting for charges related to the Transition Tax. Reduction of U.S. Federal Corporate Tax Rate : The reduction of the corporate income tax rate requires companies to remeasure their deferred tax assets and liabilities as of the date of enactment. The amount recorded for the year ended October31, 2018 for the remeasurement due to tax rate change is $53 million . We have completed our accounting for the measurement of deferred taxes. GILTI: The Tax Act subjects a U.S. corporation to tax on its GILTI. U.S. GAAP allows companies to make an accounting policy election to either (1) treat taxes due on future GILTI inclusions in the U.S. taxable income as a current-period expense when incurred (“period cost method”) or (2) factoring such amounts into a company’s measurement of its deferred taxes (“deferred method”). We have completed our analysis and elected to treat GILTI as a “current period cost”. Indefinite Reinvestment Assertion: Prior to the enactment of the Tax Act, the company had indefinite investment assertion on a significant portion of its undistributed earnings from foreign subsidiaries. As a result of the enactment of the Tax Act, we have reevaluated our historic assertion and no longer consider these earnings to be indefinitely reinvested in our foreign subsidiaries. The company has recorded a deferred tax liability of $10 million for foreign withholding taxes on repatriation of remaining undistributed earnings. The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are: Years Ended October 31, 2019 2018 (in millions) Deferred Tax Assets Intangibles $ 131 $ — Property, plant and equipment — 8 Pension benefits and retiree medical benefits 71 49 Employee benefits, other than retirement 34 34 Net operating loss, capital loss, and credit carryforwards 195 185 Share-based compensation 32 31 Deferred revenue 38 38 Other 35 19 Deferred tax assets $ 536 $ 364 Tax valuation allowance (134 ) (135 ) Deferred tax assets, net of valuation allowance $ 402 $ 229 Deferred Tax Liabilities Intangibles $ — $ (112 ) Property, plant and equipment (16 ) — Other (7 ) (21 ) Deferred tax liabilities $ (23 ) $ (133 ) Net deferred tax assets (liabilities) $ 379 $ 96 The increase in 2019 as compared to 2018 for the deferred tax asset and liabilities was primarily due to the benefit of $299 million related to the extension of the company’s tax incentive in Singapore. Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. As of October 31, 2019 , we continued to maintain a valuation allowance of $134 million until sufficient positive evidence exists to support reversal. The valuation allowance is primarily related to deferred tax assets for the states of California and Colorado, along with the net operating losses in the Netherlands and capital losses in the U.S. and Australia. At October 31, 2019 , we had federal, state and foreign net operating loss carryforwards of approximately $48 million , $571 million and $577 million , respectively. The federal and state net operating loss carryforwards are subject to various limitations under Section 382 of the Internal Revenue Code and applicable state tax laws. If not utilized, the federal and state net operating loss carryforwards will begin to expire in 2020. If not utilized, $155 million of the foreign net operating loss carryforwards will begin to expire in 2020. The remaining $422 million of the foreign net operating losses carry forward indefinitely. At October 31, 2019 , we had federal and foreign capital loss carryforwards of $48 million and $116 million , respectively. If not utilized, the federal capital loss carryforwards will expire in 2022. The foreign capital losses carry forward indefinitely. At October 31, 2019 , we had state tax credit carryforwards of approximately $78 million . The state tax credits carry forward indefinitely. The breakdown between long-term deferred tax assets and deferred tax liabilities was as follows: October 31, 2019 2018 (in millions) Long-term deferred tax assets (included within other assets) $ 410 $ 165 Long-term deferred tax liabilities (included within other long-term liabilities) (31 ) (69 ) Total $ 379 $ 96 The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows: October 31, 2019 2018 (in millions) Current income tax assets (included within other current assets) $ 68 $ 59 Long-term income tax assets (included within other assets) 4 19 Current income tax liabilities (included within other accrued liabilities) (292 ) (71 ) Long-term income tax liabilities (included within other long-term liabilities) (328 ) (607 ) Total $ (548 ) $ (600 ) Uncertain Tax Positions The aggregate changes in the balances of our gross unrecognized tax benefits including all federal, state and foreign tax jurisdictions are as follows: 2019 2018 2017 (in millions) Balance, beginning of year $ 214 $ 224 $ 293 Additions for tax positions related to the current year 7 27 32 Additions for tax positions from prior years 12 2 1 Reductions for tax positions from prior years (2 ) (13 ) (3 ) Settlements with taxing authorities — — (52 ) Statute of limitations expirations (25 ) (26 ) (47 ) Balance, end of year $ 206 $ 214 $ 224 As of October 31, 2019 , we had $227 million of unrecognized tax benefits, including interest and penalties of which $204 million , if recognized, would affect our effective tax rate. However, approximately $23 million of the unrecognized tax benefits were related to state income tax positions that, if recognized, would be in the form of a deferred tax asset that would likely not affect our effective tax rate due to a valuation allowance. We recognized a tax expense of $9 million , a tax expense of $11 million and a tax benefit of $9 million of interest and penalties related to unrecognized tax benefits in 2019 , 2018 and 2017 , respectively. Interest and penalties accrued as of October 31, 2019 and 2018 were $36 million and $27 million , respectively. In the U.S., tax years remain open back to the year 2016 for federal income tax purposes and the year 2015 for significant states. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2009. With these jurisdictions and the U.S., it is reasonably possible that there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement which will be partially offset by an anticipated tax liability related to unremitted foreign earnings, where applicable. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits.

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE	12 Months Ended
NET INCOME (LOSS) PER SHARE	Oct. 31, 2019
Earnings Per Share [Abstract]
NET INCOME (LOSS) PER SHARE	NET INCOME PER SHARE The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below. Years Ended October 31, 2019 2018 2017 (in millions) Numerator: Net income $ 1,071 $ 316 $ 684 Denominators: Basic weighted average shares 314 321 $ 322 Potential common shares — stock options and other employee stock plans 4 4 4 Diluted weighted average shares 318 325 326 The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards. We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share, stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value collectively were greater than the average market price of our common stock because their effect would also be anti-dilutive. In 2019 , 2018 and 2017 , we issued approximately 2 million , 2 million and 3 million , of share-based awards, respectively. For the years ended 2019 , 2018 and 2017 , the impact of the anti-dilutive potential common shares that were excluded from the calculation of diluted earnings per share was not material.

INVENTORY

INVENTORY	12 Months Ended
INVENTORY	Oct. 31, 2019
Inventory Disclosure [Abstract]
INVENTORY	INVENTORY October 31, 2019 2018 (in millions) Finished goods $ 416 $ 386 Purchased parts and fabricated assemblies 263 252 Inventory $ 679 $ 638 Inventory-related excess and obsolescence charges of $19 million were recorded in cost of products in 2019 , $26 million in 2018 and $24 million in 2017 . We record excess and obsolete inventory charges for both inventory on our site as well as inventory at our contract manufacturers and suppliers where we have non-cancelable purchase commitments.

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	12 Months Ended
PROPERTY, PLANT AND EQUIPMENT, NET	Oct. 31, 2019
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	PROPERTY, PLANT AND EQUIPMENT, NET October 31, 2019 2018 (in millions) Land $ 57 $ 55 Buildings and leasehold improvements 1,012 952 Machinery and equipment 546 512 Software 160 141 Total property, plant and equipment 1,775 1,660 Accumulated depreciation and amortization (925 ) (838 ) Property, plant and equipment, net $ 850 $ 822 There were no asset impairments in 2019 and 2017 and less than $1 million asset impairments in 2018 . Depreciation expenses were $111 million in 2019 , $102 million in 2018 and $94 million in 2017 . In 2019 we retired approximately $23 million of fully depreciated assets that were no longer in use.

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	12 Months Ended
GOODWILL AND OTHER INTANGIBLE ASSETS	Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2018 and 2019 : Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2017 $ 773 $ 1,330 $ 504 $ 2,607 Foreign currency translation impact (7 ) (4 ) (4 ) (15 ) Goodwill arising from acquisitions 37 281 63 381 Goodwill as of October 31, 2018 $ 803 $ 1,607 $ 563 $ 2,973 Foreign currency translation impact (1 ) (2 ) (2 ) (5 ) Goodwill arising from acquisitions and adjustments 636 (11 ) — 625 Goodwill as of October 31, 2019 $ 1,438 $ 1,594 $ 561 $ 3,593 As of September 30, 2019 , our annual impairment test date, we assessed goodwill impairment for our reporting units and no impairment was indicated. The component parts of other intangible assets at October 31, 2018 and 2019 are shown in the table below: Other Intangible Assets Gross Accumulated Net Book (in millions) As of October 31, 2018: Purchased technology $ 947 $ 683 $ 264 Trademark/Tradename 151 88 63 Customer relationships 107 63 44 Third-party technology and licenses $ 28 $ 19 $ 9 Total amortizable intangible assets $ 1,233 $ 853 $ 380 In-Process R&D 111 — 111 Total $ 1,344 $ 853 $ 491 As of October 31, 2019: Purchased technology $ 1,413 $ 763 $ 650 Backlog 5 5 — Trademark/Tradename 196 102 94 Customer relationships 329 87 242 Third-party technology and licenses $ 28 $ 22 $ 6 Total amortizable intangible assets $ 1,971 $ 979 $ 992 In-Process R&D 115 — 115 Total $ 2,086 $ 979 $ 1,107 In 2019, we acquired two businesses, BioTek and ACEA, for a combined purchase price of approximately $1.4 billion . See Note 3, "Acquisitions", for additional information. During fiscal year 2019 , w e recorded additions to goodwill of $636 million and to other intangible assets of $744 million related to the acquisition of ACEA and BioTek. In the second quarter of fiscal year 2019, we recorded a measurement period adjustment to goodwill of $11 million for deferred tax assets related to pre-acquisition net operating losses of Advanced Analytical Technologies, Inc. The increase to other intangible assets due to foreign currency translation was not material in 2019. During fiscal year 2018 , we recorded additions to goodwill of $381 million and to intangible assets of $262 million related to the acquisition of seven businesses. During the year other intangible assets decreased $1 million , due to the impact of foreign exchange translation. In general, for United States federal tax purposes, goodwill from asset purchases is amortizable however any goodwill created as part of a stock acquisition is not deductible. In 2019 , there were no impairments of other intangible assets recorded. During 2018 , we recorded an impairment charge of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable. In 2017 , there were no impairments of other intangible assets recorded. Amortization expense of intangible assets was $128 million in 2019 , $110 million in 2018 , and $120 million in 2017 . Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) 2020 $ 186 2021 $ 172 2022 $ 150 2023 $ 107 2024 $ 86 Thereafter $ 291

INVESTMENTS

INVESTMENTS	12 Months Ended
INVESTMENTS	Oct. 31, 2019
Schedule of Investments [Abstract]
INVESTMENTS	INVESTMENTS The following table summarizes the company's equity investments as of October 31, 2019 and 2018 (net book value): October 31, 2019 2018 (in millions) Long-Term Equity investments - without readily determinable fair value $ 47 $ 23 Equity investments - with readily determinable fair value 25 15 Trading securities 30 30 Total $ 102 $ 68 Equity investments without readily determinable fair value (RDFV) consist of non-marketable equity securities issued by private companies. These investments are accounted for using the measurement alternative at cost adjusting for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer). The adjustments are included in net income in the period in which they occur. Equity investments with RDFV consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Prior to fiscal year 2019, both equity investments without RDFV and with RDFV were accounted for using cost method of accounting, measured at historical cost less other-than-temporary impairment. Trading securities are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in earnings. During 2018, we acquired all of the remaining shares of Lasergen, Inc. (Lasergen), for an additional cash consideration of approximately $107 million , an investment that was accounted for under the cost method in 2017 for approximately $80 million . The fair value remeasurement of our previous investment immediately before the acquisition resulted in a net gain of $20 million and was recorded in other income. Our investments without RDFV, are subject to periodic impairment review. The impairment analysis requires significant judgment to identify events or circumstances that would likely have significant adverse effect on the future value of the investment. Net unrealized gains on our equity securities with RDFV were $3 million in 2019. Net unrealized gains on our equity securities without RDFV were not material in 2019. Upon adoption of new accounting guidance relating to financial instruments beginning fiscal year 2019, the gains and losses on such securities are recognized in other income (expense) and therefore not applicable in prior periods. As of November 1, 2019, total impact of adoption of said accounting guidance to our consolidated balance sheet was an increase of $7 million to equity securities with RDFV (included within long-term investments) and a net increase of $5 million to beginning retained earnings. Net unrealized gains on our trading securities portfolio were $3 million in 2019 , $1 million in 2018 and $4 million in 2017 .

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
FAIR VALUE MEASUREMENTS	Oct. 31, 2019
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	12. FAIR VALUE MEASUREMENTS The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability. Fair Value Hierarchy The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value: Level 1 — applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 — applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data. Level 3 — applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2019 were as follows: Fair Value Measurement at October 31, 2019 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 784 $ 784 $ — $ — Derivative instruments (foreign exchange contracts) 12 — 12 — Long-term Trading securities 30 30 — — Other investments 25 — 25 — Total assets measured at fair value $ 851 $ 814 $ 37 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 6 $ — $ 6 $ — Long-term Deferred compensation liability 30 — 30 — Total liabilities measured at fair value $ 36 $ — $ 36 $ — Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2018 were as follows: Fair Value Measurement at October 31, 2018 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,355 $ 1,355 $ — $ — Derivative instruments (foreign exchange contracts) 16 — 16 — Long-term Trading securities 30 30 — — Total assets measured at fair value $ 1,401 $ 1,385 $ 16 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Long-term Deferred compensation liability 30 — 30 — Total liabilities measured at fair value $ 35 $ — $ 35 $ — Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on quoted market prices, the inputs used in the calculations are observable. Other investments represent shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities. It has been classified as level 2 because, although the shares of the fund are not traded on any active stock exchange, each of the individual underlying securities are and hence we have a readily determinable value for the underlying securities, from which we are able to determine the fair market value for the special fund itself. Trading securities, which is comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive loss within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis Long-Lived Assets For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income for the years ended October 31, 2019 , 2018 and 2017 : Years Ended October 31, 2019 2018 2017 (in millions) Long-lived assets held and used $ — $ 21 $ — Long-lived assets held for sale $ — $ — $ — There were no impairments of long-lived assets held and used in 2019 and 2017. For 2018, long lived assets held and used with a carrying amount of $21 million were written down to their fair value of zero , resulting in an impairment charge of $21 million , which relates to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable and was included in net income. There were no impairments of long-lived assets held for sale in 2019, 2018 and 2017. Fair values for the impaired long-lived assets during 2018 were measured using level 3 inputs. To determine the fair value of long-lived assets in 2018, we used the income approach based on projected discounted cash flows expected to be generated by the long-lived assets over the remaining useful life. For 2019, there were no impairments or material changes in non-marketable securities without readily determinable fair value. As of October 31, 2019 and October 31, 2018, the carrying amount of non-marketable equity securities without readily determinable fair values was $47 million and $23 million , respectively. Fair values for the non-marketable securities included in long-term investments on the consolidated balance sheet were measured using Level 3 inputs because they are primarily equity stock issued by private companies without quoted market prices. To estimate the fair value of our non-marketable securities, we use the measurement alternative to record these investments at cost and to adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) as and when it occurs.

DERIVATIVES

DERIVATIVES	12 Months Ended
DERIVATIVES	Oct. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES	13. DERIVATIVES We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates. Fair Value Hedges We are exposed to interest rate risk due to the mismatch between the interest expense we pay on our loans at fixed rates and the variable rates of interest we receive from cash, cash equivalents and other short-term investments. We have issued long-term debt in U.S. dollars at fixed interest rates based on the market conditions at the time of financing. The fair value of our fixed rate debt changes when the underlying market rates of interest change, and, in the past, we have used interest rate swaps to change our fixed interest rate payments to U.S. dollar LIBOR-based variable interest expense to match the floating interest income from our cash, cash equivalents and other short-term investments. As of October 31, 2019 , all interest rate swap contracts had either been terminated or had expired. On August 9, 2011, we terminated five interest rate swap contracts related to our 2020 senior notes that represented the notional amount of $500 million . On September 17, 2019, the 2020 senior notes were redeemed, and the remaining gain associated with the terminated interest rate swap contracts was realized. Cash Flow Hedges We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. For open contracts as of October 31, 2019 and entered into on or after November 1, 2018, changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the foreign exchange contract. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified to cost of sales in the consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense), net in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense), net in the consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the option contract. For the years ended October 31, 2019 , 2018 and 2017 , ineffectiveness and gains and losses recognized in other income (expense),net due to de-designation of cash flow hedge contracts were not significant. In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 10, 2012. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at October 31, 2019 was $1 million . In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of $ 10 million and we recognized this as a deferred loss in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2019 was $7 million . In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 5, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss of $6 million in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at October 31, 2019 was $6 million . Other Hedges Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative instruments are recognized in other income (expense),net in the consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities. Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties. A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions. The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of October 31, 2019 , was $2 million . The credit-risk-related contingent features underlying these agreements had not been triggered as of October 31, 2019 . There were 261 foreign exchange forward contracts open as of October 31, 2019 and designated as cash flow hedges. There were 205 foreign exchange forward contracts open as of October 31, 2019 not designated as hedging instruments. The aggregated notional amounts by currency and designation as of October 31, 2019 were as follows: Derivatives Designated as Derivatives Not Designated as Hedging Instruments Forward Forward Currency Buy/(Sell) Buy/(Sell) (in millions) Euro $ (40 ) $ 141 British Pound (45 ) 1 Canadian Dollar (38 ) 25 Australian Dollar 4 — Malaysian Ringgit — 11 Japanese Yen (82 ) (7 ) Danish Krone — 237 Korean Won (59 ) (32 ) Singapore Dollar 14 28 Swiss Franc — (2 ) Chinese Yuan Renminbi (59 ) (70 ) Swedish Krona — (8 ) Other — (23 ) $ (305 ) $ 301 Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of October 31, 2019 and 2018 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location October 31, October 31, Balance Sheet Location October 31, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 3 $ 11 Other accrued liabilities $ 2 $ 1 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 9 $ 5 Other accrued liabilities $ 4 $ 4 Total derivatives $ 12 $ 16 $ 6 $ 5 The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows: Years Ended October 31, 2019 2018 2017 (in millions) Derivatives designated as hedging instruments: Cash flow hedges Loss on interest rate swaps recognized in other comprehensive income (loss) $ (6 ) $ — $ — Loss reclassified from accumulated other comprehensive income into interest expense $ (1 ) $ (1 ) $ — Gain (loss) recognized in accumulated other comprehensive income (loss) $ — $ 7 $ — Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales $ 9 $ (3 ) $ 1 Gain (loss) on time value of forward contracts recorded in cost of sales $ 2 $ — $ — Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense), net $ 2 $ (2 ) $ 5 At October 31, 2019 the estimated amount of existing net gain that is expected to be reclassified from accumulated other comprehensive income to cost of sales within the next twelve months is $4 million .

RETIREMENT PLANS AND POST RETIR

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	12 Months Ended
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	Oct. 31, 2019
Defined Benefit Plan [Abstract]
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS General. Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Agilent provides defined benefits to U.S. employees, who meet eligibility criteria under the Agilent Technologies, Inc. Retirement Plan (the "RP"). For eligible service through October 31, 1993, the benefit payable under the Agilent Retirement Plan is reduced by any amounts due to the eligible employee under the Agilent defined contribution Deferred Profit-Sharing Plan (the "DPSP"), which was closed to new participants as of November 1993. As of October 31, 2019 and 2018 , the fair value of plan assets of the DPSP was $132 million and $141 million , respectively. Note that the projected benefit obligation for the DPSP equals the fair value of plan assets. Effective November 1, 2014, Agilent’s U.S. defined benefit retirement plan was closed to new entrants including new employees, new transfers to the U.S. payroll and rehires. As of April 30, 2016, benefits under the RP were frozen. Any pension benefit earned in the U.S. Plans through April 30, 2016 remained fully vested, and there are no additional benefit accruals after April 30, 2016. Agilent also maintains a Supplemental Benefits Retirement Plan ("SBRP") in the U.S., which is a supplemental unfunded non-qualified defined benefit plan to provide benefits that would be provided under the RP but for limitations imposed by the Internal Revenue Code. The RP and the SBRP comprise the "U.S. Plans" in the tables below. Eligible employees outside the U.S. generally receive retirement benefits under various retirement plans based upon factors such as years of service and/or employee compensation levels. Eligibility is generally determined in accordance with local statutory requirements. Post-Retirement Medical Benefit Plans. In addition to receiving retirement benefits, Agilent U.S. employees who meet eligibility requirements as of their termination date may participate in the Agilent Technologies, Inc. Health Plan for Retirees. – Eligible retirees who were less than age 50 as of January 1, 2005 and who retire after age 55 with 15 or more years of service are eligible for a fixed amount which can be utilized to pay for either sponsored plans and/or individual Medicare plans. – Effective January 1, 2012, employees who were at least age 50 as of January 1, 2005 and who retire after age 55 with 15 or more years of service are eligible for fixed dollar subsidies and stipends. Grandfathered retirees receive a fixed monthly subsidy toward pre-65 premium costs (subsidy capped at 2011 levels) and a fixed monthly stipend post-65. The subsidy amounts will not increase. – Any new employee hired on or after November 1, 2014, will not be eligible to participate in the retiree medical plans upon retiring. – As of April 30, 2016, benefits under this plan were changed for Active employees who have not met the eligibility requirement - 55 years old with at least 15 years of Agilent service, as of April 30, 2016 - for the Retiree Medical Account (RMA) under the U.S. Post Retirement Benefit Plan These employees will only be eligible for 50 percent of the current RMA reimbursement amount upon retirement. 401(k) Defined Contribution Plan . Eligible Agilent U.S. employees may participate in the Agilent Technologies, Inc. 401(k) Plan. Effective April 30, 2016, we began matching contributions to employees up to a maximum of 6 percent of an employee's annual eligible compensation. Effective May 1, 2016 until April 30, 2022, we will provide an additional transitional company contribution for certain eligible employees equal to 3 percent , 4 percent or 5 percent of an employee's annual eligible compensation due to the RP benefits being frozen. The maximum contribution to the 401(k) Plan is 50 percent of an employee's annual eligible compensation, subject to regulatory limitations. The 401(k) Plan employer expense included in income from operations was $39 million in 2019 , $37 million in 2018 and $33 million in 2017 . Japanese Welfare Pension Insurance Law . In Japan, Agilent has employees' pension fund plans, which are defined benefit pension plans established under the Japanese Welfare Pension Insurance Law (JWPIL). The plans are composed of (a) a substitutional portion based on the pay-related part of the old-age pension benefits prescribed by JWPIL (similar to social security benefits in the United States) and (b) a corporate portion based on a contributory defined benefit pension arrangement established at the discretion of the company. During the year ended October 31, 2017 , Agilent received government approval and returned the substitutional portion of Japan's pension plan to the Japanese government, as allowed by the JWPIL. The initial transfer resulted in a net gain of $32 million recorded in other income (expense), net in the consolidated statement of operations. The net gain consisted of two parts - a gain of $41 million , representing the difference between the fair values of the Accumulated Benefit Obligation (ABO) settled of $65 million and the assets transferred from the pension trust to the government of Japan of $24 million , offset by a settlement loss of $9 million related to the recognition of previously unrecognized actuarial losses included in accumulated other comprehensive income. In the first quarter of fiscal year 2018, after the Japanese government’s final review of our initial payment, we received a refund of $5 million which was recorded as a settlement gain. Components of Net periodic cost. The service cost component is recorded in cost of sales and operating expenses in the consolidated statement of operations. All other cost components are recorded in other income (expense), net in the consolidated statement of operations. The company uses alternate methods of amortization as allowed by the authoritative guidance which amortizes the actuarial gains and losses on a consistent basis for the years presented. For U.S. Plans, gains and losses are amortized over the average future lifetime of participants using the corridor method. For most Non-U.S. Plans and U.S. Post-Retirement Benefit Plans, gains and losses are amortized using a separate layer for each year's gains and losses. For the years ended October 31, 2019 , 2018 and 2017 , components of net periodic benefit cost and other amounts recognized in other comprehensive income were comprised of: Pensions U.S. Post-Retirement Benefit Plans U.S. Plans Non-U.S. Plans 2019 2018 2017 2019 2018 2017 2019 2018 2017 (in millions) Net periodic benefit cost (benefit) Service cost — benefits earned during the period $ — $ — $ — $ 20 $ 20 $ 19 $ — $ 1 $ 1 Interest cost on benefit obligation 18 16 15 14 13 12 4 3 3 Expected return on plan assets (27 ) (28 ) (25 ) (43 ) (46 ) (41 ) (7 ) (7 ) (7 ) Amortization of net actuarial loss 1 1 3 34 29 36 4 8 11 Amortization of prior service benefit — — — — — — (8 ) (8 ) (9 ) Total periodic benefit cost (benefit) $ (8 ) $ (11 ) $ (7 ) $ 25 $ 16 $ 26 $ (7 ) $ (3 ) $ (1 ) Curtailments and settlements $ — $ — $ — $ — $ (5 ) $ (32 ) $ — $ — $ — Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss Net actuarial (gain) loss $ 51 $ 2 $ (19 ) $ 104 $ 49 $ (128 ) $ 5 $ (2 ) $ (9 ) Amortization of net actuarial loss (1 ) (1 ) (3 ) (34 ) (29 ) (36 ) (4 ) (8 ) (11 ) Prior service cost (benefit) — — — — — — — — — Amortization of prior service benefit — — — — — — 8 8 9 Gain due to settlement — — — — — 32 — — — Foreign currency — — — (3 ) 1 2 — — — Total recognized in other comprehensive (income) loss $ 50 $ 1 $ (22 ) $ 67 $ 21 $ (130 ) $ 9 $ (2 ) $ (11 ) Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss $ 42 $ (10 ) $ (29 ) $ 92 $ 32 $ (136 ) $ 2 $ (5 ) $ (12 ) Funded Status. As of October 31, 2019 and 2018 , the funded status of the defined benefit and post-retirement benefit plans was: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans 2019 2018 2019 2018 2019 2018 (in millions) Change in fair value of plan assets: Fair value — beginning of year $ 401 $ 414 $ 825 $ 855 $ 90 $ 95 Actual return on plan assets 50 8 85 (9 ) 11 1 Employer contributions — — 21 21 — — Participants' contributions — — 1 — — — Benefits paid (19 ) (21 ) (29 ) (26 ) (6 ) (6 ) Settlements — — — 5 — — Currency impact — — 8 (21 ) — — Fair value — end of year $ 432 $ 401 $ 911 $ 825 $ 95 $ 90 Change in benefit obligation: Benefit obligation — beginning of year $ 420 $ 445 $ 913 $ 935 $ 87 $ 97 Service cost — — 20 20 — 1 Interest cost 18 16 14 13 4 3 Participants' contributions — — 1 — — — Plan amendment — — — 1 — — Actuarial (gain) loss 74 (19 ) 143 (6 ) 9 (7 ) Benefits paid (21 ) (22 ) (29 ) (27 ) (6 ) (7 ) Currency impact — — 5 (23 ) — — Benefit obligation — end of year $ 491 $ 420 $ 1,067 $ 913 $ 94 $ 87 Overfunded (underfunded) status of PBO $ (59 ) $ (19 ) $ (156 ) $ (88 ) $ 1 $ 3 Amounts recognized in the consolidated balance sheet consist of: Other assets $ — $ — $ 106 $ 95 $ 1 $ 3 Employee compensation and benefits (1 ) (1 ) — — — — Retirement and post-retirement benefits (58 ) (18 ) (262 ) (183 ) — — Total net asset (liability) $ (59 ) $ (19 ) $ (156 ) $ (88 ) $ 1 $ 3 Amounts Recognized in Accumulated Other Comprehensive Income (loss): Actuarial (gains) losses $ 115 $ 65 $ 330 $ 263 $ 10 $ 10 Prior service costs (benefits) — — — — (12 ) (20 ) Total $ 115 $ 65 $ 330 $ 263 $ (2 ) $ (10 ) The amounts in accumulated other comprehensive income expected to be recognized by Agilent as components of net expense during 2020 are as follows: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans (in millions) Amortization of net prior service cost (benefit) $ — $ — $ (7 ) Amortization of actuarial net loss (gain) $ 3 $ 48 $ 4 Investment Policies and Strategies as of October 31, 2019 and 2018 . In the U.S., target asset allocations for our retirement and post-retirement benefit plans are approximately 80 percent to equities and approximately 20 percent to fixed income investments. Our DPSP target asset allocation is approximately 60 percent to equities and approximately 40 percent to fixed income investments. Approximately 3 percent of our U.S. equity portfolio consists of limited partnerships. The general investment objective for all our plan assets is to obtain the optimum rate of investment return on the total investment portfolio consistent with the assumption of a reasonable level of risk. Specific investment objectives for the plans' portfolios are to: maintain and enhance the purchasing power of the plans' assets; achieve investment returns consistent with the level of risk being taken; and earn performance rates of return in accordance with the benchmarks adopted for each asset class. Outside the U.S., our target asset allocation ranges from 31 to 60 percent to equities, from 38 to 61 percent to fixed income investments, and from zero to 25 percent to real estate, depending on the plan. All plans' assets are broadly diversified. Due to fluctuations in equity markets, our actual allocations of plan assets at October 31, 2019 and 2018 differ from the target allocation. Our policy is to bring the actual allocation in line with the target allocation. Equity securities include exchange-traded common stock and preferred stock of companies from broadly diversified industries. Fixed income securities include a global portfolio of corporate bonds of companies from diversified industries, government securities, mortgage-backed securities, asset-backed securities, derivative instruments and other. Other investments include a group trust consisting primarily of private equity partnerships. Portions of the cash and cash equivalent, equity, and fixed income investments are held in commingled funds that are valued using Net Asset Value (“NAV”) as the practical expedient. In addition, some of the investments valued using NAV as the practical expedient may have limits on their redemption to weekly or monthly and/or may require prior written notice specified by each fund. Fair Value. The measurement of the fair value of pension and post-retirement plan assets uses the valuation methodologies and the inputs as described in Note 12, "Fair Value Measurements". Cash and Cash Equivalents - Cash and cash equivalents consist of short-term investment funds. The funds also invest in short-term domestic fixed income securities and other securities with debt-like characteristics emphasizing short-term maturities and quality. Some of our cash and cash equivalents are held in commingled funds. Other cash and cash equivalents are classified as Level 1 investments. Equity - Some equity securities consisting of common and preferred stock that are not traded on an active market are valued at quoted prices reported by investment dealers based on the underlying terms of the security and comparison to similar securities traded on an active market; these are classified as Level 2 investments. Securities which have quoted prices in active markets are classified as Level 1 investments. Fixed Income - Some of the fixed income securities are not actively traded and are valued at quoted prices based on the terms of the security and comparison to similar securities traded on an active market; these are classified as Level 2 investments. Securities which have quoted prices in active markets are classified as Level 1 investments. Other Investments - Other investments also includes partnership investments where, due to their private nature, pricing inputs are not readily observable. Asset valuations are developed by the general partners that manage the partnerships. These valuations are based on proprietary appraisals, application of public market multiples to private company cash flows, utilization of market transactions that provide valuation information for comparable companies and other methods. Holdings of limited partnerships are classified as Level 3. Agilent has adopted the accounting guidance related to the presentation of certain investments using the NAV practical expedient. The accounting guidance exempts investments using this practical expedient from categorization within the fair value hierarchy. The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2019 and 2018 . Fair Value Measurement at October 31, 2019 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 1 $ — $ — $ — $ 1 Equity 336 78 — — 258 Fixed Income 91 46 — — 45 Other Investments 4 — — 4 — Total assets measured at fair value $ 432 $ 124 $ — $ 4 $ 304 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. Fair Value Measurement at October 31, 2018 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 4 $ — $ — $ — $ 4 Equity 308 69 — — 239 Fixed Income 83 36 5 — 42 Other Investments 6 — — 6 — Total assets measured at fair value $ 401 $ 105 $ 5 $ 6 $ 285 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2019 and 2018 : Years Ended October 31. 2019 2018 Balance, beginning of year $ 6 $ 7 Realized gains/(losses) (1 ) — Unrealized gains/(losses) 1 1 Purchases, sales, issuances, and settlements (2 ) (2 ) Transfers in (out) — — Balance, end of year $ 4 $ 6 The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2019 and 2018 . Fair Value Measurement at October 31, 2019 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 3 $ — $ — $ — $ 3 Equity 69 18 — — 51 Fixed Income 21 11 — — 10 Other Investments 2 — — 2 — Total assets measured at fair value $ 95 $ 29 $ — $ 2 $ 64 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. Fair Value Measurement at October 31, 2018 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 3 $ — $ — $ — $ 3 Equity 65 15 — — 50 Fixed Income 18 9 — — 9 Other Investments 4 — — 4 — Total assets measured at fair value $ 90 $ 24 $ — $ 4 $ 62 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2019 and 2018 : Years Ended October 31, 2019 2018 Balance, beginning of year $ 4 $ 4 Realized gains/(losses) (1 ) — Unrealized gains/(losses) — 1 Purchases, sales, issuances, and settlements (1 ) (1 ) Transfers in (out) — — Balance, end of year $ 2 $ 4 The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2019 and 2018 : Fair Value Measurement at October 31, 2019 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 1 $ — $ 1 $ — $ — Equity 512 318 61 — 133 Fixed Income 398 98 213 — 87 Other Investments — — — — — Total assets measured at fair value $ 911 $ 416 $ 275 $ — $ 220 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. Fair Value Measurement at October 31, 2018 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 2 $ — $ 2 $ — $ — Equity 489 298 60 — 131 Fixed Income 334 76 228 — 30 Other Investments — — — — — Total assets measured at fair value $ 825 $ 374 $ 290 $ — $ 161 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation ("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the plan assets as of October 31, 2019 or 2018 . 2019 2018 Benefit Obligation Benefit Obligation Fair Value of Plan Assets Fair Value of Plan Assets PBO PBO (in millions) U.S. defined benefit plans where PBO exceeds the fair value of plan assets $ 491 $ 432 $ 420 $ 401 U.S. defined benefit plans where fair value of plan assets exceeds PBO — — — — Total $ 491 $ 432 $ 420 $ 401 Non-U.S. defined benefit plans where PBO exceeds or is equal to the fair value of plan assets $ 752 $ 490 $ 563 $ 380 Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO 315 421 350 445 Total $ 1,067 $ 911 $ 913 $ 825 ABO ABO U.S. defined benefit plans where ABO exceeds the fair value of plan assets $ 491 $ 432 $ 420 $ 401 U.S. defined benefit plans where the fair value of plan assets exceeds ABO — — — — Total $ 491 $ 432 $ 420 $ 401 Non-U.S. defined benefit plans where ABO exceeds or is equal to the fair value of plan assets $ 651 $ 418 $ 543 $ 380 Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO 381 493 343 445 Total $ 1,032 $ 911 $ 886 $ 825 Contributions and Estimated Future Benefit Payments. During fiscal year 2020 , we do not expect to contribute to the U.S. defined benefit plans and the Post-Retirement Medical Plans. We expect to contribute $24 million to plans outside the U.S. The following table presents expected future benefit payments for the next 10 years: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans (in millions) 2020 $ 35 $ 25 $ 8 2021 $ 36 $ 27 $ 8 2022 $ 33 $ 29 $ 7 2023 $ 35 $ 32 $ 7 2024 $ 37 $ 32 $ 7 2025 - 2029 $ 146 $ 170 $ 35 Assumptions. The assumptions used to determine the benefit obligations and expense for our defined benefit and post-retirement benefit plans are presented in the tables below. The expected long-term return on assets below represents an estimate of long-term returns on investment portfolios consisting of a mixture of equities, fixed income and alternative investments in proportion to the asset allocations of each of our plans. We consider long-term rates of return, which are weighted based on the asset classes (both historical and forecasted) in which we expect our pension and post-retirement funds to be invested. Discount rates reflect the current rate at which pension and post-retirement obligations could be settled based on the measurement dates of the plans - October 31. The U.S. discount rates at October 31, 2019 and 2018 , were determined based on the results of matching expected plan benefit payments with cash flows from a hypothetically constructed bond portfolio. The non-U.S. rates were generally based on published rates for high-quality corporate bonds. The range of assumptions that were used for the non-U.S. defined benefit plans reflects the different economic environments within various countries. Assumptions used to calculate the net periodic cost in each year were as follows: For years ended October 31, 2019 2018 2017 U.S. defined benefit plans: Discount rate 4.50% 3.75% 3.75% Expected long-term return on assets 7.00% 7.00% 7.25% Non-U.S. defined benefit plans: Discount rate 0.83-2.68% 0.67-2.52% 0.22-2.66% Average increase in compensation levels 2.25-3.25% 2.00-3.25% 2.00-4.25% Expected long-term return on assets 4.00-5.75% 4.00-6.00% 4.00-6.25% U.S. post-retirement benefits plans: Discount rate 4.25% 3.50% 3.50% Expected long-term return on assets 7.00% 7.00% 7.25% Current medical cost trend rate 6.00% 6.00% 6.00% Ultimate medical cost trend rate 3.50% 3.50% 3.50% Medical cost trend rate decreases to ultimate rate in year 2029 2029 2029 Assumptions used to calculate the benefit obligation were as follows: As of the Years Ending October 31, 2019 2018 U.S. defined benefit plans: Discount rate 3.25% 4.50% Non-U.S. defined benefit plans: Discount rate 0.22-1.81% 0.83-2.68% Average increase in compensation levels 2.25-3.00% 2.25-3.25% U.S. post-retirement benefits plans: Discount rate 3.00% 4.25% Current medical cost trend rate 6.25% 6.00% Ultimate medical cost trend rate 4.50% 3.50% Medical cost trend rate decreases to ultimate rate in year 2029 2029 Health care trend rates do not have a significant effect on the total service and interest cost components or on the post-retirement benefit obligation amounts reported for the U.S. Post-Retirement Benefit Plan for the year ended October 31, 2019 .

GUARANTEES

GUARANTEES	12 Months Ended
GUARANTEES	Oct. 31, 2019
Guarantees [Abstract]
GUARANTEES	GUARANTEES Standard Warranty We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net product shipments. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our consolidated balance sheet. Our standard warranty terms typically extend to one years from the date of delivery, depending on the product. A summary of the standard warranty accrual activity is shown in the table below. The standard warranty accrual balances are recorded in other accrued liabilities. October 31, 2019 2018 (in millions) Balance as of October 31, 2018 and 2017 $ 35 $ 34 Accruals for warranties including change in estimates 54 53 Settlements made during the period (57 ) (52 ) Balance as of October 31, 2019 and 2018 $ 32 $ 35 Accruals for warranties due within one year 32 35 Bank Guarantees Guarantees consist primarily of outstanding standby letters of credit and bank guarantees and were approximately $40 million as of October 31, 2019. A standby letter of credit is a guarantee of payment issued by a bank on behalf of us that is used as payment of last resort should we fail to fulfill a contractual commitment with a third party. A bank guarantee is a promise from a bank or other lending institution that if we default on a loan, the bank will cover the loss. Indemnifications in Connection with Transactions In connection with various divestitures, acquisitions, spin-offs and other transactions, we have agreed to indemnify certain parties, their affiliates and/or other related parties against certain damages and expenses that might occur in the future. These indemnifications may cover a variety of liabilities, including, but not limited to, employee, tax, environmental, intellectual property, litigation and other liabilities related to the business conducted prior to the date of the transaction. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2019 . Indemnifications to Officers and Directors Our corporate bylaws require that we indemnify our officers and directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Agilent and such other entities, including service with respect to employee benefit plans. In addition, we have entered into separate indemnification agreements with each director and each board-appointed officer of Agilent which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in the bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated. Historically, we have not made payments related to these obligations, and the fair value for these indemnification obligations was not material as of October 31, 2019 . Other Indemnifications As is customary in our industry and as provided for in local law in the U.S. and other jurisdictions, many of our standard contracts provide remedies to our customers and others with whom we enter into contracts, such as defense, settlement, or payment of judgment for intellectual property claims related to the use of our products. From time to time, we indemnify customers, as well as our suppliers, contractors, lessors, lessees, companies that purchase our businesses or assets and others with whom we enter into contracts, against combinations of loss, expense, or liability arising from various triggering events related to the sale and the use of our products and services, the use of their goods and services, the use of facilities and state of our owned facilities, the state of the assets and businesses that we sell and other matters covered by such contracts, usually up to a specified maximum amount. In addition, from time to time we also provide protection to these parties against claims related to undiscovered liabilities, additional product liability or environmental obligations. In our experience, claims made under such indemnifications are rare and the associated estimated fair value of the liability was not material as of October 31, 2019 . In connection with the sale of several of our businesses, we have agreed to indemnify the buyers of such business, their respective affiliates and other related parties against certain damages that they might incur in the future. The continuing indemnifications primarily cover damages relating to liabilities of the businesses that Agilent retained and did not transfer to the buyers, as well as other specified items. In our opinion, the fair value of these indemnification obligations was not material as of October 31, 2019 .

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Oct. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	16. COMMITMENTS AND CONTINGENCIES Operating Lease Commitments: We lease certain real and personal property from unrelated third parties under non-cancelable operating leases. Certain leases require us to pay property taxes, insurance and routine maintenance, and include escalation clauses. Total rent expense was $75 million in 2019 , $64 million in 2018 and $57 million in 2017 . Future non-cancelable minimum lease payments and future minimum lease income under operating leases at October 31, 2019 : Future Minimum Future Minimum (in millions) 2020 $ 52 $ 8 2021 $ 41 $ 6 2022 $ 29 $ 5 2023 $ 21 $ — 2024 $ 14 $ — Thereafter $ 56 $ — Other Purchase Commitments. Typically, we can cancel contracts with professional services suppliers without penalties. For those contracts that are not cancelable without penalties, the termination fees and costs or commitments for continued spending that we are obligated to pay to a supplier under each contact's termination period before such contract can be cancelled were approximately $77 million . Approximately $25 million of the penalties for the new contracts will reduce over the next 14 years. Contingencies: We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.

SHORT-TERM DEBT

SHORT-TERM DEBT	12 Months Ended
SHORT-TERM DEBT	Oct. 31, 2019
Short-term Debt [Abstract]
SHORT-TERM DEBT	SHORT-TERM DEBT Credit Facilities On March 13, 2019 , Agilent entered into a credit agreement with a group of financial institutions which provides for a $1 billion five -year unsecured credit facility that will expire on March 13, 2024. The credit facility replaces the existing credit facility which terminated on the closing date of the new facility. For the year ended October 31, 2019 , we borrowed $305 million and repaid $190 million under the credit facility. As of October 31, 2019 , the company had borrowings of $115 million outstanding under the credit facility. We were in compliance with the covenants for the credit facility during the year ended October 31, 2019 . On August 7, 2019, we entered into an amendment to the credit agreement, which provides for a $500 million short-term loan facility that was used in full to complete the BioTek acquisition and which is outstanding at October 31, 2019 . On October 21, 2019, we entered into a second amendment to the credit agreement, which refreshed the amount available for additional incremental term loan facilities under the credit agreement to permit additional incremental facilities of up to $500 million . We had no borrowings under the additional incremental facilities as of October 31, 2019. Capital Leases The company leases certain property and equipment under capital leases. As of October 31, 2019, the current portion of the company’s capital lease obligations had an aggregate carrying value of $1 million . 2020 Senior Notes On July 13, 2010 , the company issued an aggregate principal amount of $500 million in senior notes ("2020 senior notes"). The 2020 senior notes were issued at 99.54% of their principal amount. The notes were scheduled to mature on July 15, 2020 , and bear interest at a fixed rate of 5.00% per annum. On August 9, 2011 , we terminated our interest rate swap contracts related to our 2020 senior notes that represented the notional amount of $500 million . The asset value, including interest receivable, upon termination for these contracts was approximately $34 million . The gain was deferred and amortized to interest expense over the remaining life of the 2020 senior notes. On September 17, 2019 , we repaid the $500 million outstanding aggregate principal amount of our 2020 senior notes due July 15, 2020 that were called for redemption on August 16, 2019. The redemption price of approximately $512 million included a $12 million prepayment penalty. The redemption price was computed in accordance with the terms of the 2020 senior notes as the present value of the remaining scheduled payments of principal and unpaid interest related to the redemption. The prepayment penalty plus amortization of the previously deferred interest swap gain of $4 million and amortization of previously deferred debt issuance costs and discount of $ 1 million was recorded in other income (expense), net in the consolidated statement of operations. We also paid accrued and unpaid interest of $4 million on the 2020 senior notes up to but not including the redemption date. 2017 Senior Notes On October 24, 2007 , the company issued an aggregate principal amount of $600 million in senior notes ("2017 senior notes"). On October 20, 2014 , we settled the redemption of $500 million of the $600 million outstanding aggregate principal amount of our 2017 senior notes. The 2017 senior notes were repayable within one year as of October 31, 2017 and were reclassified to short-term debt. The remaining $100 million in 2017 senior notes matured and were paid in full on November 1, 2017.

LONG-TERM DEBT

LONG-TERM DEBT	12 Months Ended
LONG-TERM DEBT	Oct. 31, 2019
Debt Disclosure [Abstract]
LONG-TERM DEBT	LONG-TERM DEBT Senior Notes The following table summarizes the company's long-term senior notes and the related interest rate swaps: October 31, 2019 October 31, 2018 Amortized Principal Swap Total Amortized Principal Swap Total (in millions) 2020 Senior Notes $ — $ — $ — $ 499 $ 7 $ 506 2022 Senior Notes 399 — 399 399 — 399 2023 Senior Notes 597 — 597 597 — 597 2026 Senior Notes 298 — 298 297 — 297 2029 Senior Notes 492 — 492 — — — Total $ 1,786 $ — $ 1,786 $ 1,792 $ 7 $ 1,799 2020 Senior Notes The 2020 senior notes were repaid in 2019, see Note 17, "Short-Term Debt". 2022 Senior Notes On September 10, 2012 , the company issued an aggregate principal amount of $400 million in senior notes ("2022 senior notes"). The 2022 senior notes were issued at 99.80% of their principal amount. The notes will mature on October 1, 2022 , and bear interest at a fixed rate of 3.20% per annum. The interest is payable semi-annually on April 1st and October 1st of each year and payments commenced on April 1, 2013 . In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 10, 2012. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at October 31, 2019 was $1 million . 2023 Senior Notes On June 18, 2013 , the company issued aggregate principal amount of $600 million in senior notes ("2023 senior notes"). The 2023 senior notes were issued at 99.544% of their principal amount. The notes will mature on July 15, 2023 and bear interest at a fixed rate of 3.875% per annum. The interest is payable semi-annually on January 15th and July 15th of each year and payments commenced January 15, 2014 . 2026 Senior Notes On September 15, 2016 , the company issued aggregate principal amount of $300 million in senior notes ("2026 senior notes"). The 2026 senior notes were issued at 99.624% of their principal amount. The notes will mature on September 22, 2026 and bear interest at a fixed rate of 3.05% per annum. The interest is payable semi-annually on March 22nd and September 22nd of each year and payments commenced March 22, 2017 . In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million and we recognized this as a deferred loss in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2026 senior notes.The remaining loss to be amortized related to the interest rate swap agreements at October 31, 2019 was $7 million . 2029 Senior Notes On September 5, 2019 , the company issued an aggregate principal amount of $500 million in senior notes ("2029 senior notes"). The 2029 senior notes were issued at 99.316% of their principal amount. The notes will mature on September 15, 2029 , and bear interest at a fixed rate of 2.75% per annum. The interest is payable semi-annually on March 15th and September 15th of each year and payments commence on March 15, 2020 . In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 5, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019 and we recognized a deferred loss of $6 million in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at October 31, 2019 was $6 million . Capital Leases The company leases certain property and equipment under capital leases. As of October 31, 2019, the non-current portion of the company’s capital lease obligations had an aggregate carrying value of $5 million to be paid over 12 years.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
STOCKHOLDERS' EQUITY	Oct. 31, 2019
Stockholders' Equity Note [Abstract]
STOCKHOLDERS EQUITY	19. STOCKHOLDERS' EQUITY Stock Repurchase Program On May 28, 2015 we announced that our board of directors had approved a share repurchase program (the "2015 repurchase program"). The 2015 share repurchase program authorizes the purchase of up to $1.14 billion of our common stock at the company's discretion through and including November 1, 2018. The 2015 repurchase program did not require the company to acquire a specific number of shares and could have been suspended or discontinued at any time. During the year ended October 31, 2017 , we repurchased and retired approximately 4.1 million shares for $194 million under this authorization. During the year ended October 31, 2018 , we repurchased and retired approximately 6.4 million shares for $422 million under this authorization. As of October 31, 2018 , we had remaining authorization to repurchase up to $188 million of our common stock under this program which expired on November 1, 2018. On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 share repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the year ended October 31, 2019 , we repurchased and retired approximately 10.4 million shares for $723 million under this authorization. As of October 31, 2019 , we had remaining authorization to repurchase up to $1.03 billion of our common stock under this program. Cash Dividends on Shares of Common Stock During the year ended October 31, 2019 , cash dividends of 0.656 per share, or $206 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2018 , cash dividends of 0.596 per share, or $191 million were declared and paid on the company's outstanding common stock. During the year ended October 31, 2017 , cash dividends of 0.528 per share, or $170 million were declared and paid on the company's outstanding common stock. On November 20, 2019 we declared a quarterly dividend of $0.18 per share of common stock, or approximately $56 million which will be paid on January 22, 2020 to shareholders of record as of the close of business on December 31, 2019 . The timing and amounts of any future dividends are subject to determination and approval by our board of directors. Accumulated Other Comprehensive Income (Loss) The following table summarizes the components of our accumulated other comprehensive income (loss) as of October 31, 2019 and 2018 , net of tax effect: October 31, 2019 2018 (in millions) Foreign currency translation, net of tax expense of $(5) and $(15) for 2019 and 2018, respectively $ (204 ) (214 ) Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $153 and $132 for 2019 and 2018, respectively (306 ) (201 ) Unrealized gains (losses) on derivative instruments, net of tax benefit of $3 and $0 for 2019 and 2018, respectively (4 ) 7 Total accumulated other comprehensive loss $ (514 ) $ (408 ) Changes in accumulated other comprehensive income (loss) by component and related tax effects for the years ended October 31, 2019 and 2018 were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of October 31, 2017 $ (156 ) $ 140 $ (328 ) $ (2 ) $ (346 ) Other comprehensive income (loss) before reclassifications (51 ) — (49 ) 7 (93 ) Amounts reclassified out of accumulated other comprehensive income (loss) — (8 ) 39 4 35 Tax (expense) benefit (7 ) 2 3 (2 ) (4 ) Other comprehensive income (loss) (58 ) (6 ) (7 ) 9 (62 ) As of October 31, 2018 $ (214 ) $ 134 $ (335 ) $ 7 $ (408 ) Impact of adoption of new guidance on tax effects in accumulated other comprehensive income (loss) — 3 (9 ) (1 ) (7 ) As of November 1, 2018 (214 ) 137 (344 ) 6 (415 ) Other comprehensive loss before reclassifications — — (157 ) (6 ) (163 ) Amounts reclassified out of accumulated other comprehensive income — (8 ) 39 (8 ) 23 Tax benefit 10 2 25 4 41 Other comprehensive income (loss) 10 (6 ) (93 ) (10 ) (99 ) As of October 31, 2019 $ (204 ) $ 131 $ (437 ) $ (4 ) $ (514 ) Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31, 2019 and 2018 were as follows (in millions): Details about Accumulated Other Amounts Reclassified Affected line item in 2019 2018 Unrealized gains and (losses) on derivatives $ 8 $ (4 ) Cost of products and interest expense 8 (4 ) Total before income tax (2 ) 1 (Provision)/benefit for income tax 6 (3 ) Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (39 ) (39 ) Other (income) expense Prior service benefit 8 8 Other (income) expense (31 ) (31 ) Total before income tax 12 10 Benefit for income tax (19 ) (21 ) Total net of income tax Total reclassifications for the period $ (13 ) $ (24 ) Amounts in parentheses indicate reductions to income and increases to other comprehensive income. Reclassifications of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost (see Note 14, "Retirement Plans and Post Retirement Pension Plans").

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
SEGMENT INFORMATION	Oct. 31, 2019
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Description of Segments. We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Agilent has three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business each of which comprises a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments. In 2019, we adopted new guidance related to the presentation of the net periodic pension and postretirement benefit cost. See Note 2, "New Accounting Pronouncements" for more information. As a result, we have recast our historical segment results to conform to this new presentation required under this guidance. A description of our three reportable segments is as follows: Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry ("MP-AES") instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies. Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples. Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques utilized in clinical and life science research applications. The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, software as a service, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements. A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, real estate, insurance services, information technology services, treasury, order administration, other corporate infrastructure expenses and costs of centralized research and development. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate amortization and impairment of acquisition-related intangible assets, pension curtailment or settlement gains, restructuring and transformational initiatives expenses, acquisition and integration costs, business exit and divestiture costs, special compliance costs, some nucleic acid solutions division ("NASD") site costs and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments.Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations, in-sourcing or outsourcing of activities. The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments. The profitability of each of the segments is measured after excluding restructuring and asset impairment charges, transformational initiatives, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Year Ended October 31, 2019: Total net revenue $ 2,302 $ 1,021 $ 1,840 $ 5,163 Income from operations $ 542 $ 185 $ 475 $ 1,202 Depreciation expense $ 41 $ 35 $ 35 $ 111 Share-based compensation expense $ 33 $ 14 $ 25 $ 72 Year Ended October 31, 2018: Total net revenue $ 2,270 $ 943 $ 1,701 $ 4,914 Income from operations $ 543 $ 173 $ 388 $ 1,104 Depreciation expense $ 38 $ 33 $ 31 $ 102 Share-based compensation expense $ 33 $ 14 $ 24 $ 71 Year Ended October 31, 2017: Total net revenue $ 2,081 $ 860 $ 1,531 $ 4,472 Income from operations $ 470 $ 167 $ 336 $ 973 Depreciation expense $ 35 $ 30 $ 29 $ 94 Share-based compensation expense $ 30 $ 10 $ 21 $ 61 The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes: Years Ended October 31, 2019 2018 2017 (in millions) Total reportable segments' income from operations $ 1,202 $ 1,104 $ 973 Amortization of intangible assets related to business combinations (125 ) (105 ) (117 ) Acquisition and integration costs (48 ) (23 ) (30 ) Transformational initiatives (44 ) (25 ) (12 ) Asset impairments — (21 ) — Business exit and divestiture costs (primarily our NMR business) — (9 ) — NASD site costs (12 ) (8 ) — Special compliance costs (2 ) (4 ) — Other (1) (30 ) (5 ) (7 ) Interest Income 36 38 22 Interest Expense (74 ) (75 ) (79 ) Other income (expense), net 16 79 53 Income before taxes, as reported $ 919 $ 946 $ 803 (1) The other category primarily includes legal costs related to our pursuing our claim against a third party in addition to other miscellaneous adjustments and settlements. Major Customers. No customer represented 10 percent or more of our total net revenue in 2019 , 2018 or 2017 . The following table reflects segment assets and capital expenditures under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) As of and for the Year Ended October 31, 2019: Assets $ 3,202 $ 2,620 $ 1,331 $ 7,153 Capital expenditures $ 59 $ 48 $ 48 $ 155 As of and for the Year Ended October 31, 2018: Assets $ 1,744 $ 2,679 $ 1,267 $ 5,690 Capital expenditures $ 47 $ 92 $ 38 $ 177 The following table reconciles segment assets to Agilent's total assets: October 31, 2019 2018 (in millions) Total reportable segments' assets $ 7,153 $ 5,690 Cash, cash equivalents 1,382 2,247 Prepaid expenses 94 80 Investments 102 68 Long-term and other receivables 100 102 Other 621 354 Total assets $ 9,452 $ 8,541 The other category primarily includes deferred tax assets and overfunded pension assets which are not allocated to the segments. The following table presents summarized information for net revenue by geographic region. Revenues from external customers are generally attributed to countries based upon the customer's location. United China (1) Rest of the Total (in millions) Net revenue: Year Ended October 31, 2019 $ 1,619 $ 1,019 $ 2,525 $ 5,163 Year Ended October 31, 2018 $ 1,414 $ 1,015 $ 2,485 $ 4,914 Year Ended October 31, 2017 $ 1,314 $ 900 $ 2,258 $ 4,472 1. China also includes Hong Kong net revenue. The following table presents summarized information for long-lived assets by geographic region. Long lived assets consist of property, plant, and equipment, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of Asia and the rest of Europe. United Germany Rest of the Total (in millions) Long-lived assets: October 31, 2019 $ 621 $ 122 $ 404 $ 1,147 October 31, 2018 $ 565 $ 117 $ 362 $ 1,044

Schedule II Valuation and Quali

Schedule II Valuation and Qualifying Accounts	12 Months Ended
Schedule II Valuation and Qualifying Accounts	Oct. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS Column A Column B Column C Column D Column E Description Balance at Additions Charged to Deductions Credited to Expenses or Other Accounts** Balance at (in millions) 2019 Tax valuation allowance $ 135 $ 9 $ (10 ) $ 134 2018 Tax valuation allowance $ 138 $ 4 $ (7 ) $ 135 2017 Tax valuation allowance $ 129 $ 14 $ (5 ) $ 138 * Additions include current year additions charged to expenses and current year build due to increases in net deferred tax assets, return to provision true-ups, other adjustments and other comprehensive income impact to deferred taxes. ** Deductions include current year releases credited to expenses and current year reductions due to decreases in net deferred tax assets, return to provision true-ups, other adjustments and other comprehensive income impact to deferred taxes.

OVERVIEW AND SUMMARY OF SIGNI_2

OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Oct. 31, 2019
Accounting Policies [Abstract]
Business description and basis of presentation	Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Basis of Presentation. The accompanying consolidated financial statements have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and is in conformity with U.S. generally accepted accounting principles ("GAAP"). Our fiscal year end is October 31. Unless otherwise stated, all years and dates refer to our fiscal year.
Principles of consolidation	Principles of Consolidation. The consolidated financial statements include the accounts of the company and our wholly- and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Use of estimates	Use of Estimates. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, valuation of goodwill and purchased intangible assets, inventory valuation, retirement and post-retirement plan assumptions and accounting for income taxes.
Retirement of treasury shares	Retirement of Treasury Shares. Upon the formal retirement of treasury shares, we deduct the par value of the retired treasury shares from common stock and allocate the excess of cost over par as a deduction to additional paid-in capital, based on the pro-rata portion of additional paid-in-capital, and the remaining excess as a deduction to retained earnings. All retired treasury shares revert to the status of authorized but unissued shares.
Revenue recognition	Revenue Recognition. We enter into contracts to sell products, services or combinations of products and services. Products may include hardware or software and services may include one-time service events or services performed over time. We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers (“ASC 606’’). See also Note 2, "New Accounting Pronouncements" and Note 4, "Revenue" for additional information on revenue recognition. Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled in exchange for those products or services, the transaction price. For equipment, consumables, and most software licenses, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded. Service revenue includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. Revenue for these contracts is recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls not included in a support contract are recognized to revenue at the time a service is performed. We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis. Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue. For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per country for each performance obligation. Standalone selling prices are determined for each distinct good or service in the contract and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations. A portion of our revenue relates to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 840, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance. Deferred Revenue. Contract liabilities (deferred revenue) primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements (performance obligations) to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either in current liabilities in deferred revenue or long-term in other long-term liabilities in the consolidated balance sheet based on the timing of when we expect to complete our performance obligation.
Accounts receivable, net	Accounts Receivable, net. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Such accounts receivable have been reduced by an allowance for doubtful accounts, which is our best estimate of the amount of probable credit losses in our existing accounts receivable. We determine the allowance based on customer specific experience and the aging of such receivables, among other factors. The allowance for doubtful accounts as of October 31, 2019 and 2018 was not material. We do not have any off-balance-sheet credit exposure related to our customers. Accounts receivable are also recorded net of estimated product returns which are not material.
Shipping and handling costs	Shipping and Handling Costs. Our shipping and handling costs charged to customers are included in net revenue, and the associated expense is recorded in cost of products for all periods presented.
Inventory	Inventory. Inventory is valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. We assess the valuation of our inventory on a periodic basis and make adjustments to the value for estimated excess and obsolete inventory based on estimates about future demand. The excess balance determined by this analysis becomes the basis for our excess inventory charge. Our excess inventory review process includes analysis of sales forecasts, managing product rollovers and working with manufacturing to maximize recovery of excess inventory.
Acquisitions	Acquisitions. Agilent accounts for the acquisition of a business using the acquisition method of accounting and we allocate the fair value of the purchase price to the tangible assets acquired, liabilities assumed, and intangible assets acquired, including in-process research and development (“IPR&D”), based on their estimated fair values. The excess value of the cost of an acquired business over the fair value of the assets acquired and liabilities assumed is recognized as goodwill. The fair value of IPR&D is initially capitalized as an intangible asset with an indefinite life. When an IPR&D project is completed, the IPR&D is reclassified as an amortizable purchased intangible asset and amortized to costs of revenues over the asset’s estimated useful life. Our determination of the fair value of the intangible assets acquired involves the use of significant estimates and assumptions. Specifically, our determination of the fair value of the developed product technology and IPR&D acquired involve significant estimates and assumptions related to revenue growth rates and discount rates. Our determination of the fair value of customer relationships acquired involved significant estimates and assumptions related to revenue growth rates, discount rates, and customer attrition rates. Our determination of the fair value of the tradename acquired involved the use of significant estimates and assumptions related to revenue growth rates, royalty rates and discount rates. The company believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use. Actual results could differ materially from these estimates.
Goodwill and purchased intangible assets	Goodwill and Purchased Intangible Assets. Under the authoritative guidance we have the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The accounting standard gives an entity the option to first assess qualitative factors to determine whether performing the two-step test is necessary. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not (i.e. greater than 50% chance) that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test will be required. Otherwise, no further testing will be required. The guidance includes examples of events and circumstances that might indicate that a reporting unit's fair value is less than its carrying amount. These include macro-economic conditions such as deterioration in the entity's operating environment or industry or market considerations; entity-specific events such as increasing costs, declining financial performance, or loss of key personnel; or other events such as an expectation that a reporting unit will be sold or a sustained decrease in the stock price on either an absolute basis or relative to peers. If it is determined, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the provisions of authoritative guidance require that we perform a two-step impairment test on goodwill. In the first step, we compare the fair value of each reporting unit to its carrying value. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. We aggregate components of an operating segment that have similar economic characteristics into our reporting units. In fiscal year 2019 , we assessed goodwill impairment for our three reporting units which consisted of three segments: life sciences and applied markets, diagnostics and genomics and Agilent CrossLab. We performed a qualitative test for goodwill impairment of the three reporting units, as of September 30, 2019 , our annual impairment test date. Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of each reporting unit is greater than its respective carrying value. Each quarter we review the events and circumstances to determine if goodwill impairment is indicated. There was no impairment of goodwill during the years ended October 31, 2019 , 2018 and 2017 . Purchased intangible assets consist primarily of acquired developed technologies, proprietary know-how, trademarks, and customer relationships and are amortized using the best estimate of the asset's useful life that reflect the pattern in which the economic benefits are consumed or used up or a straight-line method ranging from 6 months to 15 years . IPR&D is initially capitalized at fair value as an intangible asset with an indefinite life and assessed for impairment thereafter. When the IPR&D project is complete, it is reclassified as an amortizable purchased intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, Agilent will record a charge for the value of the related intangible asset to Agilent's consolidated statement of operations in the period it is abandoned. Agilent's indefinite-lived intangible assets are IPR&D intangible assets. The accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the issued impairment testing guidance for goodwill and allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset to determine whether it is more-likely-than-not (i.e. greater than 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. We performed a qualitative test for impairment of indefinite-lived intangible assets as of September 30, 2019 . Based on the results of our qualitative testing, we believe that it is more-likely-than-not that the fair value of these indefinite-lived intangible assets is greater than their respective carrying values. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible asset is indicated. During the year ended October 31, 2019 , 2018 and 2017 there were no impairments of indefinite-lived intangible assets.
Share-based compensation	Share-Based Compensation. For the years ended 2019 , 2018 and 2017 , we accounted for share-based awards made to our employees and directors including employee stock option awards, restricted stock units, employee stock purchases made under our Employee Stock Purchase Plan ("ESPP") and performance share awards under Agilent Technologies, Inc. Long-Term Performance Program ("LTPP") using the estimated grant date fair value method of accounting. Under the fair value method, we recorded compensation expense for all share-based awards of $72 million in 2019 , $71 million in 2018 and $61 million in 2017 . See Note 5, "Share-based Compensation" for additional information.
Retirement and post-retirement plans	Retirement and Post-Retirement Plans. Substantially all of our employees are covered under various defined benefit and/or defined contribution retirement plans. Additionally, we sponsor post-retirement health care benefits for our eligible U.S. employees. Assumptions used to determine the benefit obligations and the expense for these plans are derived annually. See Note 14, “Retirement plans and post-retirement pension plans” for additional information.
Taxes on income	Taxes on Income.
Warranty	Warranty. Our standard warranty terms typically extend for one year from the date of delivery. We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net product revenue. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. See Note 15, "Guarantees".
Advertising	Advertising. Advertising costs are generally expensed as incurred and amounted to $36 million in 2019 , $41 million in 2018 and $38 million in 2017 .
Research and development	Research and Development. Costs related to research, design and development of our products are charged to research and development expense as they are incurred.
Sales taxes	Sales Taxes. Sales taxes collected from customers and remitted to governmental authorities are not included in our revenue.
Net income (loss) per share	Net Income Per Share. Basic net income per share is computed by dividing net income - the numerator - by the weighted average number of common shares outstanding - the denominator - during the period excluding the dilutive effect of stock options and other employee stock plans. Diluted net income per share gives effect to all potential common shares outstanding during the period unless the effect is anti-dilutive. The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense are assumed proceeds to be used to repurchase hypothetical shares. See Note 7, "Net Income Per Share".
Cash, cash equivalents and short term investments	Cash, Cash Equivalents and Short-Term Investments. We classify investments as cash equivalents if their original or remaining maturity is three months or less at the date of purchase. Cash equivalents are stated at cost, which approximates fair value. As of October 31, 2019 , approximately $1,310 million of our cash and cash equivalents is held outside of the U.S. by our foreign subsidiaries. Our cash and cash equivalents mainly consist of short-term deposits held at major global financial institutions, institutional money market funds, and similar short duration instruments with original maturities of 90 days or less. We continuously monitor the creditworthiness of the financial institutions and institutional money market funds in which we invest our funds. We classify investments as short-term investments if their original maturities are greater than three months and their remaining maturities are one year or less. Currently, we have no short-term investments.
Variable interest entity	Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). The company evaluates its investments in privately held companies on an ongoing basis. We account for these investments under either the equity method or as equity investments without determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. During the year ended October 31, 2016, Agilent made a preferred stock investment in Lasergen, Inc. ("Lasergen") for $80 million . This investment in Lasergen was accounted for under the cost method. Agilent’s initial ownership stake was 48 percent and included an option to acquire the remaining shares until March 2018. During the year ended October 31, 2018, we exercised our option and acquired all of the remaining shares of Lasergen that we did not already own for an additional cash consideration of approximately $107 million . The fair value remeasurement of our previous investment immediately before the acquisition resulted in a net gain of $20 million and was recorded in other income. Lasergen was previously considered a VIE. As of October 31, 2019 and 2018 , we have no material VIE's.
Investments	Investments. Equity investments without readily determinable fair value consist of non-marketable equity securities (typically investments in privately-held companies). These investments are accounted for using the measurement alternative at cost and we adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) included in net income as and when it occurs. Equity investments with readily determinable fair value consist of shares we own in a special fund and are reported at fair value, with gains or losses resulting from changes in fair value included in net income. Prior to fiscal year 2019, both equity investments without determinable fair value and with determinable fair value were accounted for using cost method of accounting, measured at historical cost less other-than-temporary investment. Trading securities, which is comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Equity method investments are reported at the amount of the company’s initial investment and adjusted each period for the company’s share of the investee’s income or loss and dividend paid. There are no equity method investments as of October 31, 2019 and 2018 . The company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable.
Fair value of financial instruments	Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy exceeds the carrying value by approximately $62 million as of October 31, 2019 and is lower than the carrying value by approximately $15 million as of October 31, 2018 . The change in the fair value over carrying value in the year ended October 31, 2019 is primarily due to fluctuations in market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 12, "Fair Value Measurements" for additional information on the fair value of financial instruments.
Concentration of credit risk	Concentration of Credit Risk. Financial instruments that potentially subject Agilent to significant concentration of credit risk include money market fund investments, time deposits and demand deposit balances. These investments are categorized as cash and cash equivalents. In addition, Agilent has credit risk from derivative financial instruments used in hedging activities and accounts receivable. We invest in a variety of financial instruments and limit the amount of credit exposure with any one financial institution. We have a comprehensive credit policy in place and credit exposure is monitored on an ongoing basis. Credit risk with respect to our accounts receivable is diversified due to the large number of entities comprising our customer base and their dispersion across many different industries and geographies. Credit evaluations are performed on customers requiring credit over a certain amount and we sell the majority of our products through our direct sales force. Credit risk is mitigated through collateral such as letter of credit, bank guarantees or payment terms like cash in advance. No single customer accounted for more than 10 percent of accounts receivable as of October 31, 2019 , or 2018 .
Derivative instruments	Derivative Instruments. Agilent is exposed to global foreign currency exchange rate and interest rate risks in the normal course of business. We enter into foreign exchange hedging contracts, primarily forward contracts and purchased options, interest rate swaps and interest rate locks to manage financial exposures resulting from changes in foreign currency exchange rates and interest rates. In the vast majority of cases, these contracts are designated at inception as hedges of the related foreign currency or interest exposures. Foreign currency exposures include committed and anticipated revenue and expense transactions and assets and liabilities that are denominated in currencies other than the functional currency of the subsidiary. Interest rate exposures are associated with the company's fixed-rate debt. For option contracts, we exclude time value from the measurement of effectiveness. To qualify for hedge accounting, contracts must reduce the foreign currency exchange rate and interest rate risk otherwise inherent in the amount and duration of the hedged exposures and comply with established risk management policies. Foreign exchange hedging contracts generally mature within twelve months , interest rate swaps mature at the same time as the maturity of the debt and interest rate locks mature at the same time as the issuance of debt. In order to manage foreign currency exposures in a few limited jurisdictions we may enter into foreign exchange contracts that do not qualify for hedge accounting. In such circumstances, the local foreign currency exposure is offset by contracts owned by the parent company. We do not use derivative financial instruments for trading or speculative purposes. All derivatives are recognized on the balance sheet at their fair values. For derivative instruments that are designated and qualify as a fair value hedge, changes in value of the derivative are recognized in the consolidated statement of operations in the current period, along with the offsetting gain or loss on the hedged item attributable to the hedged risk. For derivative instruments that are designated and qualify as a cash flow hedges, changes in the value of the effective portion of the derivative instrument is recognized in comprehensive income (loss), a component of stockholders' equity. Amounts associated with cash flow hedges are reclassified and recognized in income when either the forecasted transaction occurs or it becomes probable the forecasted transaction will not occur. Derivatives not designated as hedging instruments are recorded on the balance sheet at their fair value and changes in the fair values are recorded in the income statement in the current period. Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet. Changes in the fair value of the ineffective portion of derivative instruments are recognized in earnings in the current period. Ineffectiveness in 2019 , 2018 and 2017 was not material. Cash flows from derivative instruments are classified in the statement of cash flows in the same category as the cash flows from the hedged or economically hedged item, primarily in operating activities.
Property, plant and equipment	Property, Plant and Equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Additions, improvements and major renewals are capitalized; maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation and amortization are removed from our general ledger, and the resulting gain or loss is reflected in the consolidated statement of operations. Buildings and improvements are depreciated over the lesser of their useful lives or the remaining term of the lease and machinery and equipment over 3 years to 10 years . We use the straight-line method to depreciate assets.
Leases	Leases. We lease buildings, machinery and equipment under operating and capital leases for original terms ranging generally from less than 1 year to 30 years . Certain leases contain renewal options for periods up to 6 years . In addition, we lease equipment to customers in connection with our diagnostics business using both capital and operating leases. As of October 31, 2019 and 2018 our diagnostics and genomics segment has approximately $37 million and $32 million , respectively, of lease receivables related to capital leases and approximately $17 million and $20 million , respectively, of net assets for operating leases. We depreciate the assets related to the operating leases over their estimated useful lives, typically five years.
Capitalized software	Capitalized Software. We capitalize certain internal and external costs incurred to acquire or create internal use software. Capitalized software is included in property, plant and equipment and is depreciated over 3 years to 5 years once development is complete.
Impairment of long-lived assets	Impairment of Long-Lived Assets. We continually monitor events and changes in circumstances that could indicate carrying amounts of long-lived assets, including intangible assets, may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets. During 2019, there were no impairments of other assets or intangible assets. During 2018, we recorded an impairment charge of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable. During 2017, there were no impairments of other assets or intangible assets.
Employee compensation and benefits	Employee Compensation and Benefits. Amounts owed to employees, such as accrued salary, bonuses and vacation benefits are accounted for within employee compensation and benefits. The total amount of accrued vacation benefit was $115 million and $107 million as of October 31, 2019 , and 2018 , respectively.
Foreign currency translation	Foreign Currency Translation. We translate and remeasure balance sheet and income statement items into U.S. dollars. For those subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using monthly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive income (loss) in stockholders' equity. For those subsidiaries that operate in a U.S. dollar functional environment, foreign currency assets and liabilities are remeasured into U.S. dollars at current exchange rates except for non-monetary assets and capital accounts which are remeasured at historical exchange rates. Revenue and expenses are generally remeasured at monthly exchange rates which approximate average exchange rates in effect during each period. Gains or losses from foreign currency remeasurement are included in consolidated net income. Net gains or losses resulting from foreign currency transactions, including hedging gains and losses, are reported in other income (expense), net and were $7 million loss for 2019 , $3 million loss for 2018 and $2 million loss for 2017 .

NEW ACCOUNTING PRONOUNCEMENTS (

NEW ACCOUNTING PRONOUNCEMENTS (Tables)	12 Months Ended
NEW ACCOUNTING PRONOUNCEMENTS (Tables)	Oct. 31, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	The following table summarizes the impacts of recently adopted accounting pronouncements on our consolidated balance sheet as of November 1, 2018: October 31, Impact of Adopting New November 1, As Reported Revenue Recognition Guidance Tax Effects on Items in AOCI Guidance Intra-Entity Tax Guidance Investments Valuation Guidance As Adopted (in millions) ASSETS Current assets: Cash and cash equivalents $ 2,247 $ — $ — $ — $ — $ 2,247 Accounts receivable, net 776 24 — — — 800 Inventory 638 (10 ) — — — 628 Other current assets 187 3 — — — 190 Total current assets 3,848 17 — — — 3,865 Property, plant and equipment, net 822 — — — — 822 Goodwill 2,973 — — — — 2,973 Other intangible assets, net 491 — — — — 491 Long-term investments 68 — — — 7 75 Other assets 339 (3 ) — (2 ) (2 ) 332 Total assets $ 8,541 $ 14 $ — $ (2 ) $ 5 $ 8,558 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 340 $ — $ — $ — $ — $ 340 Employee compensation and benefits 304 — — — — 304 Deferred revenue 324 (11 ) — — — 313 Other accrued liabilities 203 — — — — 203 Total current liabilities 1,171 (11 ) — — — 1,160 Long-term debt 1,799 — — — — 1,799 Retirement and post-retirement benefits 239 — — — — 239 Other long-term liabilities 761 2 — — — 763 Total liabilities 3,970 (9 ) — — — 3,961 Total equity: Stockholders’ equity: Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding — — — — — — Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018 issued 3 — — — — 3 Additional paid-in-capital 5,308 — — — — 5,308 Accumulated deficit (336 ) 23 7 (2 ) 5 (303 ) Accumulated other comprehensive loss (408 ) — (7 ) — — (415 ) Total stockholders' equity 4,567 23 — (2 ) 5 4,593 Non-controlling interest 4 — — — — 4 Total equity 4,571 23 — (2 ) 5 4,597 Total liabilities and equity $ 8,541 $ 14 $ — $ (2 ) $ 5 $ 8,558 As of November 1, 2018, we adopted new accounting guidance which requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet follows: October 31 2019 2018 2017 (in millions) Cash and cash equivalents $ 1,382 $ 2,247 $ 2,678 Restricted cash included in other assets 6 7 8 Total cash, cash equivalents and restricted cash $ 1,388 $ 2,254 $ 2,686

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	12 Months Ended
ACQUISITIONS (Tables)	Oct. 31, 2019
Business Combinations [Abstract]
Schedule of the fair value of assets and liabilities assumed	The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions): Cash and cash equivalents $ 10 Accounts receivable 28 Inventories 21 Other current assets 2 Property, plant and equipment 8 Intangible assets 641 Goodwill 483 Total assets acquired 1,193 Accounts payable (4 ) Deferred revenue (5 ) Employee compensation and benefits (7 ) Other accrued liabilities (2 ) Long-term debt (4 ) Net assets acquired $ 1,171
Components of intangible assets acquired	The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions): Fair Value Estimated Useful Life Developed product technology $ 387 5-13 years Customer relationships 202 3-8 years Backlog 5 2 months Tradenames and trademarks 43 10 years Total intangible assets subject to amortization 637 In-process research and development 4 Total intangible assets $ 641
Proforma operating results	The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's consolidated statements of operations as of the beginning of fiscal 2018 (in millions, except per share amounts): 2019 2018 Net revenue $ 5,308 $ 5,112 Net income $ 1,012 $ 210 Net income per share — basic $ 3.22 $ 0.65 Net income per share — diluted $ 3.18 $ 0.65

REVENUE REVENUE (Tables)

REVENUE REVENUE (Tables)	12 Months Ended
REVENUE REVENUE (Tables)	Oct. 31, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: Year Ended October 31, 2019 Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Revenue by Region Americas $ 692 $ 505 $ 664 $ 1,861 Europe 551 368 522 1,441 Asia Pacific 1,059 148 654 1,861 Total $ 2,302 $ 1,021 $ 1,840 $ 5,163 The following table presents the company’s total revenue disaggregated by end markets and by revenue type: Year Ended October 31, 2019 (in millions) Revenue by End Markets Pharmaceutical and Biopharmaceutical $ 1,604 Chemical and Energy 1,199 Diagnostics and Clinical 785 Food 486 Academia and Government 474 Environmental and Forensics 615 Total $ 5,163 Revenue by Type Instrumentation $ 2,150 Non-instrumentation and other 3,013 Total $ 5,163
Contract with Customer, Asset and Liability	The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the year ended October 31, 2019 : Contract (in millions) Ending balance as of October 31, 2018 $ 367 Impact of adoption of new revenue recognition guidance (11 ) Net revenue deferred in the period 303 Revenue recognized that was included in the contract liability balance at the beginning of the period (287 ) Change in deferrals from customer cash advances, net of revenue recognized 5 Contract liabilities acquired in business combinations 9 Currency translation and other adjustments — Ending balance as of October 31, 2019 $ 386

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
SHARE-BASED COMPENSATION (Tables)	Oct. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]
Allocated Share-based compensation expense disclosure	The impact on our results for share-based compensation was as follows: Years Ended October 31, 2019 2018 2017 (in millions) Cost of products and services $ 18 $ 16 $ 15 Research and development 7 7 6 Selling, general and administrative 47 48 40 Total share-based compensation expense $ 72 $ 71 $ 61
Share-based compensation arrangement by share-based payment award fair value assumptions and methodology schedule	The following assumptions were used to estimate the fair value of awards granted. Years Ended October 31, 2019 2018 2017 LTPP: Volatility of Agilent shares 22% 21% 23% Volatility of selected peer-company shares 15%-66% 14%-66% 15%-63% Pair-wise correlation with selected peers 30% 32% 36% Post-vest restriction discount for all executive awards 5.0% 4.8% 5.3%
Summary of stock option award activity	The following table summarizes employee stock option award activity of our employees and directors for 2019 . Options Outstanding Weighted Average Exercise Price (in thousands) Outstanding at October 31, 2018 1,997 $ 35 Exercised (552 ) $ 33 Forfeited — $ — Outstanding at October 31, 2019 1,445 $ 36
Schedule of share-based compensation, shares authorized under stock option plans, by exercise price range	The options outstanding and exercisable for equity share-based payment awards at October 31, 2019 were as follows: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate Intrinsic Value Number Exercisable Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate Intrinsic Value (in thousands) (in years) (in thousands) (in thousands) (in years) (in thousands) $25.01 - 30 483 2.5 $ 26 23,769 483 2.5 $ 26 23,769 $30.01 - 40 296 4.1 $ 39 10,845 296 4.1 $ 39 10,845 $40.01 - over 666 5.0 $ 41 23,211 666 5.0 $ 41 23,211 1,445 4.0 $ 36 $ 57,825 1,445 4.0 $ 36 $ 57,825
Schedule of intrinsic value of options exercised and the fair value of options granted	The following table summarizes the aggregate intrinsic value of options exercised in 2019 , 2018 and 2017 : Aggregate Intrinsic Value Weighted Average Exercise Price (in thousands) Options exercised in fiscal 2017 $ 36,175 $ 30 Options exercised in fiscal 2018 $ 28,417 $ 32 Options exercised in fiscal 2019 $ 24,409 $ 33
Non-vested award activity disclosure	The following table summarizes non-vested award activity in 2019 primarily for our LTPP and restricted stock unit awards. Shares Weighted Average Grant Price (in thousands) Non-vested at October 31, 2018 3,181 $ 57 Granted 1,309 $ 68 Vested (1,530 ) $ 45 Forfeited (78 ) $ 60 Change in LTPP shares in the year due to exceeding performance targets 291 $ — Non-vested at October 31, 2019 3,173 $ 60

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
INCOME TAXES (Tables)	Oct. 31, 2019
Income Tax Disclosure [Abstract]
Income before income taxes domestic and foreign	The domestic and foreign components of income before taxes are: Years Ended October 31, 2019 2018 2017 (in millions) U.S. operations $ 189 $ 169 $ 116 Non-U.S. operations 730 777 687 Total income before taxes $ 919 $ 946 $ 803
Provision for income taxes from operations	The provision for income taxes is comprised of: Years Ended October 31, 2019 2018 2017 (in millions) U.S. federal taxes: Current $ (191 ) $ 520 $ 15 Deferred — 51 110 Non-U.S. taxes: Current 290 95 1 Deferred (267 ) (22 ) (7 ) State taxes, net of federal benefit: Current 4 1 1 Deferred 12 (15 ) (1 ) Total provision (benefit) $ (152 ) $ 630 $ 119
Tax rate reconciliation, U.S. federal statutory rate to effective tax rate from operations	The differences between the U.S. federal statutory income tax rate and our effective tax rate are: Years Ended October 31, 2019 2018 2017 (in millions) Profit before tax times statutory rate $ 193 $ 221 $ 281 Non-U.S. income taxed at different rates (8 ) (93 ) (43 ) Change in unrecognized tax benefits (13 ) (17 ) (110 ) Impact of the Tax Act — 552 — Extension of the tax incentive in Singapore (299 ) — — Other, net (25 ) (33 ) (9 ) Provision (benefit) for income taxes $ (152 ) $ 630 $ 119 Effective tax rate (16.5 )% 66.6 % 14.8 %
Significant components of deferred tax assets and deferred tax liabilities	The significant components of deferred tax assets and deferred tax liabilities included on the consolidated balance sheet are: Years Ended October 31, 2019 2018 (in millions) Deferred Tax Assets Intangibles $ 131 $ — Property, plant and equipment — 8 Pension benefits and retiree medical benefits 71 49 Employee benefits, other than retirement 34 34 Net operating loss, capital loss, and credit carryforwards 195 185 Share-based compensation 32 31 Deferred revenue 38 38 Other 35 19 Deferred tax assets $ 536 $ 364 Tax valuation allowance (134 ) (135 ) Deferred tax assets, net of valuation allowance $ 402 $ 229 Deferred Tax Liabilities Intangibles $ — $ (112 ) Property, plant and equipment (16 ) — Other (7 ) (21 ) Deferred tax liabilities $ (23 ) $ (133 ) Net deferred tax assets (liabilities) $ 379 $ 96
Current and long-term deferred tax assets and deferred tax liabilities	The breakdown between long-term deferred tax assets and deferred tax liabilities was as follows: October 31, 2019 2018 (in millions) Long-term deferred tax assets (included within other assets) $ 410 $ 165 Long-term deferred tax liabilities (included within other long-term liabilities) (31 ) (69 ) Total $ 379 $ 96
Current and Long Term Tax Assets and Liabilities [Table Text Block]	The breakdown between current and long-term income tax assets and liabilities, excluding deferred tax assets and liabilities, was as follows: October 31, 2019 2018 (in millions) Current income tax assets (included within other current assets) $ 68 $ 59 Long-term income tax assets (included within other assets) 4 19 Current income tax liabilities (included within other accrued liabilities) (292 ) (71 ) Long-term income tax liabilities (included within other long-term liabilities) (328 ) (607 ) Total $ (548 ) $ (600 )
Income tax contingencies rollforward	The aggregate changes in the balances of our gross unrecognized tax benefits including all federal, state and foreign tax jurisdictions are as follows: 2019 2018 2017 (in millions) Balance, beginning of year $ 214 $ 224 $ 293 Additions for tax positions related to the current year 7 27 32 Additions for tax positions from prior years 12 2 1 Reductions for tax positions from prior years (2 ) (13 ) (3 ) Settlements with taxing authorities — — (52 ) Statute of limitations expirations (25 ) (26 ) (47 ) Balance, end of year $ 206 $ 214 $ 224

NET INCOME (LOSS) PER SHARE (Ta

NET INCOME (LOSS) PER SHARE (Tables)	12 Months Ended
NET INCOME (LOSS) PER SHARE (Tables)	Oct. 31, 2019
Earnings Per Share [Abstract]
Reconciliation of the numerators and denominators of the basic and diluted net income per share	The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented below. Years Ended October 31, 2019 2018 2017 (in millions) Numerator: Net income $ 1,071 $ 316 $ 684 Denominators: Basic weighted average shares 314 321 $ 322 Potential common shares — stock options and other employee stock plans 4 4 4 Diluted weighted average shares 318 325 326

INVENTORY (Tables)

INVENTORY (Tables)	12 Months Ended
INVENTORY (Tables)	Oct. 31, 2019
Inventory Disclosure [Abstract]
Inventory	October 31, 2019 2018 (in millions) Finished goods $ 416 $ 386 Purchased parts and fabricated assemblies 263 252 Inventory $ 679 $ 638

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	12 Months Ended
PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	Oct. 31, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	October 31, 2019 2018 (in millions) Land $ 57 $ 55 Buildings and leasehold improvements 1,012 952 Machinery and equipment 546 512 Software 160 141 Total property, plant and equipment 1,775 1,660 Accumulated depreciation and amortization (925 ) (838 ) Property, plant and equipment, net $ 850 $ 822

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	12 Months Ended
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill balances and movements for each reportable segments during the period	The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2018 and 2019 : Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2017 $ 773 $ 1,330 $ 504 $ 2,607 Foreign currency translation impact (7 ) (4 ) (4 ) (15 ) Goodwill arising from acquisitions 37 281 63 381 Goodwill as of October 31, 2018 $ 803 $ 1,607 $ 563 $ 2,973 Foreign currency translation impact (1 ) (2 ) (2 ) (5 ) Goodwill arising from acquisitions and adjustments 636 (11 ) — 625 Goodwill as of October 31, 2019 $ 1,438 $ 1,594 $ 561 $ 3,593
Components of other intangibles during the period	The component parts of other intangible assets at October 31, 2018 and 2019 are shown in the table below: Other Intangible Assets Gross Accumulated Net Book (in millions) As of October 31, 2018: Purchased technology $ 947 $ 683 $ 264 Trademark/Tradename 151 88 63 Customer relationships 107 63 44 Third-party technology and licenses $ 28 $ 19 $ 9 Total amortizable intangible assets $ 1,233 $ 853 $ 380 In-Process R&D 111 — 111 Total $ 1,344 $ 853 $ 491 As of October 31, 2019: Purchased technology $ 1,413 $ 763 $ 650 Backlog 5 5 — Trademark/Tradename 196 102 94 Customer relationships 329 87 242 Third-party technology and licenses $ 28 $ 22 $ 6 Total amortizable intangible assets $ 1,971 $ 979 $ 992 In-Process R&D 115 — 115 Total $ 2,086 $ 979 $ 1,107
Future Amortization expense for the next five years and thereafter	Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) 2020 $ 186 2021 $ 172 2022 $ 150 2023 $ 107 2024 $ 86 Thereafter $ 291

INVESTMENTS (Tables)

INVESTMENTS (Tables)	12 Months Ended
INVESTMENTS (Tables)	Oct. 31, 2019
Schedule of Investments [Abstract]
Equity Investments	The following table summarizes the company's equity investments as of October 31, 2019 and 2018 (net book value): October 31, 2019 2018 (in millions) Long-Term Equity investments - without readily determinable fair value $ 47 $ 23 Equity investments - with readily determinable fair value 25 15 Trading securities 30 30 Total $ 102 $ 68

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Oct. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Assets And Liabilities Measured On Recurring Basis	Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2019 were as follows: Fair Value Measurement at October 31, 2019 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 784 $ 784 $ — $ — Derivative instruments (foreign exchange contracts) 12 — 12 — Long-term Trading securities 30 30 — — Other investments 25 — 25 — Total assets measured at fair value $ 851 $ 814 $ 37 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 6 $ — $ 6 $ — Long-term Deferred compensation liability 30 — 30 — Total liabilities measured at fair value $ 36 $ — $ 36 $ — Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2018 were as follows: Fair Value Measurement at October 31, 2018 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,355 $ 1,355 $ — $ — Derivative instruments (foreign exchange contracts) 16 — 16 — Long-term Trading securities 30 30 — — Total assets measured at fair value $ 1,401 $ 1,385 $ 16 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Long-term Deferred compensation liability 30 — 30 — Total liabilities measured at fair value $ 35 $ — $ 35 $ —
Impairment of Long-lived assets included in net income	For assets measured at fair value on a non-recurring basis, the following table summarizes the impairments included in net income for the years ended October 31, 2019 , 2018 and 2017 : Years Ended October 31, 2019 2018 2017 (in millions) Long-lived assets held and used $ — $ 21 $ — Long-lived assets held for sale $ — $ — $ —

DERIVATIVES (Tables)

DERIVATIVES (Tables)	12 Months Ended
DERIVATIVES (Tables)	Oct. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Aggregated notional amounts by currency and designation	The aggregated notional amounts by currency and designation as of October 31, 2019 were as follows: Derivatives Designated as Derivatives Not Designated as Hedging Instruments Forward Forward Currency Buy/(Sell) Buy/(Sell) (in millions) Euro $ (40 ) $ 141 British Pound (45 ) 1 Canadian Dollar (38 ) 25 Australian Dollar 4 — Malaysian Ringgit — 11 Japanese Yen (82 ) (7 ) Danish Krone — 237 Korean Won (59 ) (32 ) Singapore Dollar 14 28 Swiss Franc — (2 ) Chinese Yuan Renminbi (59 ) (70 ) Swedish Krona — (8 ) Other — (23 ) $ (305 ) $ 301
Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet	The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of October 31, 2019 and 2018 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location October 31, October 31, Balance Sheet Location October 31, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 3 $ 11 Other accrued liabilities $ 2 $ 1 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 9 $ 5 Other accrued liabilities $ 4 $ 4 Total derivatives $ 12 $ 16 $ 6 $ 5
Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations	The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows: Years Ended October 31, 2019 2018 2017 (in millions) Derivatives designated as hedging instruments: Cash flow hedges Loss on interest rate swaps recognized in other comprehensive income (loss) $ (6 ) $ — $ — Loss reclassified from accumulated other comprehensive income into interest expense $ (1 ) $ (1 ) $ — Gain (loss) recognized in accumulated other comprehensive income (loss) $ — $ 7 $ — Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales $ 9 $ (3 ) $ 1 Gain (loss) on time value of forward contracts recorded in cost of sales $ 2 $ — $ — Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense), net $ 2 $ (2 ) $ 5

RETIREMENT PLANS AND POST RET_2

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)	12 Months Ended
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)	Oct. 31, 2019
Defined Benefit Plan [Abstract]
Schedule of net pension and post-retirement benefit costs	For the years ended October 31, 2019 , 2018 and 2017 , components of net periodic benefit cost and other amounts recognized in other comprehensive income were comprised of: Pensions U.S. Post-Retirement Benefit Plans U.S. Plans Non-U.S. Plans 2019 2018 2017 2019 2018 2017 2019 2018 2017 (in millions) Net periodic benefit cost (benefit) Service cost — benefits earned during the period $ — $ — $ — $ 20 $ 20 $ 19 $ — $ 1 $ 1 Interest cost on benefit obligation 18 16 15 14 13 12 4 3 3 Expected return on plan assets (27 ) (28 ) (25 ) (43 ) (46 ) (41 ) (7 ) (7 ) (7 ) Amortization of net actuarial loss 1 1 3 34 29 36 4 8 11 Amortization of prior service benefit — — — — — — (8 ) (8 ) (9 ) Total periodic benefit cost (benefit) $ (8 ) $ (11 ) $ (7 ) $ 25 $ 16 $ 26 $ (7 ) $ (3 ) $ (1 ) Curtailments and settlements $ — $ — $ — $ — $ (5 ) $ (32 ) $ — $ — $ — Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss Net actuarial (gain) loss $ 51 $ 2 $ (19 ) $ 104 $ 49 $ (128 ) $ 5 $ (2 ) $ (9 ) Amortization of net actuarial loss (1 ) (1 ) (3 ) (34 ) (29 ) (36 ) (4 ) (8 ) (11 ) Prior service cost (benefit) — — — — — — — — — Amortization of prior service benefit — — — — — — 8 8 9 Gain due to settlement — — — — — 32 — — — Foreign currency — — — (3 ) 1 2 — — — Total recognized in other comprehensive (income) loss $ 50 $ 1 $ (22 ) $ 67 $ 21 $ (130 ) $ 9 $ (2 ) $ (11 ) Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss $ 42 $ (10 ) $ (29 ) $ 92 $ 32 $ (136 ) $ 2 $ (5 ) $ (12 )
Schedule of Funded status of Defined Benefit and Post-Retirement Benefit plans	Funded Status. As of October 31, 2019 and 2018 , the funded status of the defined benefit and post-retirement benefit plans was: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans 2019 2018 2019 2018 2019 2018 (in millions) Change in fair value of plan assets: Fair value — beginning of year $ 401 $ 414 $ 825 $ 855 $ 90 $ 95 Actual return on plan assets 50 8 85 (9 ) 11 1 Employer contributions — — 21 21 — — Participants' contributions — — 1 — — — Benefits paid (19 ) (21 ) (29 ) (26 ) (6 ) (6 ) Settlements — — — 5 — — Currency impact — — 8 (21 ) — — Fair value — end of year $ 432 $ 401 $ 911 $ 825 $ 95 $ 90 Change in benefit obligation: Benefit obligation — beginning of year $ 420 $ 445 $ 913 $ 935 $ 87 $ 97 Service cost — — 20 20 — 1 Interest cost 18 16 14 13 4 3 Participants' contributions — — 1 — — — Plan amendment — — — 1 — — Actuarial (gain) loss 74 (19 ) 143 (6 ) 9 (7 ) Benefits paid (21 ) (22 ) (29 ) (27 ) (6 ) (7 ) Currency impact — — 5 (23 ) — — Benefit obligation — end of year $ 491 $ 420 $ 1,067 $ 913 $ 94 $ 87 Overfunded (underfunded) status of PBO $ (59 ) $ (19 ) $ (156 ) $ (88 ) $ 1 $ 3 Amounts recognized in the consolidated balance sheet consist of: Other assets $ — $ — $ 106 $ 95 $ 1 $ 3 Employee compensation and benefits (1 ) (1 ) — — — — Retirement and post-retirement benefits (58 ) (18 ) (262 ) (183 ) — — Total net asset (liability) $ (59 ) $ (19 ) $ (156 ) $ (88 ) $ 1 $ 3 Amounts Recognized in Accumulated Other Comprehensive Income (loss): Actuarial (gains) losses $ 115 $ 65 $ 330 $ 263 $ 10 $ 10 Prior service costs (benefits) — — — — (12 ) (20 ) Total $ 115 $ 65 $ 330 $ 263 $ (2 ) $ (10 )
Amounts in accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year	The amounts in accumulated other comprehensive income expected to be recognized by Agilent as components of net expense during 2020 are as follows: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans (in millions) Amortization of net prior service cost (benefit) $ — $ — $ (7 ) Amortization of actuarial net loss (gain) $ 3 $ 48 $ 4
Defined benefit plan assets by fair value hierarchy	The following tables present the fair value of non-U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2019 and 2018 : Fair Value Measurement at October 31, 2019 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 1 $ — $ 1 $ — $ — Equity 512 318 61 — 133 Fixed Income 398 98 213 — 87 Other Investments — — — — — Total assets measured at fair value $ 911 $ 416 $ 275 $ — $ 220 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. Fair Value Measurement at October 31, 2018 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 2 $ — $ 2 $ — $ — Equity 489 298 60 — 131 Fixed Income 334 76 228 — 30 Other Investments — — — — — Total assets measured at fair value $ 825 $ 374 $ 290 $ — $ 161 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The following tables present the fair value of U.S. Defined Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2019 and 2018 . Fair Value Measurement at October 31, 2019 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 1 $ — $ — $ — $ 1 Equity 336 78 — — 258 Fixed Income 91 46 — — 45 Other Investments 4 — — 4 — Total assets measured at fair value $ 432 $ 124 $ — $ 4 $ 304 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. Fair Value Measurement at October 31, 2018 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 4 $ — $ — $ — $ 4 Equity 308 69 — — 239 Fixed Income 83 36 5 — 42 Other Investments 6 — — 6 — Total assets measured at fair value $ 401 $ 105 $ 5 $ 6 $ 285 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The following tables present the fair value of U.S. Post-Retirement Benefit Plans assets classified under the appropriate level of the fair value hierarchy as of October 31, 2019 and 2018 . Fair Value Measurement at October 31, 2019 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 3 $ — $ — $ — $ 3 Equity 69 18 — — 51 Fixed Income 21 11 — — 10 Other Investments 2 — — 2 — Total assets measured at fair value $ 95 $ 29 $ — $ 2 $ 64 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. Fair Value Measurement at October 31, 2018 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Not Subject to Leveling (1) (in millions) Cash and Cash Equivalents $ 3 $ — $ — $ — $ 3 Equity 65 15 — — 50 Fixed Income 18 9 — — 9 Other Investments 4 — — 4 — Total assets measured at fair value $ 90 $ 24 $ — $ 4 $ 62 (1) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
Defined benefit plans assets measured at fair value using significant unobservable inputs (level 3)	For U.S. Defined Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2019 and 2018 : Years Ended October 31. 2019 2018 Balance, beginning of year $ 6 $ 7 Realized gains/(losses) (1 ) — Unrealized gains/(losses) 1 1 Purchases, sales, issuances, and settlements (2 ) (2 ) Transfers in (out) — — Balance, end of year $ 4 $ 6 For U.S. Post-Retirement Benefit Plans assets measured at fair value using significant unobservable inputs (level 3), the following table summarizes the change in balances during 2019 and 2018 : Years Ended October 31, 2019 2018 Balance, beginning of year $ 4 $ 4 Realized gains/(losses) (1 ) — Unrealized gains/(losses) — 1 Purchases, sales, issuances, and settlements (1 ) (1 ) Transfers in (out) — — Balance, end of year $ 2 $ 4
Combined projected benefit obligation, accumulated benefit obligations and fair value of plan assets	The table below presents the combined projected benefit obligation ("PBO"), accumulated benefit obligation ("ABO") and fair value of plan assets, grouping plans using comparisons of the PBO and ABO relative to the plan assets as of October 31, 2019 or 2018 . 2019 2018 Benefit Obligation Benefit Obligation Fair Value of Plan Assets Fair Value of Plan Assets PBO PBO (in millions) U.S. defined benefit plans where PBO exceeds the fair value of plan assets $ 491 $ 432 $ 420 $ 401 U.S. defined benefit plans where fair value of plan assets exceeds PBO — — — — Total $ 491 $ 432 $ 420 $ 401 Non-U.S. defined benefit plans where PBO exceeds or is equal to the fair value of plan assets $ 752 $ 490 $ 563 $ 380 Non-U.S. defined benefit plans where fair value of plan assets exceeds PBO 315 421 350 445 Total $ 1,067 $ 911 $ 913 $ 825 ABO ABO U.S. defined benefit plans where ABO exceeds the fair value of plan assets $ 491 $ 432 $ 420 $ 401 U.S. defined benefit plans where the fair value of plan assets exceeds ABO — — — — Total $ 491 $ 432 $ 420 $ 401 Non-U.S. defined benefit plans where ABO exceeds or is equal to the fair value of plan assets $ 651 $ 418 $ 543 $ 380 Non-U.S. defined benefit plans where fair value of plan assets exceeds ABO 381 493 343 445 Total $ 1,032 $ 911 $ 886 $ 825
Schedule of expected benefit payments	The following table presents expected future benefit payments for the next 10 years: U.S. Defined Benefit Plans Non-U.S. Defined Benefit Plans U.S. Post-Retirement Benefit Plans (in millions) 2020 $ 35 $ 25 $ 8 2021 $ 36 $ 27 $ 8 2022 $ 33 $ 29 $ 7 2023 $ 35 $ 32 $ 7 2024 $ 37 $ 32 $ 7 2025 - 2029 $ 146 $ 170 $ 35
Assumptions used to calculate the net periodic cost and benefit obligation	Assumptions used to calculate the net periodic cost in each year were as follows: For years ended October 31, 2019 2018 2017 U.S. defined benefit plans: Discount rate 4.50% 3.75% 3.75% Expected long-term return on assets 7.00% 7.00% 7.25% Non-U.S. defined benefit plans: Discount rate 0.83-2.68% 0.67-2.52% 0.22-2.66% Average increase in compensation levels 2.25-3.25% 2.00-3.25% 2.00-4.25% Expected long-term return on assets 4.00-5.75% 4.00-6.00% 4.00-6.25% U.S. post-retirement benefits plans: Discount rate 4.25% 3.50% 3.50% Expected long-term return on assets 7.00% 7.00% 7.25% Current medical cost trend rate 6.00% 6.00% 6.00% Ultimate medical cost trend rate 3.50% 3.50% 3.50% Medical cost trend rate decreases to ultimate rate in year 2029 2029 2029 Assumptions used to calculate the benefit obligation were as follows: As of the Years Ending October 31, 2019 2018 U.S. defined benefit plans: Discount rate 3.25% 4.50% Non-U.S. defined benefit plans: Discount rate 0.22-1.81% 0.83-2.68% Average increase in compensation levels 2.25-3.00% 2.25-3.25% U.S. post-retirement benefits plans: Discount rate 3.00% 4.25% Current medical cost trend rate 6.25% 6.00% Ultimate medical cost trend rate 4.50% 3.50% Medical cost trend rate decreases to ultimate rate in year 2029 2029

GUARANTEES (Tables)

GUARANTEES (Tables)	12 Months Ended
GUARANTEES (Tables)	Oct. 31, 2019
Guarantees [Abstract]
Standard Warranty	A summary of the standard warranty accrual activity is shown in the table below. The standard warranty accrual balances are recorded in other accrued liabilities. October 31, 2019 2018 (in millions) Balance as of October 31, 2018 and 2017 $ 35 $ 34 Accruals for warranties including change in estimates 54 53 Settlements made during the period (57 ) (52 ) Balance as of October 31, 2019 and 2018 $ 32 $ 35
Schedule of Product Warranty Liability classification	Accruals for warranties due within one year 32 35

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Tables)	Oct. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future non-cancelable minimum lease payments and future minimum lease income under operating leases at October 31, 2019 : Future Minimum Future Minimum (in millions) 2020 $ 52 $ 8 2021 $ 41 $ 6 2022 $ 29 $ 5 2023 $ 21 $ — 2024 $ 14 $ — Thereafter $ 56 $ —

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	12 Months Ended
LONG-TERM DEBT (Tables)	Oct. 31, 2019
Debt Disclosure [Abstract]
Schedule of Interest Rate Swaps pertaining to Senior Notes offered	The following table summarizes the company's long-term senior notes and the related interest rate swaps: October 31, 2019 October 31, 2018 Amortized Principal Swap Total Amortized Principal Swap Total (in millions) 2020 Senior Notes $ — $ — $ — $ 499 $ 7 $ 506 2022 Senior Notes 399 — 399 399 — 399 2023 Senior Notes 597 — 597 597 — 597 2026 Senior Notes 298 — 298 297 — 297 2029 Senior Notes 492 — 492 — — — Total $ 1,786 $ — $ 1,786 $ 1,792 $ 7 $ 1,799

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
STOCKHOLDERS' EQUITY (Tables)	Oct. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	The following table summarizes the components of our accumulated other comprehensive income (loss) as of October 31, 2019 and 2018 , net of tax effect: October 31, 2019 2018 (in millions) Foreign currency translation, net of tax expense of $(5) and $(15) for 2019 and 2018, respectively $ (204 ) (214 ) Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $153 and $132 for 2019 and 2018, respectively (306 ) (201 ) Unrealized gains (losses) on derivative instruments, net of tax benefit of $3 and $0 for 2019 and 2018, respectively (4 ) 7 Total accumulated other comprehensive loss $ (514 ) $ (408 ) Changes in accumulated other comprehensive income (loss) by component and related tax effects for the years ended October 31, 2019 and 2018 were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of October 31, 2017 $ (156 ) $ 140 $ (328 ) $ (2 ) $ (346 ) Other comprehensive income (loss) before reclassifications (51 ) — (49 ) 7 (93 ) Amounts reclassified out of accumulated other comprehensive income (loss) — (8 ) 39 4 35 Tax (expense) benefit (7 ) 2 3 (2 ) (4 ) Other comprehensive income (loss) (58 ) (6 ) (7 ) 9 (62 ) As of October 31, 2018 $ (214 ) $ 134 $ (335 ) $ 7 $ (408 ) Impact of adoption of new guidance on tax effects in accumulated other comprehensive income (loss) — 3 (9 ) (1 ) (7 ) As of November 1, 2018 (214 ) 137 (344 ) 6 (415 ) Other comprehensive loss before reclassifications — — (157 ) (6 ) (163 ) Amounts reclassified out of accumulated other comprehensive income — (8 ) 39 (8 ) 23 Tax benefit 10 2 25 4 41 Other comprehensive income (loss) 10 (6 ) (93 ) (10 ) (99 ) As of October 31, 2019 $ (204 ) $ 131 $ (437 ) $ (4 ) $ (514 )
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	Reclassifications out of accumulated other comprehensive income (loss) for the years ended October 31, 2019 and 2018 were as follows (in millions): Details about Accumulated Other Amounts Reclassified Affected line item in 2019 2018 Unrealized gains and (losses) on derivatives $ 8 $ (4 ) Cost of products and interest expense 8 (4 ) Total before income tax (2 ) 1 (Provision)/benefit for income tax 6 (3 ) Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (39 ) (39 ) Other (income) expense Prior service benefit 8 8 Other (income) expense (31 ) (31 ) Total before income tax 12 10 Benefit for income tax (19 ) (21 ) Total net of income tax Total reclassifications for the period $ (13 ) $ (24 )

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
SEGMENT INFORMATION (Tables)	Oct. 31, 2019
Revenue from External Customer [Line Items]
Segment profitability	The profitability of each of the segments is measured after excluding restructuring and asset impairment charges, transformational initiatives, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Year Ended October 31, 2019: Total net revenue $ 2,302 $ 1,021 $ 1,840 $ 5,163 Income from operations $ 542 $ 185 $ 475 $ 1,202 Depreciation expense $ 41 $ 35 $ 35 $ 111 Share-based compensation expense $ 33 $ 14 $ 25 $ 72 Year Ended October 31, 2018: Total net revenue $ 2,270 $ 943 $ 1,701 $ 4,914 Income from operations $ 543 $ 173 $ 388 $ 1,104 Depreciation expense $ 38 $ 33 $ 31 $ 102 Share-based compensation expense $ 33 $ 14 $ 24 $ 71 Year Ended October 31, 2017: Total net revenue $ 2,081 $ 860 $ 1,531 $ 4,472 Income from operations $ 470 $ 167 $ 336 $ 973 Depreciation expense $ 35 $ 30 $ 29 $ 94 Share-based compensation expense $ 30 $ 10 $ 21 $ 61
Reconciliation of segment results to total enterprise results	The following table reconciles reportable segments' income from operations to Agilent's total enterprise income before taxes: Years Ended October 31, 2019 2018 2017 (in millions) Total reportable segments' income from operations $ 1,202 $ 1,104 $ 973 Amortization of intangible assets related to business combinations (125 ) (105 ) (117 ) Acquisition and integration costs (48 ) (23 ) (30 ) Transformational initiatives (44 ) (25 ) (12 ) Asset impairments — (21 ) — Business exit and divestiture costs (primarily our NMR business) — (9 ) — NASD site costs (12 ) (8 ) — Special compliance costs (2 ) (4 ) — Other (1) (30 ) (5 ) (7 ) Interest Income 36 38 22 Interest Expense (74 ) (75 ) (79 ) Other income (expense), net 16 79 53 Income before taxes, as reported $ 919 $ 946 $ 803 (1) The other category primarily includes legal costs related to our pursuing our claim against a third party in addition to other miscellaneous adjustments and settlements.
Assets and capital expenditures directly managed by each segment	The following table reflects segment assets and capital expenditures under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets. Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) As of and for the Year Ended October 31, 2019: Assets $ 3,202 $ 2,620 $ 1,331 $ 7,153 Capital expenditures $ 59 $ 48 $ 48 $ 155 As of and for the Year Ended October 31, 2018: Assets $ 1,744 $ 2,679 $ 1,267 $ 5,690 Capital expenditures $ 47 $ 92 $ 38 $ 177 The following table reconciles segment assets to Agilent's total assets: October 31, 2019 2018 (in millions) Total reportable segments' assets $ 7,153 $ 5,690 Cash, cash equivalents 1,382 2,247 Prepaid expenses 94 80 Investments 102 68 Long-term and other receivables 100 102 Other 621 354 Total assets $ 9,452 $ 8,541 The other category primarily includes deferred tax assets and overfunded pension assets which are not allocated to the segments.
Revenue and assets by geographic areas	The following table presents summarized information for net revenue by geographic region. Revenues from external customers are generally attributed to countries based upon the customer's location. United China (1) Rest of the Total (in millions) Net revenue: Year Ended October 31, 2019 $ 1,619 $ 1,019 $ 2,525 $ 5,163 Year Ended October 31, 2018 $ 1,414 $ 1,015 $ 2,485 $ 4,914 Year Ended October 31, 2017 $ 1,314 $ 900 $ 2,258 $ 4,472 1. China also includes Hong Kong net revenue. The following table presents summarized information for long-lived assets by geographic region. Long lived assets consist of property, plant, and equipment, long-term receivables and other long-term assets excluding intangible assets. The rest of the world primarily consists of Asia and the rest of Europe. United Germany Rest of the Total (in millions) Long-lived assets: October 31, 2019 $ 621 $ 122 $ 404 $ 1,147 October 31, 2018 $ 565 $ 117 $ 362 $ 1,044

OVERVIEW AND SUMMARY OF SIGNI_3

OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions	Mar. 02, 2016	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Goodwill and Intangible Assets
Goodwill impairment		$ 0	$ 0	$ 0
Impairment of indefinite-lived intangible assets		0	0	0
Share-based Payment Arrangement, Noncash Expense [Abstract]
Share-based compensation expense		72	71	61
Advertising Expense
Advertising costs expensed as incurred		36	41	38
Cash and Cash Equivalents
Cash and cash equivalents held outside the U.S.		1,310
Variable Interest Entity
Remeasurement Gain on step acquisition		0	20	0
Variable interest entity		0	0
Fair Value Disclosures
Equity Method Investments		0	0
Fair value of long term debt in excess of carrying value			$ 15
Fair value lower than carrying value		$ 62
Accounts Receivable
Maximum percentage of accounts receivable a single customer accounts for		less than 10 percent	less than 10 percent
Derivative Instruments
Hedging contracts general maturity		12 months
Long -Lived Assets
Lease renewal options		6 years
Lease receivable		$ 37	$ 32
operating lease net assets		17	20
Impairment of finite-lived intangible assets		0	21	0
Employee Compensation and Benefits
Employee compensation and benefits accrued		115	107
Foreign Currency Translation
Foreign currency translation net gain (Ioss)		$ (7)	(3)	$ (2)
Lasergen [Member]
Variable Interest Entity
Cost method investments, original cost	$ 80
Ownership percentage	48.00%
Purchase price for acquisition			107
Remeasurement Gain on step acquisition			$ 20
Minimum
Goodwill and Intangible Assets
Finite Lived Intangible Assets Useful Life		6 months
Long -Lived Assets
Operating Lease Term - Minimum		1 year
Minimum \| Machinery and Equipment [Member]
Long -Lived Assets
Property, Plant and Equipment, Useful Life		3 years
Minimum \| Software Development [Member]
Long -Lived Assets
Property, Plant and Equipment, Useful Life		3 years
Maximum
Goodwill and Intangible Assets
Finite Lived Intangible Assets Useful Life		15 years
Long -Lived Assets
Operating Lease Term - Minimum		30 years
Maximum \| Machinery and Equipment [Member]
Long -Lived Assets
Property, Plant and Equipment, Useful Life		10 years
Maximum \| Software Development [Member]
Long -Lived Assets
Property, Plant and Equipment, Useful Life		5 years

NEW ACCOUNTING PRONOUNCEMENTS -

NEW ACCOUNTING PRONOUNCEMENTS - Impact of adopting new guidance (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Nov. 01, 2018	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2016
Cash and cash equivalents	$ 1,382	$ 2,247	$ 2,247	$ 2,678
Accounts receivable, net	930	800	776
Inventory	679	628	638
Other current assets	198	190	187
Total current assets	3,189	3,865	3,848
Property, plant and equipment, net	850	822	822
Goodwill	3,593	2,973	2,973	2,607
Other intangible assets, net	1,107	491	491
Long-term Investments	102	75	68
Other assets	611	332	339
Total assets	9,452	8,558	8,541
Accounts payable	354	340	340
Employee compensation and benefits	334	304	304
Deferred revenue	336	313	324
Other accrued liabilities	440	203	203
Total current liabilities	2,080	1,160	1,171
Long-term debt	1,791	1,799	1,799
Retirement and post-retirement benefits	360	239	239
Other long-term liabilities	473	763	761
Total liabilities	4,704	3,961	3,970
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding	0	0	0
Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018 issued	3	3	3
Additional paid-in-capital	5,277	5,308	5,308
Accumulated deficit	$ (18)	(303)	(336)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Accumulated other comprehensive loss	$ (514)	(415)	(408)	(346)
Total stockholders' equity	4,748	4,593	4,567
Non-controlling interest	0	4	4
Total equity	4,748	4,597	4,571	$ 4,835	$ 4,246
Total liabilities and equity	$ 9,452	8,558	$ 8,541
Impact of Adopting New Revenue Recognition Guidance [Member]
Cash and cash equivalents		0
Accounts receivable, net		24
Inventory		(10)
Other current assets		3
Total current assets		17
Property, plant and equipment, net		0
Goodwill		0
Other intangible assets, net		0
Long-term Investments		0
Other assets		(3)
Total assets		14
Accounts payable		0
Employee compensation and benefits		0
Deferred revenue		(11)
Other accrued liabilities		0
Total current liabilities		(11)
Long-term debt		0
Retirement and post-retirement benefits		0
Other long-term liabilities		2
Total liabilities		(9)
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding		0
Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018 issued		0
Additional paid-in-capital		0
Accumulated deficit		23
Accumulated other comprehensive loss		0
Total stockholders' equity		23
Non-controlling interest		0
Total equity		23
Total liabilities and equity		14
Impact of Adopting New Tax Effects in AOCI Guidance [Member]
Cash and cash equivalents		0
Accounts receivable, net		0
Inventory		0
Other current assets		0
Total current assets		0
Property, plant and equipment, net		0
Goodwill		0
Other intangible assets, net		0
Long-term Investments		0
Other assets		0
Total assets		0
Accounts payable		0
Employee compensation and benefits		0
Deferred revenue		0
Other accrued liabilities		0
Total current liabilities		0
Long-term debt		0
Retirement and post-retirement benefits		0
Other long-term liabilities		0
Total liabilities		0
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding		0
Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018 issued		0
Additional paid-in-capital		0
Accumulated deficit		7
Accumulated other comprehensive loss		(7)
Total stockholders' equity		0
Non-controlling interest		0
Total equity		0
Total liabilities and equity		0
Impact of Adopting New Intra-Entity Tax Guidance [Member]
Cash and cash equivalents		0
Accounts receivable, net		0
Inventory		0
Other current assets		0
Total current assets		0
Property, plant and equipment, net		0
Goodwill		0
Other intangible assets, net		0
Long-term Investments		0
Other assets		(2)
Total assets		(2)
Accounts payable		0
Employee compensation and benefits		0
Deferred revenue		0
Other accrued liabilities		0
Total current liabilities		0
Long-term debt		0
Retirement and post-retirement benefits		0
Other long-term liabilities		0
Total liabilities		0
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding		0
Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018 issued		0
Additional paid-in-capital		0
Accumulated deficit		(2)
Accumulated other comprehensive loss		0
Total stockholders' equity		(2)
Non-controlling interest		0
Total equity		(2)
Total liabilities and equity		(2)
Impact of Adopting New Investments Valuation Guidance [Member]
Cash and cash equivalents		0
Accounts receivable, net		0
Inventory		0
Other current assets		0
Total current assets		0
Property, plant and equipment, net		0
Goodwill		0
Other intangible assets, net		0
Long-term Investments		7
Other assets		(2)
Total assets		5
Accounts payable		0
Employee compensation and benefits		0
Deferred revenue		0
Other accrued liabilities		0
Total current liabilities		0
Long-term debt		0
Retirement and post-retirement benefits		0
Other long-term liabilities		0
Total liabilities		0
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding		0
Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018 issued		0
Additional paid-in-capital		0
Accumulated deficit		5
Accumulated other comprehensive loss		0
Total stockholders' equity		5
Non-controlling interest		0
Total equity		5
Total liabilities and equity		$ 5

NEW ACCOUNTING PRONOUNCEMENTS_2

NEW ACCOUNTING PRONOUNCEMENTS - Textuals (Details) - USD ($) $ in Millions	Nov. 01, 2018	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	$ (7)
Retained Earnings (Accumulated Deficit)	(303)	$ (18)	$ (336)
Long-term Investments	75	$ 102	68
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%
Operating Lease, Right-of-Use Asset		$ 195
Impact of Adopting New Revenue Recognition Guidance [Member]
Retained Earnings (Accumulated Deficit)	23
Long-term Investments	0
Impact of Adopting New Tax Effects in AOCI Guidance [Member]
Retained Earnings (Accumulated Deficit)	7
Long-term Investments	0
Impact of Adopting New Intra-Entity Tax Guidance [Member]
Retained Earnings (Accumulated Deficit)	(2)
Long-term Investments	0
Impact of Adopting New Investments Valuation Guidance [Member]
Retained Earnings (Accumulated Deficit)	5
Long-term Investments	$ 7
Impact of Adopting New Retirement Benefits Guidance [Member]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification		$ 10	$ 24	$ 34

NEW ACCOUNTING PRONOUNCEMENTS N

NEW ACCOUNTING PRONOUNCEMENTS NEW ACCOUNTING PRONOUNCEMENTS - Restricted cash (Details) - USD ($) $ in Millions	Oct. 31, 2019	Nov. 01, 2018	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2016
Statement of Cash Flows [Abstract]
Cash and cash equivalents	$ 1,382	$ 2,247	$ 2,247	$ 2,678
Restricted cash included in other assets	6		7	8
Cash, cash equivalents and restricted cash	$ 1,388		$ 2,254	$ 2,686	$ 2,295

ACQUISITIONS - Text (Details)

ACQUISITIONS - Text (Details) - USD ($) $ in Millions	12 Months Ended
ACQUISITIONS - Text (Details) - USD ($) $ in Millions	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Business Acquisition [Line Items]
Net revenue	$ 5,163	$ 4,914	$ 4,472
Net income	1,071	$ 316	$ 684
Cash payment to acquire business	107
ACEA Biosciences, Inc. [Member]
Business Acquisition [Line Items]
Purchase price for acquisition	250
BioTek [Member]
Business Acquisition [Line Items]
Purchase price for acquisition	1,170
Net revenue	35
Net income	(12)
Cash payment to acquire business	470
Liability incurred to pay for acquisition	700
Acquisition transaction costs	4
Estimated costs to complete in-process research and development projects	$ 2

ACQUISITIONS - Assets and Liabi

ACQUISITIONS - Assets and Liabilities Assumed (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Business Acquisition [Line Items]
Goodwill Additions	$ 625	$ 381
BioTek [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	10
Accounts receivables	28
Inventories	21
Other current assets	2
Property, plant, and equipment	8
Intangible assets	641
Goodwill Additions	483
Total assets acquired	1,193
Accounts payable	4
Deferred revenue	5
Employee compensation and benefits	7
Other accrued liabilities	2
Long-term debt	4
Net assets acquired	$ 1,171

ACQUISITIONS ACQUISITIONS - Int

ACQUISITIONS ACQUISITIONS - Intangible Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Business Acquisition [Line Items]
Finite-lived intangible assets acquired	$ 1,971	$ 1,233
In-Process R&D	115	111
Total intangible assets acquired - excluding goodwill	2,086	1,344
BioTek [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets acquired	637
In-Process R&D	4
Total intangible assets acquired - excluding goodwill	641
Developed product technology
Business Acquisition [Line Items]
Finite-lived intangible assets acquired	1,413	947
Developed product technology \| BioTek [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets acquired	387
Customer relationships
Business Acquisition [Line Items]
Finite-lived intangible assets acquired	329	$ 107
Customer relationships \| BioTek [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets acquired	202
Backlog
Business Acquisition [Line Items]
Finite-lived intangible assets acquired	5
Backlog \| BioTek [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets acquired	$ 5
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	2 months
Tradenames and trademarks \| BioTek [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets acquired	$ 43
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
Minimum \| Developed product technology \| BioTek [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	5 years
Minimum \| Customer relationships \| BioTek [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	3 years
Maximum \| Developed product technology \| BioTek [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	13 years
Maximum \| Customer relationships \| BioTek [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	8 years

ACQUISITIONS ACQUISITIONS - Pro

ACQUISITIONS ACQUISITIONS - Proforma Operating Results (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Business Acquisition [Line Items]
Proforma net revenue	$ 5,308	$ 5,112
Proforma net income	$ 1,012	$ 210
Proforma net income per share - basic	$ 3.22	$ 0.65
Proforma net income per share - diluted	$ 3.18	$ 0.65

REVENUE - Revenue by Region (De

REVENUE - Revenue by Region (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Disaggregation of Revenue [Line Items]
Net revenue	$ 5,163	$ 4,914	$ 4,472
Americas
Disaggregation of Revenue [Line Items]
Net revenue	1,861
Europe
Disaggregation of Revenue [Line Items]
Net revenue	1,441
Asia Pacific
Disaggregation of Revenue [Line Items]
Net revenue	1,861
Life Sciences and Applied Markets
Disaggregation of Revenue [Line Items]
Net revenue	2,302	2,270	2,081
Life Sciences and Applied Markets \| Americas
Disaggregation of Revenue [Line Items]
Net revenue	692
Life Sciences and Applied Markets \| Europe
Disaggregation of Revenue [Line Items]
Net revenue	551
Life Sciences and Applied Markets \| Asia Pacific
Disaggregation of Revenue [Line Items]
Net revenue	1,059
Diagnostics and Genomics
Disaggregation of Revenue [Line Items]
Net revenue	1,021	943	860
Diagnostics and Genomics \| Americas
Disaggregation of Revenue [Line Items]
Net revenue	505
Diagnostics and Genomics \| Europe
Disaggregation of Revenue [Line Items]
Net revenue	368
Diagnostics and Genomics \| Asia Pacific
Disaggregation of Revenue [Line Items]
Net revenue	148
Agilent CrossLab
Disaggregation of Revenue [Line Items]
Net revenue	1,840	$ 1,701	$ 1,531
Agilent CrossLab \| Americas
Disaggregation of Revenue [Line Items]
Net revenue	664
Agilent CrossLab \| Europe
Disaggregation of Revenue [Line Items]
Net revenue	522
Agilent CrossLab \| Asia Pacific
Disaggregation of Revenue [Line Items]
Net revenue	$ 654

REVENUE - Revenue by End Market

REVENUE - Revenue by End Markets (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Disaggregation of Revenue [Line Items]
Net revenue	$ 5,163	$ 4,914	$ 4,472
Pharmaceutical and Biopharmaceutical Market
Disaggregation of Revenue [Line Items]
Net revenue	1,604
Chemical and Energy Market
Disaggregation of Revenue [Line Items]
Net revenue	1,199
Diagnostics and Clinical Market
Disaggregation of Revenue [Line Items]
Net revenue	785
Food Market
Disaggregation of Revenue [Line Items]
Net revenue	486
Academia and Government Market
Disaggregation of Revenue [Line Items]
Net revenue	474
Environmental and Forensics Market
Disaggregation of Revenue [Line Items]
Net revenue	$ 615

REVENUE REVENUE - Revenue by Ty

REVENUE REVENUE - Revenue by Type (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Disaggregation of Revenue [Line Items]
Net revenue	$ 5,163	$ 4,914	$ 4,472
Instrumentation
Disaggregation of Revenue [Line Items]
Net revenue	2,150
Non-Instrumentation and Other
Disaggregation of Revenue [Line Items]
Net revenue	$ 3,013

REVENUE REVENUE - Contract Bala

REVENUE REVENUE - Contract Balances (Details) - USD ($) $ in Millions	Nov. 01, 2018	Oct. 31, 2019
Revenue, Remaining Performance Obligation, Amount		$ 207
Contract with Customer, Asset, after Allowance for Credit Loss	$ 57	110
Contract Liability ending balance as of October 31, 2018	367	367
Increase (Decrease) in Contract with Customer, Liability		303
Contract with Customer, Liability, Revenue Recognized		(287)
Increase (Decrease) in Deferred Revenue and Customer Advances and Deposits		5
Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination		9
Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)		0
Contract Liability ending balance as of October 31, 2019		386
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Contract with Customer, Asset, after Allowance for Credit Loss		$ 53
Deferred Revenue, Period Increase (Decrease)	$ (11)

SHARE-BASED COMPENSATION Genera

SHARE-BASED COMPENSATION General Disclosures (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Employee stock purchase plan [Abstract]
Compensation percentage maximum eligible contribution to purchase shares of common stock	10.00%
ESPP eligible employee common stock purchase price ratio	85.00%
Maximum number of shares authorized for issuance under the ESPP (in shares)	75,000,000
Number of shares purchased under ESPP (in shares)	603,488	558,116	618,270
Aggregate Value stock issued under Employee Stock Purchase Plan	$ 37	$ 32	$ 26
Aggregate participants contributions to ESPP	$ 20
Incentive compensation plans [Abstract]
Term of the 2018 Stock Plan (in years)	ten years
Common stock available for future awards under the 2018 Stock Plan (in shares)	28,676,526
Maximum contractual term (in years)	10 years
Percentage market value of the common stock option exercise price is generally not less than (in hundredths)	100.00%
Minimum final share award percentage of the target award based on performance metrics (in hundredths)	0.00%
Maximum final share award percentage of the target award based on performance metrics (in hundredths)	200.00%
Time period after which participants of the performance stock award plan are entitled to receive unrestricted share of the company's stock, if specified performance targets are met	3 years
Employee Stock Purchase Plan
Incentive compensation plans [Abstract]
Common stock available for future awards under the 2018 Stock Plan (in shares)	26,055,571
Share-based Payment Arrangement, Option [Member]
Incentive compensation plans [Abstract]
Percentage which rate options generally vest per year (in hundredths)	25.00%
Number of years from the date of grant generally vest (in years)	4 years
Restricted Stock Units (RSUs) [Member]
Incentive compensation plans [Abstract]
Percentage which rate options generally vest per year (in hundredths)	25.00%
Number of years from the date of grant generally vest (in years)	4 years

SHARE-BASED COMPENSATION Alloca

SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Share-based compensation disclosures
Share-based compensation expense	$ 72	$ 71	$ 61
Cost of Product and Services
Share-based compensation disclosures
Share-based compensation expense	18	16	15
Research and Development
Share-based compensation disclosures
Share-based compensation expense	7	7	6
Selling, General and Administrative
Share-based compensation disclosures
Share-based compensation expense	47	48	$ 40
Inventories
Share-based Payment Arrangement, Expensed and Capitalized, Amount
Share-based compensation expense	$ 0	$ 0

SHARE-BASED COMPENSATION-Fair V

SHARE-BASED COMPENSATION-Fair Value Assumptions (Details)	12 Months Ended
SHARE-BASED COMPENSATION-Fair Value Assumptions (Details)	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
LTPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility of Agilent shares (in hundreths)	22.00%	21.00%	23.00%
Volatility of selected peer-company shares, Minimum (in hundreths)	15.00%	14.00%	15.00%
Volatility of selected peer-company shares, Maximum (in hundreths)	66.00%	66.00%	63.00%
Pair-wise correlation with selected peers (in hundredths)	30.00%	32.00%	36.00%
LTPP & RSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Post-vest restriction discount for all executive awards	5.00%	4.80%	5.30%

SHARE-BASED COMPENSATION Stock

SHARE-BASED COMPENSATION Stock Option Activity (Details) - $ / shares shares in Thousands	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning balance (in shares)	1,997
Exercised (in shares)	(552)
Options Forfeited (in shares)	0
Outstanding, ending balance (in shares)	1,445	1,997
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted-average exercise price per share, beginning of period (in dollars per share)	$ 35
Weighted-average exercise price per share, exercised (in dollars per share)	33	$ 32	$ 30
Weighted-average exercise price per share, cancelled, expired and forfeited (in dollars per shares)	0
Weighted-average exercise price per share, end of period (in dollars per share)	$ 36

SHARE-BASED COMPENSATION Shares

SHARE-BASED COMPENSATION Shares Authorized by Exercise Price Range (Details) - USD ($) $ / shares in Units, shares in Thousands	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Number Outstanding (in shares)	1,445
Weighted Average Remaining Contractual Life (in years)	4 years
Weighted Average Exercise Price (in dollars per share)	$ 36
Aggregate Intrinsic Value - Options outstanding	$ 57,825,000
Number Exercisable (in shares)	1,445
Weighted Average Remaining Contractual Life (in years)	4 years
Weighted Average Exercise Price (in dollars per share)	$ 36
Aggregate Intrinsic Value - Options Exercisable	$ 57,825,000
Closing stock price basis for aggregate intrinsic value (in dollars per share)	$ 75.75
In-the-money awards exercisable (in shares)	1,400
Aggregate instrinsic value of options [Abstract]
Options exercised in period aggregate intrinsic value	$ 24,409,000	$ 28,417,000	$ 36,175,000
Options exercised in period aggregate weighted average exercise price (in dollars per share)	$ 33	$ 32	$ 30
Amount of cash received from the exercise of share-based awards granted	$ 54,000,000	$ 56,000,000	$ 66,000,000
Range of Exercise Prices - $25.01 - $30 [Member]
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Minimum price of options outstanding, end of the period (in dollars per share)	$ 25.01
Maximum price of options outstanding, end of the period (in dollars per share)	$ 30
Number Outstanding (in shares)	483
Weighted Average Remaining Contractual Life (in years)	2 years 6 months
Weighted Average Exercise Price (in dollars per share)	$ 26
Aggregate Intrinsic Value - Options outstanding	$ 23,769,000
Number Exercisable (in shares)	483
Weighted Average Remaining Contractual Life (in years)	2 years 6 months
Weighted Average Exercise Price (in dollars per share)	$ 26
Aggregate Intrinsic Value - Options Exercisable	$ 23,769,000
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 02 [Member]
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Minimum price of options outstanding, end of the period (in dollars per share)	$ 30.01
Maximum price of options outstanding, end of the period (in dollars per share)	$ 40
Number Outstanding (in shares)	296
Weighted Average Remaining Contractual Life (in years)	4 years 1 month
Weighted Average Exercise Price (in dollars per share)	$ 39
Aggregate Intrinsic Value - Options outstanding	$ 10,845,000
Number Exercisable (in shares)	296
Weighted Average Remaining Contractual Life (in years)	4 years 1 month
Weighted Average Exercise Price (in dollars per share)	$ 39
Aggregate Intrinsic Value - Options Exercisable	$ 10,845,000
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range 03 [Member]
Sharebased Compensation Arrangement By Exercise Price Range [Abstract]
Minimum price of options outstanding, end of the period (in dollars per share)	$ 40.01
Number Outstanding (in shares)	666
Weighted Average Remaining Contractual Life (in years)	5 years
Weighted Average Exercise Price (in dollars per share)	$ 41
Aggregate Intrinsic Value - Options outstanding	$ 23,211,000
Number Exercisable (in shares)	666
Weighted Average Remaining Contractual Life (in years)	5 years
Weighted Average Exercise Price (in dollars per share)	$ 41
Aggregate Intrinsic Value - Options Exercisable	$ 23,211,000
Share-based Payment Arrangement, Option [Member]
Aggregate instrinsic value of options [Abstract]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 0

SHARE-BASED COMPENSATION Non-ve

SHARE-BASED COMPENSATION Non-vested award activity disclosure (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Oct. 31, 2019USD ($)yr$ / sharesshares	Oct. 31, 2018USD ($)shares	Oct. 31, 2017USD ($)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested beginning (in shares) \| shares	3,181
Granted (in shares) \| shares	1,309
Vested (in shares) \| shares	(1,530)
Forfeited (in shares) \| shares	(78)
Change in LTPP shares vested in the year due to performance conditions \| shares	291
Non-vested ending (in shares) \| shares	3,173	3,181
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Non-vested at October 31, 2018 -Weighted Average Grant Price (in dollars per share) \| $ / shares	$ 57
Granted - Weighted Average Grant Price (in dollars per share) \| $ / shares	68
Vested- Weighted Average Grant Price (in dollars per share) \| $ / shares	45
Foreited- Weighted Average Grant Price (in dollars per share) \| $ / shares	60
Change in LTPP shares vested in the year due to performance conditions Fair Value \| $ / shares	0
Non-vested at October 31, 2019 -Weighted Average Grant Price (in dollars per share) \| $ / shares	$ 60
Unrecognized share-based compensation costs for non-vested restricted stock awards, net of expected forfeitures \| $	$ 94
Weighted-average period non-vested restricted stock awards are expected to be amortized over (in years) \| yr	2.2
Total fair value of restricted stock awards vested \| $	$ 69	$ 58	$ 42

INCOME TAXES INCOME TAXES- Prov

INCOME TAXES INCOME TAXES- Provision (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount	$ (299)	$ 0	$ 0
Deferred Income Tax Expense (Benefit)	(255)	(16)	102
Taxes Payable, Current	231
Income before income tax
U.S. operations	189	169	116
Non-U.S. operations	730	777	687
Income before taxes	919	946	803
Provision (benefit) for income taxes
U.S. federal taxes - current	(191)	520	15
U.S. federal taxes - deferred	0	51	110
Non-U.S. taxes - current	290	95	1
Non-U.S. taxes - deferred	(267)	(22)	(7)
State taxes, net of federal benefit - current	4	1	1
State taxes, net of federal benefit - deferred	12	(15)	(1)
Income tax expense (benefit)	$ (152)	$ 630	$ 119

INCOME TAXES INCOME TAXES Effe

INCOME TAXES INCOME TAXES Effective tax rate and tax holidays (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Effective Income Tax Rate Reconciliation
Profit before tax times statutory rate	$ 193	$ 221	$ 281
Non-U.S. income taxed at different rates	(8)	(93)	(43)
Change in unrecognized tax benefits	(13)	(17)	(110)
U.S. Tax Reform	0		0
Tax Cuts and Jobs Act, Income Tax Expense (Benefit)		552
Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount	(299)	0	0
Adjustments to earnings of foreign subsidiaries	(25)	(33)	(9)
Income tax expense (benefit)	$ (152)	$ 630	$ 119
Effective tax rate (in hundredths)	(16.50%)	66.60%	14.80%
Tax Holidays [Abstract]
Impact of the income tax holidays	$ 368	$ 87	$ 93
Benefit of income tax holidays on net income per share	$ 1.16	$ 0.27	$ 0.29
Foreign
Tax Holidays [Abstract]
Benefit of income tax holidays on net income per share	$ 0.94

INCOME TAXES - 2017 U.S. Tax Re

INCOME TAXES - 2017 U.S. Tax Reform - Tax Cuts and Jobs Act (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Operating Loss Carryforwards [Line Items]
Tax Cuts and Jobs Act, Income Tax Expense (Benefit)		$ 552
U.S. Tax Reform tax expense	$ 0		$ 0
Tax Cuts and Jobs Act, Decrease in Deferred Tax Liability due to Transition Tax		152
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)		53
Net transition tax		651
Defered Tax Liability for Unremmitted earnings of foreign subsidiaries		10
U.S. Tax Cuts and Jobs Act of 2017 [Member]
Operating Loss Carryforwards [Line Items]
Net transition tax		$ 499

INCOME TAXES INCOME TAXES - Def

INCOME TAXES INCOME TAXES - Deferred Taxes and other (Details) - USD ($) $ in Millions	Oct. 31, 2019	Oct. 31, 2018
Components of Deferred Tax Assets
Intangibles	$ 131	$ 0
Property, plant and equipment	0	8
Pension benefits and retiree medical benefits	71	49
Employee benefits, other than retirement	34	34
Net operating loss, capital loss and credit carryforwards	195	185
Share-based compensation	32	31
Deferred revenue	38	38
Other	35	19
Subtotal	536	364
Tax valuation allowance	(134)	(135)
Total deferred tax assets	402	229
Components of Deferred Tax Liabilities
Intangibles	0	(112)
Property, plant and equipment	(16)	0
Unremmitted earnings of foreign subsidiaries		10
Other	(7)	(21)
Subtotal	(23)	(133)
Long Term Deferred Tax Assets And Liabilities [Abstract]
Long-term deferred tax assets (included within other assets)	410	165
Long-term deferred tax liabilities (included within other long-term liabilities)	(31)	(69)
Total	$ 379	$ 96

INCOME TAXES - Carryforwards (D

INCOME TAXES - Carryforwards (Details) $ in Millions	Oct. 31, 2019USD ($)
Net Operating loss carryforwards
Federal net operating loss carryforwards	$ 48
State net operating loss carryforwards	571
Foreign net operating loss carryforwards	577
Foreign
Net Operating loss carryforwards
Net operating loss carryforwards, subject to expiration	155
Net operating loss carryforwards, not subject to expiration	422
Capital Loss Carryforward
Capital loss carryforwards	116
Domestic
Capital Loss Carryforward
Capital loss carryforwards	48
State
Tax Credit Carryforwards
Tax credit carryforwards	$ 78

INCOME TAXES - Current and long

INCOME TAXES - Current and long-term income tax assets and liabilities (Details) - USD ($) $ in Millions	Oct. 31, 2019	Oct. 31, 2018
Income Tax Disclosure [Abstract]
Current income tax assets (included within other current assets)	$ 68	$ 59
Long-term income tax assets (included within other assets)	4	19
Current income tax liabilities (included within other accrued liabilities)	292	71
Long-term income tax liabilities (included within other long-term liabilities)	328	607
Total	$ 548	$ 600

INCOME TAXES INCOME TAXES - Unc

INCOME TAXES INCOME TAXES - Uncertain Tax Positions (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Operating Loss Carryforwards [Line Items]
Unrecognized tax benefit including interest and penalties	$ 227
Unrecognized Tax Benefits Rollforward
Balance, beginning of year	214	$ 224	$ 293
Additions for tax positions related to the current year	7	27	32
Additions for tax positions from prior years	12	2	1
Reductions for tax positions from prior years	2	13	3
Settlements with taxing authorities	0	0	(52)
Statute of limitations expirations	(25)	(26)	(47)
Balance, end of year	206	214	224
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]
Interest and penalties accrued related to unrecognized tax benefits accrued and reported	36	27
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	204
Income tax expense (benefit)	(152)	630	119
Unrecognized tax benefits that would not impact the effective tax rate	23
Tax Interest and Penalties [Member]
Operating Loss Carryforwards [Line Items]
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	$ 9	$ 11	$ (9)

NET INCOME (LOSS) PER SHARE (De

NET INCOME (LOSS) PER SHARE (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Numerator:
Net income	$ 1,071	$ 316	$ 684
Denominator:
Basic weighted average shares	314	321	322
Potential common shares - stock options and other employeee stock plans	4	4	4
Diluted weighted average shares	318	325	326
Share-based awards issued
Total number of share-based awards issued (in shares)	2	2	3

INVENTORY (Details)

INVENTORY (Details) - USD ($) $ in Millions	12 Months Ended
INVENTORY (Details) - USD ($) $ in Millions	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017	Nov. 01, 2018
Inventory [Line Items]
Finished goods	$ 416	$ 386
Purchased parts and fabricated assemblies	263	252
Inventory	679	638		$ 628
Inventory-related excess and obsolescence charges	$ 19	$ 26	$ 24

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT, NET (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017	Nov. 01, 2018
Property, Plant and Equipment [Line Items]
Land	$ 57	$ 55
Buildings and leasehold improvements	1,012	952
Machinery and equipment	546	512
Software	160	141
Total property, plant and equipment	1,775	1,660
Accumulated depreciation and amortization	(925)	(838)
Property, plant and equipment, net	850	822		$ 822
Tangible Asset Impairment Charges	0	1	$ 0
Depreciation expense	111	$ 102	$ 94
Fully depreciated assets no longer in use	$ 23

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS Text (Details) - USD ($)	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Intangible Assets, Including Goodwill)
Goodwill Additions	$ 625,000,000	$ 381,000,000
Additions and adjustments to other intangibles		262,000,000
Foreign exchange translation impact to other intangible assets		1,000,000
Goodwill and Intangible Asset Impairment [Abstract]
Goodwill impairment	0	0	$ 0
Impairment of finite-lived intangible assets	0	21,000,000	0
Impairment of indefinite-lived intangible assets	$ 0	$ 0	$ 0
Business Acquisition
Number of Businesses Acquired	2	7
Diagnostics and Genomics
Intangible Assets, Including Goodwill)
Goodwill Additions		$ 281,000,000
Indefinite-lived Intangible Assets, Purchase Accounting Adjustments	$ (11,000,000)
Life Sciences and Applied Markets
Intangible Assets, Including Goodwill)
Goodwill Additions	636,000,000	$ 37,000,000
Advanced Analytical Technologies, Inc (AATI) [Member] \| Diagnostics and Genomics
Intangible Assets, Including Goodwill)
Indefinite-lived Intangible Assets, Purchase Accounting Adjustments	(11,000,000)
BioTek and ACEA [Member]
Intangible Assets, Including Goodwill)
Additions and adjustments to other intangibles	744,000,000
Business Acquisition
Purchase price for acquisition	1,400,000,000
BioTek and ACEA [Member] \| Life Sciences and Applied Markets
Intangible Assets, Including Goodwill)
Goodwill Additions	$ 636,000,000

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS Roll forward (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Goodwill - Rollforward
Beginning Balance	$ 2,973	$ 2,607
Foreign currency translation impact	(5)	(15)
Goodwill arising from acquisitions	625	381
Ending Balance	3,593	2,973
Life Sciences and Applied Markets
Goodwill - Rollforward
Beginning Balance	803	773
Foreign currency translation impact	(1)	(7)
Goodwill arising from acquisitions	636	37
Ending Balance	1,438	803
Diagnostics and Genomics
Goodwill - Rollforward
Beginning Balance	1,607	1,330
Foreign currency translation impact	(2)	(4)
Goodwill arising from acquisitions		281
Indefinite-lived Intangible Assets, Purchase Accounting Adjustments	(11)
Ending Balance	1,594	1,607
Agilent CrossLab
Goodwill - Rollforward
Beginning Balance	563	504
Foreign currency translation impact	(2)	(4)
Goodwill arising from acquisitions	0	63
Ending Balance	$ 561	$ 563

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Other Intangibles (Details) - USD ($) $ in Millions	Oct. 31, 2019	Nov. 01, 2018	Oct. 31, 2018
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	$ 1,971		$ 1,233
Accumulated Amortization	979		853
Other intangible assets, net	1,107	$ 491	491
Total amortizable intangible assets	992		380
Gross Book Value	2,086		1,344
In-Process R&D	115		111
Purchased technology
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	1,413		947
Accumulated Amortization	763		683
Other intangible assets, net	650		264
Backlog
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	5
Accumulated Amortization	5
Other intangible assets, net	0
Trademark/Tradename
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	196		151
Accumulated Amortization	102		88
Other intangible assets, net	94		63
Customer Relationships
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	329		107
Accumulated Amortization	87		63
Other intangible assets, net	242		44
Third-Party Technology and Licenses [Member]
Schedule of Other Intangible Assets By Major Class [Abstract]
Gross Carrying Amount	28		28
Accumulated Amortization	22		19
Other intangible assets, net	$ 6		$ 9

GOODWILL AND OTHER INTANGIBLE_6

GOODWILL AND OTHER INTANGIBLE ASSETS Amortization Expense and Future Amortization Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Amortization Expense, Maturity Schedule [Abstract]
Amortization of intangible assets during the period	$ 128	$ 110	$ 120
Future amortization expense for 2020	186
Future amortization expense for 2021	172
Future amortization expense for 2022	150
Future amortization expense for 2023	107
Future amortization expense for 2024	86
Future amortization thereafter	$ 291

INVESTMENTS (Details)

INVESTMENTS (Details) - USD ($) $ in Millions	12 Months Ended
INVESTMENTS (Details) - USD ($) $ in Millions	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017	Nov. 01, 2018
Long-Term [Abstract]
Equity investments - without readily determinable fair value	$ 47	$ 23
Equity investments - with readily determinable fair value	25	15
Trading securities	30	30
Total	102	68		$ 75
Lasergen
Additional consideration paid	107
Gain on step acquisition	0	20	$ 0
Cost method investment, VIE		80
Amounts included in other income (expense), net [Abstract]
Net unrealized gains on our equity securities with RDFV	3
Net unrealized gains on trading securities	3	1	$ 4
Accumulated deficit	$ (18)	$ (336)		(303)
Impact of Adopting New Investments Valuation Guidance [Member]
Long-Term [Abstract]
Total				7
Amounts included in other income (expense), net [Abstract]
Accumulated deficit				$ 5

FAIR VALUE MEASUREMENTS, Fair v

FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - USD ($) $ in Millions	Oct. 31, 2019	Oct. 31, 2018
Assets, Long-term [Abstract]
Trading securities	$ 30	$ 30
Fair Value, Recurring [Member]
Assets, Short-term [Abstract]
Cash equivalents (money market funds)	784	1,355
Derivative instruments (foreign exchange contracts)	12	16
Assets, Long-term [Abstract]
Trading securities	30	30
Other investments	25
Total assets measured at fair value	851	1,401
Liabilities, Short-term [Abstract]
Derivative instruments (foreign exchange contracts)	6	5
Liabilities, Long-term [Abstract]
Deferred compensation liability	30	30
Total liabilities measured at fair value	36	35
Fair Value, Recurring [Member] \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets, Short-term [Abstract]
Cash equivalents (money market funds)	784	1,355
Derivative instruments (foreign exchange contracts)	0	0
Assets, Long-term [Abstract]
Trading securities	30	30
Other investments	0
Total assets measured at fair value	814	1,385
Liabilities, Short-term [Abstract]
Derivative instruments (foreign exchange contracts)	0	0
Liabilities, Long-term [Abstract]
Deferred compensation liability	0	0
Total liabilities measured at fair value	0	0
Fair Value, Recurring [Member] \| Significant Other Observable Inputs (Level 2)
Assets, Short-term [Abstract]
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	12	16
Assets, Long-term [Abstract]
Trading securities	0	0
Other investments	25
Total assets measured at fair value	37	16
Liabilities, Short-term [Abstract]
Derivative instruments (foreign exchange contracts)	6	5
Liabilities, Long-term [Abstract]
Deferred compensation liability	30	30
Total liabilities measured at fair value	36	35
Fair Value, Recurring [Member] \| Significant Unobservable Inputs (Level 3)
Assets, Short-term [Abstract]
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	0	0
Assets, Long-term [Abstract]
Trading securities	0	0
Other investments	0
Total assets measured at fair value	0	0
Liabilities, Short-term [Abstract]
Derivative instruments (foreign exchange contracts)	0	0
Liabilities, Long-term [Abstract]
Deferred compensation liability	0	0
Total liabilities measured at fair value	$ 0	$ 0

FAIR VALUE MEASUREMENTS FAIR VA

FAIR VALUE MEASUREMENTS FAIR VALUE MEASURMENTS - Fair value of assets and liabilities measured on non recurring (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying value of long-lived asset		$ 21
Long lived assets held for use impairment	$ 0	21	$ 0
impairments or material changes in non-marketable securities without readily determinable fair value	0
Fair value of assets, nonrecurring	0
Long lived assets held for sale Impairment	0	0	$ 0
carrying amount of non-marketable equity securities without readily determinable fair values	$ 47	$ 23

DERIVATIVES (Details)

DERIVATIVES (Details) $ in Millions	Sep. 15, 2016USD ($)	Oct. 20, 2014USD ($)	Oct. 31, 2019USD ($)contracts	Oct. 31, 2018USD ($)	Oct. 31, 2017USD ($)	Aug. 01, 2019USD ($)	Feb. 01, 2016USD ($)	Jul. 01, 2012USD ($)	Aug. 09, 2011USD ($)contracts	Jul. 13, 2010USD ($)	Oct. 24, 2007USD ($)
Terminated Interest Rate Swaps
Notional Amount of Terminated Interest Rate Swaps	$ 10
Derivative Instruments and Hedging Activities Disclosure [Abstract]
interest rate swap payments	$ 10		$ 6	$ 0	$ 0
Derivative, Net Liability Position, Aggregate Fair Value			$ 2
Derivative Contracts [Abstract]
Number Of Foreign Exchange Forward Contracts Designated As Cash Flow Hedge \| contracts			261
Number Of Foreign Exchange Forward Contracts Not Designated As Hedges \| contracts			205
Senior Notes 2022 [Member] \| Treasury Lock [Member]
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative, Notional Amount								$ 400
Remaining gain loss to be amortized on derivative			$ 1
Senior Notes 2020 [Member]
Terminated Interest Rate Swaps
Notional Amount of Terminated Interest Rate Swaps									$ 500
Asset value of terminated interest rate swaps									$ 34
Senior Notes 2026 [Member] \| Treasury Lock [Member] \| Cash Flow Hedges
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative, Notional Amount							$ 300
Remaining gain loss to be amortized on derivative			7
Senior Notes 2029 [Member] \| Treasury Lock [Member]
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative, Notional Amount						$ 250
Remaining gain loss to be amortized on derivative			$ 6
Senior Notes 2020 [Member]
Terminated Interest Rate Swaps
Number of Interest Rate Swap Contracts Designated as Fair Value Hedges Terminated \| contracts									5
Debt Instrument, Face Amount									$ 500	$ 500
Senior Notes 2017 [Member]
Terminated Interest Rate Swaps
Extinguishment of Debt, Amount		$ 500
Debt Instrument, Face Amount											$ 600

DERIVATIVES, Disclosures and de

DERIVATIVES, Disclosures and derivative instrument aggregated notional amounts by currency and designations (Details) - Forward Contracts Buy/(Sell) [Member] $ in Millions	Oct. 31, 2019USD ($)
Designated as Hedging Instrument \| Cash Flow Hedges \| Buy \| Australian Dollars
Derivative [Line Items]
Derivative, Notional Amount	$ 4
Designated as Hedging Instrument \| Cash Flow Hedges \| Buy \| Singapore, Dollars
Derivative [Line Items]
Derivative, Notional Amount	14
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell
Derivative [Line Items]
Derivative, Notional Amount	305
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell \| Euro
Derivative [Line Items]
Derivative, Notional Amount	40
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell \| British Pounds
Derivative [Line Items]
Derivative, Notional Amount	45
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell \| Canadian Dollars
Derivative [Line Items]
Derivative, Notional Amount	38
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell \| Japanese Yen
Derivative [Line Items]
Derivative, Notional Amount	82
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell \| Korean Won
Derivative [Line Items]
Derivative, Notional Amount	59
Designated as Hedging Instrument \| Cash Flow Hedges \| Sell \| China, Yuan Renminbi
Derivative [Line Items]
Derivative, Notional Amount	59
Derivatives Not Designated as Hedging Instruments \| Buy
Derivative [Line Items]
Derivative, Notional Amount	301
Derivatives Not Designated as Hedging Instruments \| Buy \| Euro
Derivative [Line Items]
Derivative, Notional Amount	141
Derivatives Not Designated as Hedging Instruments \| Buy \| British Pounds
Derivative [Line Items]
Derivative, Notional Amount	1
Derivatives Not Designated as Hedging Instruments \| Buy \| Canadian Dollars
Derivative [Line Items]
Derivative, Notional Amount	25
Derivatives Not Designated as Hedging Instruments \| Buy \| Malaysian Ringgit
Derivative [Line Items]
Derivative, Notional Amount	11
Derivatives Not Designated as Hedging Instruments \| Buy \| Danish Krone
Derivative [Line Items]
Derivative, Notional Amount	237
Derivatives Not Designated as Hedging Instruments \| Buy \| Singapore, Dollars
Derivative [Line Items]
Derivative, Notional Amount	28
Derivatives Not Designated as Hedging Instruments \| Sell \| Japanese Yen
Derivative [Line Items]
Derivative, Notional Amount	7
Derivatives Not Designated as Hedging Instruments \| Sell \| Korean Won
Derivative [Line Items]
Derivative, Notional Amount	32
Derivatives Not Designated as Hedging Instruments \| Sell \| Swiss Franc
Derivative [Line Items]
Derivative, Notional Amount	2
Derivatives Not Designated as Hedging Instruments \| Sell \| China, Yuan Renminbi
Derivative [Line Items]
Derivative, Notional Amount	70
Derivatives Not Designated as Hedging Instruments \| Sell \| Sweden, Kronor
Derivative [Line Items]
Derivative, Notional Amount	8
Derivatives Not Designated as Hedging Instruments \| Sell \| Other Currency
Derivative [Line Items]
Derivative, Notional Amount	$ 23

DERIVATIVES, Fair value of deri

DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) - USD ($) $ in Millions	Oct. 31, 2019	Oct. 31, 2018
Derivative, Fair Value, Net [Abstract]
Derivative Asset, Fair Value	$ 12	$ 16
Derivative Liability, Fair Value	6	5
Derivatives Not Designated as Hedging Instruments \| Foreign Exchange Contracts [Member] \| Other Current Assets [Member]
Derivative, Fair Value, Net [Abstract]
Derivative Asset, Fair Value	9	5
Derivatives Not Designated as Hedging Instruments \| Foreign Exchange Contracts [Member] \| Accrued Liabilities [Member]
Derivative, Fair Value, Net [Abstract]
Derivative Liability, Fair Value	4	4
Cash Flow Hedges \| Derivatives Designated as Hedging Instrument \| Foreign Exchange Contracts [Member] \| Other Current Assets [Member]
Derivative, Fair Value, Net [Abstract]
Derivative Asset, Fair Value	3	11
Cash Flow Hedges \| Derivatives Designated as Hedging Instrument \| Foreign Exchange Contracts [Member] \| Accrued Liabilities [Member]
Derivative, Fair Value, Net [Abstract]
Derivative Liability, Fair Value	$ 2	$ 1

DERIVATIVES, Effect of derivati

DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jan. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Derivative [Line Items]
Loss on interest rate swaps recognized in other comprehensive income		$ 6	$ (7)
Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net		(1)	(1)	$ 0
Gain (loss) recognized in accumulated other comprehensive income(loss)		(6)	7
Gain(loss reclassified from accumulated other comprehensive income (loss) into cost of sales		(8)	(4)
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months		4
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months	$ 4
Derivatives Not Designated as Hedging Instruments \| Other income (expense) [Member]
Derivative [Line Items]
Gain (loss) recognized in other income (expense), net within continuing operations		2	(2)	5
Cash Flow Hedges \| Derivatives Designated as Hedging Instrument \| Interest Rate Swap [Member] \| Other Comprehensive Income (Loss) [Member]
Derivative [Line Items]
Loss on interest rate swaps recognized in other comprehensive income		(6)	0	0
Gain (loss) recognized in accumulated other comprehensive income(loss)		6	0	0
Cash Flow Hedges \| Derivatives Designated as Hedging Instrument \| Forward Contracts Buy/(Sell) [Member] \| Cost of Sales [Member]
Derivative [Line Items]
Gain (loss) recognized in other income (expense), net within continuing operations		2	0	0
Cash Flow Hedges \| Derivatives Designated as Hedging Instrument \| Foreign Exchange Contracts [Member] \| Accumulated Other Comprehensive Income (Loss)
Derivative [Line Items]
Loss on interest rate swaps recognized in other comprehensive income		0	(7)	0
Gain (loss) recognized in accumulated other comprehensive income(loss)		0	7	0
Cash Flow Hedges \| Derivatives Designated as Hedging Instrument \| Foreign Exchange Contracts [Member] \| Cost of Sales [Member]
Derivative [Line Items]
Gain(loss reclassified from accumulated other comprehensive income (loss) into cost of sales		$ 9	$ (3)	$ 1

RETIREMENT PLANS AND POST RETIE

RETIREMENT PLANS AND POST RETIEMENT PENSION PLANS - Deferred Profit Sharing Plan (Details) - USD ($) $ in Millions	Oct. 31, 2019	Oct. 31, 2018
Deferred Profit Sharing [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair Value of Plan Assets	$ 132	$ 141

RETIREMENT PLANS AND POST RET_3

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Defined Contribution (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Defined Contribution Plan Disclosure [Line Items]
Maximum employer matching contribution in the 401(k) plan (in hundredths)	6.00%
Maximum employee contribution to 401(k)	50.00%
401(k) Plan employer expense	$ 39	$ 37	$ 33
401(k) Additional company contribution
Defined Contribution Plan Disclosure [Line Items]
Transitional company contribution to employee 401(k)	4.00%
401(k) Additional company contribution \| 3 Percent
Defined Contribution Plan Disclosure [Line Items]
Transitional company contribution to employee 401(k)	3.00%
401(k) Additional company contribution \| 5 Percent
Defined Contribution Plan Disclosure [Line Items]
Transitional company contribution to employee 401(k)	5.00%

RETIREMENT PLANS AND POST RET_4

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, JWPIL (Details) - Pension Plan - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jan. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
JAPAN
Defined Benefit Plan Disclosure [Line Items]
Settlement gain (loss)	$ 5			$ 32
Benefit Obligation				65
JAPAN \| Difference Between Fair Values of the Obligation Settled and Assets Transferred [Member]
Defined Benefit Plan Disclosure [Line Items]
Settlement gain (loss)				41
JAPAN \| Accumulated Other Comprehensive Income (Loss)
Defined Benefit Plan Disclosure [Line Items]
Settlement gain (loss)				(9)
Fair Value of Plan Assets				24
Non-U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Settlement gain (loss)		$ 0	$ 0	(32)
Benefit Obligation		1,067	913	935
Fair Value of Plan Assets		$ 911	$ 825	$ 855

RETIREMENT PLANS AND POST RET_5

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Components of Net Periodic Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]
Net actuarial (gain) loss	$ 157	$ 49
Amortization of net actuarial loss	(39)	(39)
Prior service cost (benefit)	0	0
Amortization of prior service benefit	8	8
Pension Plan \| U.S. Plan
Net periodic benefit cost (benefit) [Abstract]
Service cost - benefits earned during the period	0	0	$ 0
Interest cost on benefit obligation	18	16	15
Expected return on plan assets	(27)	(28)	(25)
Amortization of net actuarial loss	1	1	3
Amortization of prior service benefit	0	0	0
Total periodic benefit cost (benefit)	(8)	(11)	(7)
Curtaliment and settlement	0	0	0
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]
Net actuarial (gain) loss	51	2	(19)
Amortization of net actuarial loss	(1)	(1)	(3)
Prior service cost (benefit)	0	0	0
Amortization of prior service benefit	0	0	0
Gain due to settlement	0	0	0
Foreign currency	0	0	0
Total recognized in other comprehensive (income) loss	50	1	(22)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss	42	(10)	(29)
Pension Plan \| Non-U.S. Plans
Net periodic benefit cost (benefit) [Abstract]
Service cost - benefits earned during the period	20	20	19
Interest cost on benefit obligation	14	13	12
Expected return on plan assets	(43)	(46)	(41)
Amortization of net actuarial loss	34	29	36
Amortization of prior service benefit	0	0	0
Total periodic benefit cost (benefit)	25	16	26
Curtaliment and settlement	0	5	32
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]
Net actuarial (gain) loss	104	49	(128)
Amortization of net actuarial loss	(34)	(29)	(36)
Prior service cost (benefit)	0	0	0
Amortization of prior service benefit	0	0	0
Gain due to settlement	0	0	(32)
Foreign currency	(3)	1	2
Total recognized in other comprehensive (income) loss	67	21	(130)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss	92	32	(136)
Post-Retirement Benefit Plan \| U.S. Plan
Net periodic benefit cost (benefit) [Abstract]
Service cost - benefits earned during the period	0	1	1
Interest cost on benefit obligation	4	3	3
Expected return on plan assets	(7)	(7)	(7)
Amortization of net actuarial loss	4	8	11
Amortization of prior service benefit	(8)	(8)	(9)
Total periodic benefit cost (benefit)	(7)	(3)	(1)
Curtaliment and settlement	0	0	0
Other changes in plan assets and benefit obligations recognized in other comprehensive (income) loss [Abstract]
Net actuarial (gain) loss	5	(2)	(9)
Amortization of net actuarial loss	(4)	(8)	(11)
Prior service cost (benefit)	0	0	0
Amortization of prior service benefit	(8)	(8)	(9)
Gain due to settlement	0	0	0
Foreign currency	0	0	0
Total recognized in other comprehensive (income) loss	9	(2)	(11)
Total recognized in net periodic benefit cost (benefit) and other comprehensive (income) loss	$ 2	$ (5)	$ (12)

RETIREMENT PLANS AND POST RET_6

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Non-U.S. Plans \| Pension Plan
Change in fair value of plan assets: [Roll Forward]
Fair Value Balance, beginning of year	$ 825	$ 855
Actual return on plan assets	85	(9)
Employer contributions	21	21
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	1	0
Benefits paid	29	26
Settlements	0
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement		5
Currency impact	8	(21)
Fair Value Balance, end of year	911	825	$ 855
Change in benefit obligation: [Roll Forward]
Benefit Obligation Balance, Beginning of year	913	935
Service cost	20	20	19
Interest cost	14	13	12
Participant's contributions	1	0
Plan amendment	0	1
Actuarial (gain) loss	143	(6)
Benefits paid	29	27
Currency impact	5	(23)
Benefit Obligation Balance, end of year	1,067	913	935
Funded status of plan [Abstract]
Funded status of plan	(156)	(88)
Actuarial (gains) losses	(330)	(263)
Prior service costs (benefits)	0	0
Total	330	263
U.S. Plan \| Pension Plan
Change in fair value of plan assets: [Roll Forward]
Fair Value Balance, beginning of year	401	414
Actual return on plan assets	50	8
Employer contributions	0	0
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Benefits paid	19	21
Settlements	0	0
Currency impact	0	0
Fair Value Balance, end of year	432	401	414
Change in benefit obligation: [Roll Forward]
Benefit Obligation Balance, Beginning of year	420	445
Service cost	0	0	0
Interest cost	18	16	15
Participant's contributions	0	0
Plan amendment	0	0
Actuarial (gain) loss	74	(19)
Benefits paid	21	22
Currency impact	0	0
Benefit Obligation Balance, end of year	491	420	445
Funded status of plan [Abstract]
Funded status of plan	(59)	(19)
Actuarial (gains) losses	(115)	(65)
Prior service costs (benefits)	0	0
Total	115	65
U.S. Plan \| Post-Retirement Benefit Plan
Change in fair value of plan assets: [Roll Forward]
Fair Value Balance, beginning of year	90	95
Actual return on plan assets	11	1
Employer contributions	0	0
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Benefits paid	6	6
Settlements	0	0
Currency impact	0	0
Fair Value Balance, end of year	95	90	95
Change in benefit obligation: [Roll Forward]
Benefit Obligation Balance, Beginning of year	87	97
Service cost	0	1	1
Interest cost	4	3	3
Participant's contributions	0	0
Plan amendment	0	0
Actuarial (gain) loss	9	(7)
Benefits paid	6	7
Currency impact	0	0
Benefit Obligation Balance, end of year	94	87	$ 97
Funded status of plan [Abstract]
Funded status of plan	1	3
Actuarial (gains) losses	(10)	(10)
Prior service costs (benefits)	(12)	(20)
Total	(2)	(10)
Other Assets [Member] \| Non-U.S. Plans \| Pension Plan
Funded status of plan [Abstract]
Funded status of plan	106	95
Other Assets [Member] \| U.S. Plan \| Pension Plan
Funded status of plan [Abstract]
Funded status of plan	0	0
Other Assets [Member] \| U.S. Plan \| Post-Retirement Benefit Plan
Funded status of plan [Abstract]
Funded status of plan	1	3
Employee compensation and benefits [Member] \| Non-U.S. Plans \| Pension Plan
Funded status of plan [Abstract]
Funded status of plan	0	0
Employee compensation and benefits [Member] \| U.S. Plan \| Pension Plan
Funded status of plan [Abstract]
Funded status of plan	1	1
Employee compensation and benefits [Member] \| U.S. Plan \| Post-Retirement Benefit Plan
Funded status of plan [Abstract]
Funded status of plan	0	0
Retirement and post-retirement benefits \| Non-U.S. Plans \| Pension Plan
Funded status of plan [Abstract]
Funded status of plan	262	183
Retirement and post-retirement benefits \| U.S. Plan \| Pension Plan
Funded status of plan [Abstract]
Funded status of plan	58	18
Retirement and post-retirement benefits \| U.S. Plan \| Post-Retirement Benefit Plan
Funded status of plan [Abstract]
Funded status of plan	$ 0	$ 0

RETIREMENT PLANS AND POST RET_7

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Financial Statement Location (Details) $ in Millions	Oct. 31, 2019USD ($)
Pension Plan \| Non-U.S. Plans
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]
Amortization of net prior service cost (benefit)	$ 0
Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year	48
Pension Plan \| U.S. Plan
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]
Amortization of net prior service cost (benefit)	0
Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year	3
Post-Retirement Benefit Plan \| U.S. Plan
Accumulated other comprehensive income expected to be recognized as components of net expense during the next fiscal year [Abstract]
Amortization of net prior service cost (benefit)	(7)
Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year	$ 4

RETIREMENT PLANS AND POST RET_8

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Target Allocations (Details)	Oct. 31, 2019	Oct. 31, 2018
U.S. Plan \| Deferred Profit Sharing [Member] \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	60.00%	60.00%
U.S. Plan \| Deferred Profit Sharing [Member] \| Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	40.00%	40.00%
U.S. Plan \| Pension Plan \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	80.00%	80.00%
U.S. Plan \| Pension Plan \| Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	20.00%	20.00%
U.S. Plan \| Pension Plan \| Other Investments
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments	3.00%	3.00%
U.S. Plan \| Post-Retirement Benefit Plan \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	80.00%	80.00%
U.S. Plan \| Post-Retirement Benefit Plan \| Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	20.00%	20.00%
U.S. Plan \| Post-Retirement Benefit Plan \| Other Investments
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan Us Portfolio Equity Securities Percentage Of Alternative Investments	3.00%	3.00%
Non-U.S. Plans \| Pension Plan \| Minimum \| Cash and Cash Equivalents
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	0.00%	0.00%
Non-U.S. Plans \| Pension Plan \| Minimum \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	31.00%	31.00%
Non-U.S. Plans \| Pension Plan \| Minimum \| Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	38.00%	38.00%
Non-U.S. Plans \| Pension Plan \| Minimum \| Real Estate
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	0.00%	0.00%
Non-U.S. Plans \| Pension Plan \| Maximum \| Cash and Cash Equivalents
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	25.00%	25.00%
Non-U.S. Plans \| Pension Plan \| Maximum \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	60.00%	60.00%
Non-U.S. Plans \| Pension Plan \| Maximum \| Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	61.00%	61.00%
Non-U.S. Plans \| Pension Plan \| Maximum \| Real Estate
Defined Benefit Plan Disclosure [Line Items]
Target Allocation Percentage of Plan Assets	25.00%	25.00%

RETIREMENT PLANS AND POST RET_9

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Fair Value of Plan Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Pension Plan \| U.S. Plan
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	$ 432	$ 401	$ 414
Net asset value excluded from fair value by input	304	285
Other assets	432	401
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets	491	420
Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets.	432	401
Projected benefit obligation and fair value of plan assets [Abstract]
Defined Benefit obligation where Fair Value exceeds Pension benefit obligation	0	0
Fair Value of plan assets where fair value exceeds pension benefit obligation	0	0
Benefit Obligation	491	420	445
Accumulated benefit obligation and fair value of plan assets
Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation	491	420
Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets	432	401
Accumulated Benefit Obligation where Fair Value of plan Assets exceeds ABO	0	0
Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds ABO.	0	0
Pension Plan \| U.S. Plan \| Cash and Cash Equivalents
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	1	4
Net asset value excluded from fair value by input	1	4
Pension Plan \| U.S. Plan \| Equity Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	336	308
Net asset value excluded from fair value by input	258	239
Pension Plan \| U.S. Plan \| Fixed Income Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	91	83
Net asset value excluded from fair value by input	45	42
Pension Plan \| U.S. Plan \| Other Investments
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	4	6
Net asset value excluded from fair value by input	0	0
Pension Plan \| U.S. Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair value of plan assets [Abstract]
Other assets	124	105
Pension Plan \| U.S. Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Cash and Cash Equivalents
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0	0
Pension Plan \| U.S. Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Equity Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	78	69
Pension Plan \| U.S. Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Fixed Income Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	46	36
Pension Plan \| U.S. Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Other Investments
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0	0
Pension Plan \| U.S. Plan \| Significant Unobservable Inputs (Level 3)
Fair value of plan assets [Abstract]
Other assets	4	6
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Balance, beginning of year	6	7
Realized gains/(losses)	(1)	0
Unrealized gains/(losses)	(1)	1
Purchases, sales, issuances, and settlements	(2)	(2)
Transfers in (out)	0	0
Balance, end of year	4	6
Pension Plan \| U.S. Plan \| Significant Unobservable Inputs (Level 3) \| Cash and Cash Equivalents
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0	0
Pension Plan \| U.S. Plan \| Significant Unobservable Inputs (Level 3) \| Equity Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0	0
Pension Plan \| U.S. Plan \| Significant Unobservable Inputs (Level 3) \| Fixed Income Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0	0
Pension Plan \| U.S. Plan \| Significant Unobservable Inputs (Level 3) \| Other Investments
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	4	6
Pension Plan \| U.S. Plan \| Significant Other Observable Inputs (Level 2)
Fair value of plan assets [Abstract]
Other assets	0	5
Pension Plan \| U.S. Plan \| Significant Other Observable Inputs (Level 2) \| Cash and Cash Equivalents
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0	0
Pension Plan \| U.S. Plan \| Significant Other Observable Inputs (Level 2) \| Equity Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0	0
Pension Plan \| U.S. Plan \| Significant Other Observable Inputs (Level 2) \| Fixed Income Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0	5
Pension Plan \| U.S. Plan \| Significant Other Observable Inputs (Level 2) \| Other Investments
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0	0
Pension Plan \| Non-U.S. Plans
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	911	825	855
Net asset value excluded from fair value by input	220	161
Other assets	911	825
Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets	752	563
Fair value of plan assets for defined benefit plan with benefit obligation in excess of plan assets.	490	380
Projected benefit obligation and fair value of plan assets [Abstract]
Total projected benefit obligation - aggregate benefit obligation	1,067	913
Defined Benefit obligation where Fair Value exceeds Pension benefit obligation	315	350
Fair Value of plan assets where fair value exceeds pension benefit obligation	421	445
Benefit Obligation	1,067	913	935
Accumulated benefit obligation and fair value of plan assets
Accumulated benefit obligation in excess of fair value of plan assets - aggregate benefit obligation	651	543
Total accumulated benefit obligation - aggregate benefit obligation	1,032	886
Accumulated benefit obligation in excess of accumulated benefit obligation - aggregate fair value of plan assets	418	380
Accumulated Benefit Obligation where Fair Value of plan Assets exceeds ABO	381	343
Fair value of plan assets for defined benefit pension plan where the fair value of plan assets exceeds ABO.	493	445
Pension Plan \| Non-U.S. Plans \| Cash and Cash Equivalents
Fair value of plan assets [Abstract]
Net asset value excluded from fair value by input	0	0
Other assets	1	2
Pension Plan \| Non-U.S. Plans \| Equity Securities
Fair value of plan assets [Abstract]
Net asset value excluded from fair value by input	133	131
Other assets	512	489
Pension Plan \| Non-U.S. Plans \| Fixed Income Securities
Fair value of plan assets [Abstract]
Net asset value excluded from fair value by input	87	30
Other assets	398	334
Pension Plan \| Non-U.S. Plans \| Other Investments
Fair value of plan assets [Abstract]
Net asset value excluded from fair value by input	0	0
Other assets	0	0
Pension Plan \| Non-U.S. Plans \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair value of plan assets [Abstract]
Other assets	416	374
Pension Plan \| Non-U.S. Plans \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Cash and Cash Equivalents
Fair value of plan assets [Abstract]
Other assets	0	0
Pension Plan \| Non-U.S. Plans \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Equity Securities
Fair value of plan assets [Abstract]
Other assets	318	298
Pension Plan \| Non-U.S. Plans \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Fixed Income Securities
Fair value of plan assets [Abstract]
Other assets	98	76
Pension Plan \| Non-U.S. Plans \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Other Investments
Fair value of plan assets [Abstract]
Other assets	0	0
Pension Plan \| Non-U.S. Plans \| Significant Unobservable Inputs (Level 3)
Fair value of plan assets [Abstract]
Other assets	0	0
Pension Plan \| Non-U.S. Plans \| Significant Unobservable Inputs (Level 3) \| Cash and Cash Equivalents
Fair value of plan assets [Abstract]
Other assets	0	0
Pension Plan \| Non-U.S. Plans \| Significant Unobservable Inputs (Level 3) \| Equity Securities
Fair value of plan assets [Abstract]
Other assets	0	0
Pension Plan \| Non-U.S. Plans \| Significant Unobservable Inputs (Level 3) \| Fixed Income Securities
Fair value of plan assets [Abstract]
Other assets	0	0
Pension Plan \| Non-U.S. Plans \| Significant Unobservable Inputs (Level 3) \| Other Investments
Fair value of plan assets [Abstract]
Other assets	0	0
Pension Plan \| Non-U.S. Plans \| Significant Other Observable Inputs (Level 2)
Fair value of plan assets [Abstract]
Other assets	275	290
Pension Plan \| Non-U.S. Plans \| Significant Other Observable Inputs (Level 2) \| Cash and Cash Equivalents
Fair value of plan assets [Abstract]
Other assets	1	2
Pension Plan \| Non-U.S. Plans \| Significant Other Observable Inputs (Level 2) \| Equity Securities
Fair value of plan assets [Abstract]
Other assets	61	60
Pension Plan \| Non-U.S. Plans \| Significant Other Observable Inputs (Level 2) \| Fixed Income Securities
Fair value of plan assets [Abstract]
Other assets	213	228
Pension Plan \| Non-U.S. Plans \| Significant Other Observable Inputs (Level 2) \| Other Investments
Fair value of plan assets [Abstract]
Other assets	0	0
Post-Retirement Benefit Plan \| U.S. Plan
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	95	90	95
Net asset value excluded from fair value by input	64	62
Other assets		90
Projected benefit obligation and fair value of plan assets [Abstract]
Benefit Obligation	94	87	$ 97
Post-Retirement Benefit Plan \| U.S. Plan \| Cash and Cash Equivalents
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	3
Net asset value excluded from fair value by input	3	3
Other assets		3
Post-Retirement Benefit Plan \| U.S. Plan \| Equity Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	69
Net asset value excluded from fair value by input	51	50
Other assets		65
Post-Retirement Benefit Plan \| U.S. Plan \| Fixed Income Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	21
Net asset value excluded from fair value by input	10	9
Other assets		18
Post-Retirement Benefit Plan \| U.S. Plan \| Other Investments
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	2
Net asset value excluded from fair value by input	0	0
Other assets		4
Post-Retirement Benefit Plan \| U.S. Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	29
Other assets		24
Post-Retirement Benefit Plan \| U.S. Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Cash and Cash Equivalents
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0
Other assets		0
Post-Retirement Benefit Plan \| U.S. Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Equity Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	18
Other assets		15
Post-Retirement Benefit Plan \| U.S. Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Fixed Income Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	11
Other assets		9
Post-Retirement Benefit Plan \| U.S. Plan \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Other Investments
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0
Other assets		0
Post-Retirement Benefit Plan \| U.S. Plan \| Significant Unobservable Inputs (Level 3)
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	2
Other assets		4
Defined Benefit plan, change in fair value of plan assets, significant unobservable inputs (Level 3) (Roll Forward]
Balance, beginning of year	4	4
Realized gains/(losses)	(1)	0
Unrealized gains/(losses)	0	1
Purchases, sales, issuances, and settlements	(1)	(1)
Transfers in (out)	0	0
Balance, end of year	2	4
Post-Retirement Benefit Plan \| U.S. Plan \| Significant Unobservable Inputs (Level 3) \| Cash and Cash Equivalents
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0
Other assets		0
Post-Retirement Benefit Plan \| U.S. Plan \| Significant Unobservable Inputs (Level 3) \| Equity Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0
Other assets		0
Post-Retirement Benefit Plan \| U.S. Plan \| Significant Unobservable Inputs (Level 3) \| Fixed Income Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0
Other assets		0
Post-Retirement Benefit Plan \| U.S. Plan \| Significant Unobservable Inputs (Level 3) \| Other Investments
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	2
Other assets		4
Post-Retirement Benefit Plan \| U.S. Plan \| Significant Other Observable Inputs (Level 2)
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0
Other assets		0
Post-Retirement Benefit Plan \| U.S. Plan \| Significant Other Observable Inputs (Level 2) \| Cash and Cash Equivalents
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0
Other assets		0
Post-Retirement Benefit Plan \| U.S. Plan \| Significant Other Observable Inputs (Level 2) \| Equity Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0
Other assets		0
Post-Retirement Benefit Plan \| U.S. Plan \| Significant Other Observable Inputs (Level 2) \| Fixed Income Securities
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	0
Other assets		0
Post-Retirement Benefit Plan \| U.S. Plan \| Significant Other Observable Inputs (Level 2) \| Other Investments
Fair value of plan assets [Abstract]
Fair Value of Plan Assets	$ 0
Other assets		$ 0

RETIREMENT PLANS AND POST RE_10

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Expected Benefit Payments (Details) $ in Millions	Oct. 31, 2019USD ($)
Pension Plan \| U.S. Plan
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	$ 0
Future benefit payments [Abstract]
2020	35
2021	36
2022	33
2023	35
2024	37
2025 - 2029	146
Pension Plan \| Non-U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	24
Future benefit payments [Abstract]
2020	25
2021	27
2022	29
2023	32
2024	32
2025 - 2029	170
Post-Retirement Benefit Plan \| U.S. Plan
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	0
Future benefit payments [Abstract]
2020	8
2021	8
2022	7
2023	7
2024	7
2025 - 2029	$ 35

RETIREMENT PLANS AND POST RE_11

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS, Assumptions (Details)	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
U.S. Plan \| Pension Plan
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)	4.50%	3.75%	3.75%
Expected long-term return on assets (in hundredths)	7.00%	7.00%	7.25%
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)	3.25%	4.50%
U.S. Plan \| Post-Retirement Benefit Plan
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)	4.25%	3.50%	3.50%
Expected long-term return on assets (in hundredths)	7.00%	7.00%	7.25%
Current medical cost trend rate	6.00%	6.00%	6.00%
Ultimate medical cost trend rate	3.50%	3.50%	3.50%
Medical cost trend rate decreases to ultimate rate in year	2029	2029	2029
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)	3.00%	4.25%
Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year	6.25%	6.00%
Defined Benefit Plan, Ultimate Health Care Cost Trend Rate	4.50%	3.50%
Non-U.S. Plans \| Pension Plan \| Minimum
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)	0.83%	0.67%	0.22%
Average increase in compensation levels (in hundredths)	2.25%	2.00%	2.00%
Expected long-term return on assets (in hundredths)	4.00%	4.00%	4.00%
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)	0.22%	0.83%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase	2.25%	2.25%
Non-U.S. Plans \| Pension Plan \| Maximum
Assumptions used to calculate the net periodic cost
Discount rate (in hundredths)	2.68%	2.52%	2.66%
Average increase in compensation levels (in hundredths)	3.25%	3.25%	4.25%
Expected long-term return on assets (in hundredths)	5.75%	6.00%	6.25%
Assumptions used to calculate the benefit obligation
Discount rate (in hundredths)	1.81%	2.68%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase	3.00%	3.25%

GUARANTEES (Details)

GUARANTEES (Details) - USD ($) $ in Millions	12 Months Ended
GUARANTEES (Details) - USD ($) $ in Millions	Oct. 31, 2019	Oct. 31, 2018
Summary of standard warranty accrual activity
Beginning balance	$ 35	$ 34
Accruals for warranties including change in estimates	54	53
Settlements made during the period	(57)	(52)
Ending balance	32	35
Standard Product Warranty Accrual, Balance Sheet Classification [Abstract]
Accruals for warranties due within one year	32	$ 35
Bank Guarantees	$ 40

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Loss Contingencies [Line Items]
Other Commitment	$ 77
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Future minimum lease payments 2020	52
Future minimum lease payments 2021	41
Future minimum lease payments 2022	29
Future minimum lease payments 2023	21
Future minimum lease payments 2024	14
Future minimum lease payments thereafter	56
Operating Leases, Future Minimum Payments Receivable [Abstract]
Future minimum lease income 2020	8
Future minimum lease income 2021	6
Future minimum lease income 2022	5
Total rent expense	75	$ 64	$ 57
Penalty reduce over period of time [Member]
Loss Contingencies [Line Items]
Other Commitment	$ 25

SHORT-TERM DEBT - Credit Facili

SHORT-TERM DEBT - Credit Facility and Capital Lease (Details) - USD ($) $ in Millions	Mar. 13, 2019	Oct. 31, 2019	Oct. 21, 2019	Aug. 07, 2019
Line of Credit Facility [Abstract]
Credit facility initiation date	Mar. 13, 2019
Short-term debt terms (years)		five
Short-term Debt		$ 305
Repayments of Lines of Credit		190
Maximum borrowing capacity after increase		1,000
Line of credit outstanding balance		115
Short-term Bank Loans and Notes Payable			$ 500	$ 500
Capital Lease Obligations [Abstract]
Capital Lease Obligations, Current		$ 1

SHORT-TERM DEBT - Senior Notes

SHORT-TERM DEBT - Senior Notes (Details) - USD ($) $ in Millions	Sep. 17, 2019	Nov. 01, 2017	Oct. 20, 2014	Aug. 09, 2011	Jul. 13, 2010	Oct. 24, 2007	Sep. 15, 2016
Short-term Debt [Line Items]
Notional Amount Of Terminated Interest Rate Fair Value Hedge Derivatives							$ 10
Senior Notes 2017 [Member]
Short-term Debt [Line Items]
Issuance date of debt						Oct. 24, 2007
Debt Instrument, Face Amount						$ 600
Debt Instrument, Redemption Period, Start Date			Oct. 20, 2014
Extinguishment of Debt, Amount			$ 500
Repayments of senior debt		$ 100
Senior Notes 2020 [Member]
Short-term Debt [Line Items]
Issuance date of debt					Jul. 13, 2010
Debt Instrument, Face Amount				$ 500	$ 500
Percentage Of Face Amount Of Senior Note Instrument Issued					99.54%
Maturity date					Jul. 15, 2020
Fixed interest rate per annum (in hundredths)					5.00%
Debt Instrument, Redemption Period, End Date	Sep. 17, 2019
Early Repayment of Senior Debt	$ 500
Early repayment of senior notes including prepayment penalty	512
Early repayment of senior notes prepayment penalty	12
accelerated amortization of interest rate swap gain	4
Amortization of Debt Issuance Costs and Discounts	1
Debt Instrument, Increase, Accrued Interest	$ 4
Senior Notes 2020 [Member]
Short-term Debt [Line Items]
Interest Rate Derivatives Terminated Date				Aug. 9, 2011
Notional Amount Of Terminated Interest Rate Fair Value Hedge Derivatives				$ 500
Terminated Interest Rate Fair Value Hedge Derivative Assets At Fair Value				$ 34

LONG-TERM DEBT - Carrying Value

LONG-TERM DEBT - Carrying Value (Details) - USD ($) $ in Millions	Oct. 31, 2019	Oct. 31, 2018	Feb. 01, 2016
Debt Instrument [Line Items]
Debt Instrument Net Discount Premium Amount	$ 1,786	$ 1,792
Interest Rate Swap	0	7	$ 300
Long-term Debt, Gross	1,786	1,799
Senior Notes 2020 [Member]
Debt Instrument [Line Items]
Debt Instrument Net Discount Premium Amount		499
Interest Rate Swap		7
Long-term Debt, Gross		506
Senior Notes 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument Net Discount Premium Amount	399	399
Interest Rate Swap	0	0
Long-term Debt, Gross	399	399
Senior Notes 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument Net Discount Premium Amount	597	597
Interest Rate Swap	0	0
Long-term Debt, Gross	597	597
Senior Notes 2026 [Member]
Debt Instrument [Line Items]
Debt Instrument Net Discount Premium Amount	298	297
Interest Rate Swap	0	0
Long-term Debt, Gross	298	297
Senior Notes 2029 [Member]
Debt Instrument [Line Items]
Debt Instrument Net Discount Premium Amount	492	0
Interest Rate Swap	0	0
Long-term Debt, Gross	$ 492	$ 0

LONG-TERM DEBT - Senior Notes (

LONG-TERM DEBT - Senior Notes (Details) - USD ($) $ in Millions	Sep. 05, 2019	Sep. 15, 2016	Jun. 18, 2013	Sep. 10, 2012	Jul. 13, 2010	Oct. 31, 2019	Aug. 01, 2019	Oct. 31, 2018	Jul. 01, 2012	Aug. 09, 2011
Debt Instrument [Line Items]
Debt Instrument Net Discount Premium Amount						$ 1,786		$ 1,792
Senior Notes 2020 [Member]
Debt Instrument [Line Items]
Debt Instrument Net Discount Premium Amount								499
Issuance date of debt					Jul. 13, 2010
Aggregate face amount of debt					$ 500					$ 500
Issue rate percentage of principal amount					99.54%
Maturity date					Jul. 15, 2020
Fixed interest rate per annum (in hundredths)					5.00%
Senior Notes 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument Net Discount Premium Amount						399		399
Issuance date of debt				Sep. 10, 2012
Aggregate face amount of debt				$ 400
Issue rate percentage of principal amount				99.80%
Maturity date				Oct. 1, 2022
Fixed interest rate per annum (in hundredths)				3.20%
Interest payment frequency				semi-annually
Date payments commenced				Apr. 1, 2013
Senior Notes 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument Net Discount Premium Amount						597		597
Issuance date of debt			Jun. 18, 2013
Aggregate face amount of debt			$ 600
Issue rate percentage of principal amount			99.544%
Maturity date			Jul. 15, 2023
Fixed interest rate per annum (in hundredths)			3.875%
Interest payment frequency			semi-annually
Date payments commenced			Jan. 15, 2014
Senior Notes 2026 [Member]
Debt Instrument [Line Items]
Debt Instrument Net Discount Premium Amount						298		297
Issuance date of debt		Sep. 15, 2016
Aggregate face amount of debt		$ 300
Issue rate percentage of principal amount		99.624%
Maturity date		Sep. 22, 2026
Fixed interest rate per annum (in hundredths)		3.05%
Interest payment frequency		semi-annually
Date payments commenced		Mar. 22, 2017
Senior Notes 2029 [Member]
Debt Instrument [Line Items]
Debt Instrument Net Discount Premium Amount						492		$ 0
Issuance date of debt	Sep. 5, 2019
Aggregate face amount of debt	$ 500
Issue rate percentage of principal amount	99.316%
Maturity date	Sep. 15, 2029
Fixed interest rate per annum (in hundredths)	2.75%
Interest payment frequency	semi-annually
Date payments commenced	Mar. 15, 2020
Treasury Lock [Member] \| Senior Notes 2029 [Member]
Debt Instrument [Line Items]
Derivative, Notional Amount							$ 250
Remaining gain loss to be amortized on derivative						6
Treasury Lock [Member] \| Senior Notes 2022 [Member]
Debt Instrument [Line Items]
Derivative, Notional Amount									$ 400
Remaining gain loss to be amortized on derivative						$ 1

LONG-TERM DEBT LONG-TERM DEBT -

LONG-TERM DEBT LONG-TERM DEBT - Other (Details) - USD ($) $ in Millions	Sep. 15, 2016	Aug. 09, 2011	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017	Feb. 01, 2016
Debt Instrument [Line Items]
interest rate swap payments	$ 10		$ 6	$ 0	$ 0
Interest Rate Swap			0	$ 7		$ 300
Notional Amount Of Terminated Interest Rate Fair Value Hedge Derivatives	$ 10
Capital Lease Obligations, Noncurrent			5
Senior Notes 2020 [Member]
Debt Instrument [Line Items]
Interest Rate Derivatives Terminated Date		Aug. 9, 2011
Notional Amount Of Terminated Interest Rate Fair Value Hedge Derivatives		$ 500
Terminated Interest Rate Fair Value Hedge Derivative Assets At Fair Value		$ 34
Cash Flow Hedges \| Treasury Lock [Member] \| Senior Notes 2026 [Member]
Debt Instrument [Line Items]
Remaining gain loss to be amortized on derivative			$ 7

STOCKHOLDERS' EQUITY Stock Repu

STOCKHOLDERS' EQUITY Stock Repurchases (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017	Nov. 19, 2018	May 28, 2015
2015 Repurchase Program [Member]
Share Repurchase Program [Line Items]
Stock Repurchase Program, Authorized Amount					$ 1,140
Stock Repurchased and Retired During Period, Shares		6.4	4.1
Stock Repurchased and Retired During Period, Value		$ 422	$ 194
Remaining authorized repurchase amount		$ 188
2019 Repurchase Program [Member]
Share Repurchase Program [Line Items]
Stock Repurchase Program, Authorized Amount				$ 1,750
Stock Repurchased and Retired During Period, Shares	10.4
Stock Repurchased and Retired During Period, Value	$ 723
Remaining authorized repurchase amount	$ 1,030

STOCKHOLDERS' EQUITY STOCKHOLDE

STOCKHOLDERS' EQUITY STOCKHOLDERS EQUITY DIvidends (Details) - USD ($) $ / shares in Units, $ in Millions	Nov. 20, 2019	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Dividends [Abstract]
Cash Dividends Declared (per common share)		$ 0.656	$ 0.596	$ 0.528
Cash dividends declared		$ 206	$ 191	$ 170
Aggregate cash dividends paid (per common share)		$ 0.656	$ 0.596	$ 0.528
Aggregate cash dividends paid		$ 206	$ 191	$ 170
Subsequent Event [Member]
Dividends [Abstract]
Cash Dividends Declared (per common share)	$ 0.18
Cash dividends declared	$ 56
Dividends Payable, Date Declared	Nov. 20, 2019
Dividends payment date	Jan. 22, 2020
Dividends date of record	Dec. 31, 2019

STOCKHOLDERS' EQUITY -Accumulat

STOCKHOLDERS' EQUITY -Accumulated other comprehensive income (Details) - USD ($) $ in Millions	Oct. 31, 2019	Nov. 01, 2018	Oct. 31, 2018	Oct. 31, 2017
Foreign currency translation, net of tax expense of $(5) and $(15) for 2019 and 2018, respectively	$ (204)	$ (214)	$ (214)	$ (156)
Unrealized losses (including prior service benefit) on defined benefit plans, net of tax benefit of $153 and $132 for 2019 and 2018, respectively	(306)		(201)
Unrealized gains (losses) on derivative instruments, net of tax benefit of $3 and $0 for 2019 and 2018, respectively	(4)	6	7	(2)
Accumulated other comprehensive loss	(514)	$ (415)	(408)	$ (346)
Foreign currency translation, tax	5		15
Unrealized losses on defined benefit plans, tax	153		132
Unrealized gains (losses) on derivative instruments, tax	$ 3		$ 0

STOCKHOLDERS' EQUITY - Changes

STOCKHOLDERS' EQUITY - Changes in accumulated other comprehensive income (Details) - USD ($) $ in Millions	Nov. 01, 2018	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Beginning Balance	$ (408)	$ (408)	$ (346)
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	(7)
Other Comprehensive Income (Loss), before Reclassifications		(163)	(93)
Amounts Reclassified out of Accumulated Other Comprehensive Income		23	35
Tax (expense) benefit		41	(4)
Other Comprehensive Income (Loss)		(99)	(62)	$ 157
Ending Balance	(415)	(514)	(408)	(346)
Foreign Currency Translation
Beginning Balance	(214)	(214)	(156)
Other Comprehensive Income (Loss), before Reclassifications		0	(51)
Amounts Reclassified Amounts Reclassified out of Accumulated Other Comprehensive Income		0	0
Tax (expense) benefit		10	(7)	(3)
Other Comprehensive Income (Loss)		10	(58)
Ending Balance	(214)	(204)	(214)	(156)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax [Abstract]
Beginning Balance	134	134	140
Other Comprehensive (Income) Loss, before Reclassifications		0	0
Amounts Reclassified out of Accumulated Other Comprehensive Income		(8)	(8)
Tax (expense) benefit		2	2	3
Other Comprehensive (Income) Loss		(6)	(6)	(6)
Ending Balance	137	131	134	140
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax [Abstract]
Beginning Balance	(335)	(335)	(328)
Other Comprehensive Income (Loss), before Reclassifications		(157)	(49)
Amounts reclassified out of accumulated other comprehensive income		39	39
Tax (expense) benefit		25	3
Other comprehensive income (loss)		(93)	(7)	123
Ending Balance	(344)	(437)	(335)	(328)
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax [Abstract]
Beginning Balance	7	7	(2)
Other Comprehensive Income (Loss), before Reclassifications		(6)	7
Amounts Reclassified out of Accumulated Other Comprehensive Income		(8)	4
Tax (expense) benefit		4	(2)
Other Comprehensive Income (Loss)		(10)	9
Ending Balance	6	$ (4)	$ 7	$ (2)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	0
Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	3
Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	(9)
AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	$ (1)

STOCKHOLDERS' EQUITY STOCKHOL_2

STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY - Reclassifications out of accumulated other comprehensive income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Unrealized gains (losses) on derivatives reclassification out of AOCI to cost of sales	$ (8)	$ (4)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax	(2)	1	$ 0
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax	6	(3)	$ 1
Other Comprehensive Income Defined Benefit Plan Amortization Of Net Actuarial Loss	(39)	(39)
Amortization of prior service benefit	(8)	(8)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax	(31)	(31)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax	12	10
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax	(19)	(21)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	$ (13)	$ (24)

SEGMENT INFORMATION Profitabili

SEGMENT INFORMATION Profitability (Details) $ in Millions	12 Months Ended
SEGMENT INFORMATION Profitability (Details) $ in Millions	Oct. 31, 2019USD ($)segment	Oct. 31, 2018USD ($)	Oct. 31, 2017USD ($)
Segment Reporting [Abstract]
Number of operating segments \| segment	3
Percentage of revenue from a single customer	Less than 10 percent	Less than 10 percent	Less than 10 percent
Select income statement components
Net revenue	$ 5,163	$ 4,914	$ 4,472
Income from operations	941	904	807
Depreciation expense	111	102	94
Share-based compensation	72	70	60
Life Sciences and Applied Markets
Select income statement components
Net revenue	2,302	2,270	2,081
Income from operations	542	543	470
Depreciation expense	41	38	35
Share-based compensation	33	33	30
Diagnostics and Genomics
Select income statement components
Net revenue	1,021	943	860
Income from operations	185	173	167
Depreciation expense	35	33	30
Share-based compensation	14	14	10
Agilent CrossLab
Select income statement components
Net revenue	1,840	1,701	1,531
Income from operations	475	388	336
Depreciation expense	35	31	29
Share-based compensation	25	24	21
Segment Total [Member]
Select income statement components
Net revenue	5,163	4,914	4,472
Income from operations	1,202	1,104	973
Depreciation expense	111	102	94
Share-based compensation	$ 72	$ 71	$ 61

SEGMENT INFORMATION Reconciliat

SEGMENT INFORMATION Reconciliation of Reportable Results (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Reconcilitation between statement results and enterprise results [Abstract]
Total reportable segment income from operations	$ 1,202	$ 1,104	$ 973
Amortization	(125)	(105)	(117)
Acquisition and integration costs	(48)	(23)	(30)
Transformational initiatives	(44)	(25)	(12)
Asset impairment charges	0	21	0
Business exit and divestiture costs (primarily our NMR business)	0	(9)	0
NASD Site costs	(12)	(8)	0
Special compliance costs	(2)	(4)	0
Other	(30)	(5)	(7)
Interest income	36	38	22
Interest Expense	(74)	(75)	(79)
Other income (expense), net	16	79	53
Income before taxes	$ 919	$ 946	$ 803

SEGMENT INFORMATION Segment Ass

SEGMENT INFORMATION Segment Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017	Nov. 01, 2018
Segment Reporting Information [Line Items]
Segment Reporting Reconciliation Item Assets	$ 7,153	$ 5,690
Cash and cash equivalents	1,382	2,247
Prepaid expenses	94	80
Investments	102	68
Long term and other receivables	100	102
Other	621	354
Total assets	9,452	8,541		$ 8,558
Capital expenditures	155	177	$ 176
Life Sciences and Applied Markets
Segment Reporting Information [Line Items]
Total assets	3,202	1,744
Capital expenditures	59	47
Diagnostics and Genomics
Segment Reporting Information [Line Items]
Total assets	2,620	2,679
Capital expenditures	48	92
Agilent CrossLab
Segment Reporting Information [Line Items]
Total assets	1,331	1,267
Capital expenditures	48	38
Segment Total [Member]
Segment Reporting Information [Line Items]
Total assets	7,153	5,690
Capital expenditures	$ 155	$ 177

SEGMENT INFORMATION - Entity-Wi

SEGMENT INFORMATION - Entity-Wide Disclosures Revenue (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Revenue by geography
Net revenue	$ 5,163	$ 4,914	$ 4,472
UNITED STATES
Revenue by geography
Net revenue	1,619	1,414	1,314
CHINA
Revenue by geography
Net revenue	1,019	1,015	900
Rest Of World
Revenue by geography
Net revenue	$ 2,525	$ 2,485	$ 2,258

SEGMENT INFORMATION - Entity-_2

SEGMENT INFORMATION - Entity-Wide Disclosure Long-Lived Assets (Details) - USD ($) $ in Millions	Oct. 31, 2019	Oct. 31, 2018
Segment Reporting Information [Line Items]
Long-Lived Assets	$ 1,147	$ 1,044
UNITED STATES
Segment Reporting Information [Line Items]
Long-Lived Assets	621	565
GERMANY
Segment Reporting Information [Line Items]
Long-Lived Assets	122	117
Rest Of World
Segment Reporting Information [Line Items]
Long-Lived Assets	$ 404	$ 362

Schedule II Valuation and Qua_2

Schedule II Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Movement in valuation and qualifying accounts [Roll Forward]
Balance at Beginning of Period	$ 135	$ 138	$ 129
Additions Charged to Expenses or Other Accounts	9	4	14
Deductions Credited to Expenses or Other Accounts	(10)	(7)	(5)
Balance at End of Period	$ 134	$ 135	$ 138